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III INTRODUCTION 
 
 
1  Introduction 
 
The major functions of the gastrointestinal tract are not only digestion,  excretion and 
absorption but also recognition of food signals and transduction of these signals to various 
internal body systems. The intestine is unique in the body with regard to its constant exposure 
to an abundant commensal bacterial microbiota combined with regular if not frequent contact 
with pathogenic invaders, e.g. microbes and germs in contaminated foods. Although the 
normal host’s relationship with resident luminal bacteria is often mutually beneficial, the host 
also requires protection against these microorganisms. Effective control of the invaders either 
in the intestinal lumen or after invasion into the mucosa is not only important for protecting 
the host from infections with enteric pathogens but also for maintaining intestinal structure 
and function. This protection is provided to a large extent by the mucosal immune system 
consisting of multiple specific and non-specific components. Thus, the human intestine forms 
an interface with the environment serving to both protect the body and absorb nutrients. The 
relationship between the mammalian host and its microbiotica is to a large extent symbiotic. 
Disturbance of the delicate balance can result in several gastrointestinal diseases, especially 
inflammatory bowel diseases (IBD) and colorectal cancer (CRC). The disruption of the 
epithelial lining elicits the secretion of potent inflammatory mediators, such as the activation 
of the nuclear transcription factor NFκB, altered expression of antimicrobial peptides (APs), 
and abnormalities in apoptotic functions, e.g. regulated by the caspase cascade. Moreover, 
there is strong evidence that these processes are under control of nuclear hormone receptors, 
in particular the peroxisome proliferator-activated receptor γ (PPARγ) and the vitamin D 
receptor (VDR).  
Mesalazine and the dietary histone deacetylase (HDAC) inhibitors butyrate and 
sulforaphane (SFN) have attracted substantial interest as chemopreventive and anti-
inflammatory agents, especially in the gastrointestinal tract. However, the exact mechanisms 
underlying their effects are not entirely understood. Therefore, the aim of this thesis was to 
further unravel the influence of the drugs on above mentioned pathways and molecules with 
regard to the potential involvement of the nuclear hormone receptors, especially PPARγ. 
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2  The gastrointestinal ecosystem 
2.1  The intestinal epithelium and gastrointestinal diseases 
2.1.1  The intestinal epithelium 
 
Besides the absorption of nutrients and water, epithelial cells of the gastrointestinal mucosa 
forms an important mechanical barrier separating the host’s internal milieu from the 
environment to keep microorganisms out [1, 2]. The strong physical barrier is achieved by 
several defence mechanisms both constitutive and inducible [3]. Innate immune defences 
produced by intestinal epithelial cells include mucins and a variety of antimicrobial 
compounds, such as lysozymes, cathelicidins and defensins [4, 5]. These molecules directly 
inhibit bacterial growth and protect the epithelium by preventing microbial adhesion and by 
retaining APs and secretory antibody close to the epithelial surface [4, 5]. Additionally, 
epithelial cells secrete several cytokines, monocyte chemoattractant proteins, granulocyte-
macrophage colony-stimulating factors, the tumor necrosis factor α (TNFα) and the 
transforming growth factor β (TGF-β) [1]. Moreover, intestinal peristaltic movements of food 
and infectious agents are further examples of defensive mechanisms [3]. 
The intestinal epithelium has a well defined architecture. A number of invaginations, 
called the crypts of Lieberkühn are the functional proliferative units. In the small intestine 
these crypts are surrounded by numerous villi [1, 6]. This crypt-villi unit results in a greater 
surface area available for the absorption of nutrients. The epithelium is continuously and 
rapidly renewed by a process involving cell generation and migration from the stem cell 
population located at the bottom of the crypt [Figure 1] [1]. The cells then migrate upwards to 
the top of the villi where they preferentially die by apoptosis [1, 7]. The turnover time is 
considered to be 3-5 days. The plasticity of the system ensures that damaged and/or infected 
cells are dismissed and leave the body with the faeces, providing yet another defence 
mechanism against pathogenic bacteria [1].  
Three of the four principal epithelial cell lineages arising from the multipotent stem 
cell differentiate during an upward migration from the crypt to an associated villus [1, 8]. 
They include columnar absorptive enterocytes, comprising 80% of all epithelial cells, mucus-
producing goblet cells and enteroendocrine cells [1, 8]. Paneth cells represent the fourth 
lineage arising from the multipotent stem cell [8]. A variety of functions have been attributed 
to paneth cells, including modulation of the microbial flora through secretion of lysozyme and  
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Figure 1: The effector side of the gastrointestinal ecosystem. The gastrointestinal ecosystem consists of a 
rapidly renewing epithelial stem cell population that differentiates into multiple intestinal epithelial cell types 
(goblet cells, enteroendocrine cells, enterocytes, Paneth cells and M cells). These epithelial cells serve as a 
barrier between the luminal contents (food antigens and resident microbiota) and the complex mucosal immune 
system. [adapted from [1]] 
 
of APs [4]. A specialised type of epithelial cells is the M cell [1]. This cell line is an epithelial 
cell by all characteristics, but executes important functions in antigen presentation to the gut 
associated lymphoid tissue [1]. 
Hence, the intestinal epithelium is a complex ecosystem system generated by alliance 
of a rapidly renewing epithelial stem cell population and a number of defence processes [1]. 
Disturbance of the balance will lead to structural and functional changes, contributing to the 
pathogenesis of several gastrointestinal diseases. Unlike to normal colonic mucosa, however, 
inflamed colonic mucosa shows alterations e.g. in the defence mechanisms. Moreover, in 
IBD, like Crohn’s disease (CD) and ulcerative colitis (UC), as well as in CRC enhanced 
secretion of pro-inflammatory cytokines and rapid epithelial cell turnover with increased cell 
proliferation and reduced cell death was observed, respectively [9, 10]. 
3 THE GASTROINTESTINAL ECOSYSTEM 
 
 
2.1.2  Gastrointestinal diseases 
2.1.2.1  Inflammatory bowel disease 
 
The inflammatory bowel diseases (IBD) UC and CD are inflammatory disorders of the 
gastrointestinal tract, which are characterised by chronic and spontaneously relapsing 
inflammation of the gut [9, 11]. Both diseases lead to long-term and sometimes irreversible 
impairment of gastrointestinal structure and function [9]. Although UC and CD share many 
clinical and pathological characteristics, they also have some markedly different features [9]. 
In UC, inflammation appears continuously and is limited to the colon and invariably involves 
the rectum [11]. Inflammation in UC only affects superficial layers of the mucosa with 
infiltration of granulocytes and lymphocytes with a frequent appearance of ulcerations and 
crypt abscesses [9]. In contrast, CD is a transmural inflammatory process that may affect any 
part of the gastrointestinal tract from the mouth to the anorectum. Moreover, the disease is not 
confined to the lining of the bowel, but affects all layers of the intestinal wall with dense 
infiltrations of macrophages and lymphocytes to form abscesses and fistulas, thereby 
sometimes causing bowel obstruction. The presence of granulomas is common [9, 11]. A 
further characteristic of CD is the presence of normal bowel segments between affected areas 
in contrast to the continuous inflammatory process seen in UC [9]. In some of the patients, 
IBD is associated with extra-intestinal manifestations involving the liver, skin, eyes and/or the 
joints [11]. UC and CD manifest in the young population, the onset often occurs during the 
early twenties [12]. Symptoms can include abdominal pain, diarrhoea, weight loss, loss of 
appetite, arthralgias, fever and fatigue and anemia [13, 14]. The symptoms and the possible 
complications of the diseases can impact significantly on patients’ physical and systemic 
performance, leading to emotional anxiety, psychological distress and an overall reduction in 
quality of life [14].  
Although the aetiology of IBD remain obscure, its pathogenesis is gradually being 
unravelled [11]. IBD is a result of an inappropriate and exaggerated mucosal immune 
response directed against constitutes of the mucosal microflora, normally present in the 
intestinal milieu [15, 16]. The interaction of environmental factors with genetic susceptibility 
leads to inflammation of the gut mucosa [15]. CD is associated with a Th1-type immune 
response with excessive production of TNFα, interferon-γ and interleukin-12 (IL-12) [9]. In 
contrast, UC results mainly of a Th2-type response, associated with increased production of 
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IL-4, IL-5 and IL-13 [17]. Thus, the consequent excessive production of inflammatory 
mediators and, in addition, reactive oxygen metabolites, eicosanoids and proteases, together 
with defective repair mechanisms, perpetuate the inflammatory reaction resulting in tissue 
damage [11]. A further area is the identification of specific genetic abnormalities, responsible 
for IBD. The most important finding is the detection of mutations in the gene encoding NOD2 
on chromosome 16 occurring exclusively in patients with CD but not in patients with UC [9]. 
Besides the conventional medical treatment with corticosteroids and aminosalicylates, 
especially mesalazine, alternative immune-modulatory medication, such as methotrexate, and 
specific targeted cytokine therapies, e.g. infliximab, a monoclonal antibody to TNFα, are 
increasingly used in patients suffering from IBD [11]. Severe cases of IBD may require 
surgery, such as bowel resection, strictureplasty, or a temporary or permanent colostomy or 
ileostomy [11, 12]. 
Patients suffering from CD or UC have an increased risk for the development of CRC 
and the risk depends on disease duration and the extent of inflammation [18, 19]. The risk of 
CRC for patients with UC is estimated to 2% after 10 years, 8% after 20 years and 18% after 
30 years of disease [19]. CD also increases the hazard of CRC. The relative risk with 
extensive colonic involvement appears to be similar to that of UC [19]. 
 
2.1.2.2  Colorectal cancer 
 
Colorectal cancer (CRC) is the third most common malignant disease and the second most 
frequent cause of cancer-related death in the United States, with 145.290 new cases and 
56.290 deaths anticipated in 2005 [20, 21]. Worldwide, CRC is the fourth most commonly 
diagnosed malignant disease, with an estimated 1.023.000 new cases and 529.000 deaths each 
year [21]. In developed countries, the lifetime incidence of CRC is 5% [21]. Both men and 
women are almost equally affected [20]. The disease is rare in persons below the age of 50 
years, but thereafter increases with age [20]. The median age at diagnosis is slightly above 70 
years. The mortality ratio of patients suffering from CRC can decrease substantially in the 
next years, if the available measures for prevention, e.g. colonoscopy, will be implemented 
effectively [20]. There are at least three major types of CRC, which includes sporadic, 
IBD-associated and hereditary CRC [Table 1] [19]. Only a small population of cases are 
attributed in the setting of the two main forms of hereditary cancer syndromes, the familial
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Table 1: Classification of CRC, risk factors and causes. [adapted from [19]] 
 
adenomatous polyposis (FAP) and the hereditary nonpolyposis colorectal cancer (HNPCC), 
while the majority of CRC are considered sporadic [19]. The third type of CRC is the result of 
long-standing UC and CD of the colon. CRC accounts for approximately 15% of all deaths in 
patients with IBD [22]. 
Several factors have been suggested to be associated with a higher risk of CRC in 
patients with IBD. The magnitude of CRC risk increases e.g. with early age at IBD diagnosis, 
more extensive colitis, anatomic extent of disease and in patients having concomitant primary 
sclerosing cholangitis [22]. The most important risk factors for sporadic CRC are familial 
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Figure 2: Schematic overview of tumor progression in the digestive tract. Haematoxylin/eosin stained 
murine tissue sections. From left to right: normal tissue from the duodenum, an adenomatous polyp, and a 
malignant, invasive adenocarcinoma. See text for further explanations. [depicted modified from [10]] 
 
history, genetic mutations, epigenetic changes as well as lifestyle factors such as nutrition, 
obesity, inactivity and smoking [19]. Lifestyle-related risks offer a broad area for 
implementing primary preventive measures, which have not yet been adequately exhausted 
[19]. Several methods are available for secondary prevention e.g. fecal occult blood test and 
endoscopy [23]. Consistent encouragement of these possibilities for prevention could reduce 
incidence and mortality substantially and render colorectal tumors less frequent [23]. 
The intestinal epithelium with its distinct crypt-villus units is an intriguing model for 
several basic aspects of cellular behaviour, such as the control of cell number in a mammalian 
tissue [10]. The continuous process of self-renewal involves an intricate interplay between 
proliferation, controlled cell death, and cellular differentiation [10]. Imbalance of this tightly 
regulated system results in hyper-proliferation and de-differentiation, and can lead to drastic 
changes of the cell growth of the digestive tract, notably colorectal tumors [10]. The 
development of CRC from an adenoma to a carcinoma may take several decades [Figure 2] 
[10]. The process can be divided into three phases, tumor initiation, tumor promotion and 
tumor progression [24]. According to Hanahan and Weinberg, cancer then is the result of an 
accumulation of genetic alterations that allows growth of neoplastic cells with phenotypic 
characteristics  e.g. self-sufficiency in growth signals, insensitivity to anti-growth signals, 
evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and the ability to 
invade tissues and metastasis [25, 26]. 
The first phase of tumorigenesis, tumor initiation, involves multiple steps of genetic 
alterations, including the loss of function of tumor suppressor genes, and the activation of 
oncogenes [26]. Traditionally, colorectal carcinogenesis is explained by two pathways, the 
microsatellite instability (MSI) pathway also called the caretaker pathway, and the 
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chromosomal instability (CIN) pathway - the gatekeeper pathway [27]. The CIN pathway has 
originally been identified by Fearon and Vogelstein and is characterised by numeric and 
structural defects in chromosomes [28]. The authors proposed a multistep model of colorectal 
carcinogenesis, in which tumor suppressor genes, mainly the adenomatous polyposis coli 
(APC) gene, frequently called the “gatekeeper of CRC”, mutated in 60-80% of the cases, and 
the oncogene K-ras with a mutation rate of 50% are involved [28]. Several studies indicate 
that many other tumor suppressor genes (e.g. DCC, DPC4/Smad4, p53) and oncogenes (e.g. 
c-myc, c-neu) contribute to this regulation [19]. Besides the mutation of oncogenes and tumor 
suppressor genes in the CIN pathway, the MSI pathway is characterised by mutations or 
epigenetic changes of genes that maintain genetic stability e.g. mismatch repair genes (MSH1, 
MSH2) [29]. In addition, tumor suppressor genes such as TGF-β-RII and BAX are mutated in 
this pathway; changes in K-ras, APC and p53 are rare [19, 27]. The CIN pathway is 
responsible for about 85% of the sporadic CRC, and is the mechanism leading to 
carcinogenesis in patients with FAP. On the other hand, the MSI pathway is responsible for 
15% of sporadic CRC and also for the HNPCC [19]. Colorectal cancer of the CIN pathway is 
mainly located to the distal colon, whereas the MSI pathway can primarily be found in the 
proximal colon [27]. The major carcinogenic pathways that lead to sporadic CRC, namely 
CIN and MSI also occur in IBD-associated CRC [22]. However, recent progress in molecular 
biology has shown that colorectal carcinogenesis is not necessarily clearly divided into these 
two pathways, since the APC gene can act as a caretaker and mismatch repair gene [30]. 
Moreover, additional pathways exist, e.g.  the serrated pathway, the distinct pathways for 
carcinogenesis of flat and depressed colorectal neoplasms and the pathway for the 
carcinogenesis in IBD [19]. Epigenetic mechanisms such as change in DNA methylation, loss 
of imprinting, and histone acetylation, as well as modifier genes, such as cyclooxygenase-2 
(COX-2), PPARγ and VDR also seem to be involved in the genesis of CRC [19]. 
The second phase of tumorigenesis, tumor promotion, is characterized by the clonal 
expansion of initiated cells, owing to increased cell proliferation and/or reduced cell death 
[24]. Finally, invasion and metastasis, as well as an increase in tumor size, are characteristics 
of the third phase of tumorigenesis, the tumor progression [24]. The molecular pathway 
leading to IBD-associated CRC appears to differ from the well-known adenoma to CRC 
sequence as described above. These cancers seem to arise from either flat dysplastic tissue or 
dysplasia-associated lesions or masses [22]. An important model for IBD-associated 
carcinogenesis follows progression from an absence of dysplasia, to indefinite dysplasia, to 
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Figure 3: Molecular pathogenesis of CRC. (A) Sporadic CRC and (B) Colitis (ulcerative colitis, Crohn’s 
coltis)-associated CRC. Abbreviations:  COX, cyclooxygenase; CIN, chromasomal instability; MSI, 
microsatellite instability; mut., mutation; LOH, loss of heterozygosity; DCC, deleted in colorectal cancer; APC, 
adenomatous polyposis coli. [adapted from [18]] 
 
low-grade dysplasia, on to high-grade dysplasia, and ultimately to invasive CRC [Figure 3] 
[18]. Molecular events distinguishing sporadic CRC and IBD-associated CRC can mainly be 
associated in frequency and timing of the alteration of tumor suppressor genes, especially of 
APC and p53 [Figure 3] [18]. For example, APC loss of function, considered to be a very 
common early event in sporadic CRC, is much less frequent and usually occurs late in the 
IBD-associated dysplasia carcinoma sequence [18]. Loss of p53 gene function plays an early 
instrumental role in IBD-associated CRC. p53 mutations are often detected in mucosa that is 
nondysplastic or only indefinite for dysplasia. In contrast, loss of p53 gene function occurs 
late in sporadic CRC [18]. 
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2.2  Peroxisome proliferator-activated receptor γ (PPARγ) as a molecular 
target of epithelial functions in the intestinal tract 
2.2.1  PPARγ structure and activation 
 
Peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription factors 
belonging to the nuclear hormone receptor superfamily, also including the receptors for 
estrogen, thyroid, glucocorticoid and vitamin D [31, 32]. The PPAR subfamily consists of 
distinct genes which code for three PPAR isoforms termed α, β and γ, sharing about 60-80% 
homology in their ligand binding (LBDs) and DNA binding domains (DBDs) [32]. Amongst 
the three subtypes, PPARγ has been the most intensively investigated receptor in the intestine 
[32]. Three PPARγ mRNA isoforms have been described in the human genome, i.e. PPAR-
γ1, -γ2 and -γ3, differing at their 5’-end as a consequence of alternate promoter usage and 
splicing [32]. However, up to now the precise actions of these distinct PPARγ isoforms 
remain unclear [32].  
As shown for most members of the nuclear hormone receptor superfamily, PPARγ has 
a characteristic modular structure consisting of several functional domains [Figure 4]: the 
NH2-terminal A/B domain harbors a ligand-independent transcriptional activation function 
(AF-1) which can be regulated by phosphorylation [31]. The central C region contains the 
DBD, composed of two zinc fingers, which target the receptor to specific DNA sequences 
known as peroxisome proliferator response elements (PPREs) [31]. The hinge region D is 
important for coactivator docking [31]. The complex multifunctional region (E) encompasses 
the LBD and the ligand-dependent activation domain AF-2 [31]. The LBD contributes to 
ligand binding, dimerization, nuclear import signalling, interaction with the transcriptional 
machinery, and transcriptional activation/inhibition. In addition, it contains several helices 
and dimerization interfaces [31]. For the F domain on the COOH-terminal end of the receptor, 
no functional relevance has been described yet [33]. 
Upon activation in the cytoplasm, PPARγ changes its confirmation in the AF-2 
domain to the active form, heterodimerizes with retinoid X receptors (RXR), and forms a 
complex that translocates to the nucleus [Figure 5] [32]. The heterodimer then binds to 
PPREs located within the promoter region of target genes consisting of a direct repetitition of 
the consensus AGGTCA half-site, thereby regulating gene expression [32].  
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Figure 4: Structural organisation of the nuclear hormone receptor PPARγ. See text for explanation. 
 
 
In addition to the heterodimer complex, several accessory proteins i.e. coactivators and 
corepressors can bind to the nuclear receptor PPARγ/RXRα in a ligand-dependent manner 
e.g. steroid receptor coactivator-1 (SCR-1) and CBP/p300 [32]. They impact the 
transcriptional process by either remodelling chromatin structure or acting as adapter 
molecules linking the nuclear receptor complex to the key transcriptional machinery [32]. 
Ligand binding to PPARγ appears to trigger conformational changes that permit its 
dissociation from corepressors and favours its association with coactivators [32]. The 
coactivator proteins either possess or recruit histone acetyltransferase (HAT) activity to the 
transcription start site [32]. There, acetylation of histone proteins alters chromatin structure, 
thus facilitating the binding of RNA polymerase II and initiating transcription [32]. This is 
often achieved through the recruitment of HDACs [32]. Besides to its stimulatory effect on 
gene transcription, PPARγ can suppress gene expression in a DNA binding-dependent manner 
through the recruitment of corepressors to unliganded PPARγ bonded to PPRE or in a DNA 
binding-independent manner by interfering with key transcription factors via physical 
interaction [32].  
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Figure 5: Activation mechanism of PPARγ. PPARγ may be activated by different natural and synthetic ligands 
allowing its heterodimerisation with RXR in the cytoplasm. The heterodimer complex is then translocated to the 
nucleus of the cell and binds to peroxisome proliferator response elements (PPREs) located within the promoter 
region of target genes consisting of a direct repetitition of the consensus AGGTCA half-site, thereby regulating 
gene expression of many biological processes. 
 
2.2.2  Expression of PPARγ in humans 
 
Originally described as a receptor expressed by adipose tissue where it plays a role in 
adipocyte differentiation and in the regulation of insulin responses, other tissues and cells are 
now known to express PPARγ [Figure 6 A] [34]. Amongst them, the colon is a major tissue 
expressing PPARγ in epithelial cells and to a lesser degree in macrophages and lymphocytes 
[34]. In both humans and rodents the expression of PPARγ has been reported to be higher in 
the distal parts of the colon compared to the more proximal parts and the small intestine [35]. 
Furthermore, human CRC cell lines, tumors and polyps derived from CRC often contain high 
levels of PPARγ [36]. Since expression is primarily localised to the postmitotic, differentiated 
epithelial cells facing the lumen, the expression pattern in the colon mucosa is consistent with 
the proposed role of PPARγ in differentiation [35]. Thus, in colon cells, the expression of the 
receptor has been shown to increase during the differentiation process [Figure 6 B] [36, 37].  
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Figure 6: Expression of PPARγ in different tissues and in the colonic crypt (A) PPARγ mRNA expression in 
different tissues. PPARγ mRNA was quantified by reverse transcription-competitive polymerase chain reaction 
in different human organs and tissues. The main sources of PPARγ are adipose tissue and the colon. 
Abbreviation: PBMC, peripheral blood mononuclear cells. [adapted from [34]] (B) Expression of PPARγ in the 
colonic crypt. Stem cells are located at the bottom of the crypt and migrate up through zones of proliferation to 
their final destination as terminally differentiated cells on the top where they preferentially die by apoptosis. 
Expression of PPARγ increases upon differentiation of colon cells. 
 
2.2.3  Natural and synthetic ligands of PPARγ 
 
Several groups of endogenous synthetic and natural compounds are known to bind and to 
selectively activate PPARγ [ Figure 7] [31, 34]. Thiazolidinediones (TZDs), a class of 
synthetic insulin-sensitizing agents useful in the therapy of non-insulin dependent diabetes 
mellitus (diabetes-type II) including troglitazone (Rezulin
®, withdrawn from the market in the 
year 2000 due to an increased incidence of drug-induced hepatitis [38]), rosiglitazone 
(Avandia
®) and pioglitazone (Actos
®) were amongst the initially studied PPARγ agonists [31, 
34, 39]. In addition, a variety of nonsteroidal anti-inflammatory drugs (NSAIDs) e.g. 
indomethacin, ibuprofen, mesalazine and several natural ligands have been described to 
activate PPARγ in vitro and in vivo [34, 40, 41]. Natural ligands include 15-deoxy-Δ
12,14-
prostaglandin J2 (15-PGJ2), 9-hydroxyoctadecadienoic acid (9-HODE), 13-
hydroxyoctadecadienoic acid (13-HODE) and 8(S)-hydroxyeicosatetraenoic acid (8(S)-
HETE), all derived from the metabolism of arachidonic acid as well as certain 
polyunsaturated fatty acids [31, 34]. Moreover, our group could demonstrate that also the 
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Figure 7: Selection of natural and synthetic PPARγ ligands 
 
SCFA butyrate is able to up-regulate and to activate PPARγ [42, 43]. However, ligands are 
not the only way to modulate PPARγ activity, e.g. phosphorylation of specific serine 
structures by members of the mitogen-activated protein kinase (MAPK) family has been 
shown to activate PPARγ in a ligand-independent fashion [44]. 
 
2.2.4  Functions of PPARγ  
 
Much attention has been addressed to the role of PPARγ in controlling the expression of a 
large number of regulatory genes in lipid metabolism and insulin sensitisation [31]. PPARγ is 
the master regulator of differentiation and energy storage by adipocytes [31, 45]. As adipose 
tissue is required for proper glucose homeostasis, it has been demonstrated that absence leads 
to severe insulin resistance [46]. Classical PPARγ agonists such as rosiglitazone not only 
induce adipose differentiation, but also improve glucose control [46]. Besides those 
fundamental mechanisms, a variety of pleiotropic functions for PPARγ affecting multiple 
fundamental pathways in the cell have been described [31]. PPARγ has been demonstrated to 
play important roles in cellular proliferation and differentiation, inflammation, apoptosis, 
immune-modulation and angiogenesis [31, 47]. Thus, PPARγ is part of a group of versatile 
and potent regulators of several cellular functions [47]. 
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2.2.5  Role of PPARγ in colorectal cancer and inflammatory bowel disease 
 
PPARγ is highly expressed in the colonic epithelium (see 2.2.2), indicating an important role 
of the receptor in the physiology of the human colon [32, 47, 48]. Moreover, PPARγ has been 
implicated in the pathogenesis of CRC and IBD by modulating a variety of cellular functions 
involved in the pathogenesis of both diseases [32, 49].  
In the gastrointestinal tract, PPARγ is known to regulate cellular proliferation, and 
differentiation, induction of apoptosis and to modulate cell cycling [50, 51]. Moreover, 
reports demonstrate that PPARγ ligands lead to tumor suppression and inhibition of perineal 
ice is inhibited by activators of PPARγ, 
cluding troglitazone, rosiglitazone and 15-PGJ2 [52-55]. In addition, several reports not only 
ls, 
 CRC in 
-58]. 
tion of PPARγ can contribute 
 the carcinogenic process and that PPARγ can function as a tumor suppressor gene by 
inhibiting cell growth and inducing apoptosis [47]. However, the role of PPARγ in tumor 
formati ebated [32, 50]. Beyond the tumor-inhibiting effects, 
lso tumor-promoting effects were reported for PPARγ agonists in models
 of CRC [50, 59]. 
opic and histological lesions, as well 
s levels
 of biological markers of colonic inflammation [60]. Moreover PPARγ deficient mice 
exhibited an aggravation of inflammation in a trinitrobenzene sulfonic acid (TNBS) model 
metastasis in gastrointestinal cancer cells in vivo and in vitro. The growth of cultured human 
colon tumor cells and transplanted tumors in nude m
in
describe the initiation of the caspase cascade by PPARγ ligands in a variety of cancer cel
but also an association between loss of function mutations and the development of
humans, suggesting the involvement of the receptor in the regulation of apoptosis [56
These observations raised the possibility that the somatic muta
to
on is still uncertain and highly d
a
These differences can, in part, be explained
 by PPARγ-independent effects of PPARγ agonists 
and by differences
 in the models that were used [50]. Since it is still unclear how PPARγ 
impacts
  on CRC, careful monitoring of patients receiving PPARγ
  agonists and additional 
basic research is indicated before recommendations
 on the use of PPARγ ligands in CRC can 
be
 made [32, 50].  
Besides the role of PPARγ in the modulation of cell growth and cell proliferation, the 
involvement of the receptor in immune and inflammatory responses has been indicated [40, 
49]. In particular, the participation of PPARγ in the pathogenesis of IBD has been established 
[40, 49]. The PPARγ agonists troglitazone and rosiglitazone dramatically
 reduced disease 
severity in several experimental colitis animal models compared with the placebo
  treated 
group, thereby, reducing mortality,
 intensity of macrosc
a
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Figure 8: Possible mechanisms of anti-inflammatory effects of PPARγ-associated pathways. Abbreviations: 
AP1, activator protein 1; CRE, cAMP response element; IκB, inhibitor of NFκB; JNK, cJun N-terminal kinase; 
IL, interleukin; NFκB, nuclear factor κB; TNFα, tumor necrosis factor α. [adapted from [49]] 
 
compared to wild-type mice [60]. However, decreased expression of PPARγ was observed in 
the colon of UC patients compared with patients suffering from CD and with the control 
group, both in the mucosa of healthy and inflamed colon [40]. All these observations indicate 
a role of PPARγ as an anti-inflammatory brake such that a decrease in PPARγ levels might 
cause the development or exacerbation of inflammation [49]. However, it is still unclear if 
either decreases in the endogenous ligands for PPARγ, which remain to be identified, or 
decreases in the levels of PPARγ itself might be associated with the pathogenesis of IBD [49]. 
Elucidating the molecular pathways involved in the interaction between the receptor and IBD, 
recently it was indicated that activation of PPARγ may interfere
 with a variety of signalling 
pathways regulating the expression of pro-inflammatory
 genes, such as those controlled by 
NFκB, signal transducers and activators of transcription
 e.g. signal transducers and activators 
of transcription (STATs), activating protein 1 (AP1), and the nuclear factor of activated
 T-
cells [32, 34, 49]. Moreover, a network of interactions between NFκB and MAPK signalling 
has been established which is summarised in Figure 8 [49]. Consequent to the inhibition
 of 
these pathways, PPARγ activators may reduce the production
  of inflammatory cytokines, 
chemokines, and cell-adhesion molecules,
 thereby limiting the recruitment of inflammatory 
cells [60].   
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2.3  The vitamin D receptor (VDR) as a molecular target of epithelial 
function in the intestinal tract 
2.3.1  VDR structure and activation 
 
The vitamin D receptor (VDR) also belongs to the nuclear steroid hormone receptor 
superfamily [61]. The amino acid sequence and the functional domains of VDR show a 
significant homology with other members of its superfamily, with highest similarity to the 
thyroid, PPARγ and RXR [61]. VDR is believed to be located in the nucleus prior to 
activation with the active form of vitamin D hormone, which then dissociates from the serum 
vitamin D binding protein, or other carrier proteins; enters the cell by diffusion and binds with 
the receptor [62]. Moreover, substantial amounts of unoccupied VDR have been detected in 
ational 
hanges of the receptor, exposure of surfaces for coactivating factor binding, and in the 
65]. Coactivators such as SRC-1 and PCAF and cointegrators like CBP/p300 
the cytoplasm [63]. VDR has a similar structural and functional organisation as described for 
PPARγ (see 2.2.1). In contrast to other nuclear receptors, VDR lacks a ligand-independent 
AF-1 motif in its aminoterminal A/B domain [64]. Ligand activation results in conform
c
induction of heterodimerization usually with RXR [64]. The VDR-RXR heterodimer then 
binds with high affinity to the vitamin D response element (VDRE), present within the 
promoter region of vitamin D controlling genes [64]. These initial macromolecular 
interactions initiate a communication process that ultimately influences the rate of RNA 
polymerase II-directed transcription [65]. Moreover, calcitriol-dependent phosphorylation at 
distinct serine residues in the ligand/hinge domains of VDR has been reported and might also 
be involved in the regulation of DNA binding, ligand binding, nuclear localisation and gene 
transactivation [63]. 
VDR has been shown to interact with various compounds of the transcriptional 
machinery [65]. Several members of the steroid receptor coactivator gene family (e.g. 
SRC/p160), transcriptional intermediary factors (e.g. SRC-1), receptor associated coactivator 
integrator proteins (e.g. CBP/p300), the coactivator complex DRIP, corepressor proteins (e.g. 
SMRT) and a variety of other factors have emerged as central players in the communication 
process, connecting ligand-activated receptors to the preinitiation VDR complex [65]. The 
group of coactivator integrator proteins such as CBP/p300 can cooperate with VDR, 
coactivators, corepressors, and the preinitiation complex, thereby forming larger coactivator 
complexes [
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Figure 9: Model for VDR-mediated gene regulation. The VDR and RXR bind to the promoter of a target gene 
as a heterodimer in response to 1,25(OH)2D3. Transcriptionally active complexes that include the SRC1, 
CBP/p300 HAT coactivator complex or the DRIP-Mediator complex or perhaps others are subsequently 
recruited to facilitate changes in chromatin architecture and to enhance RNA polymerase II entry. Both may be 
needed to modulate gene expression. [Figure taken from [66]]
 
contain intrinsic HAT activities forming a link between nuclear receptor signalling and 
chromatin organization [65]. Presumably, coactivator function is primarily the recruitment of 
CBP/p300 appearing to be the primary source of HAT activity [Figure 9] [67]. 
 
2.3.2  Ligands for VDR 
 
The main ligand for VDR is the active form of vitamin D, the seco-steroid hormone 1α,25-
dihydroxyvitamin D3 (1,25(OH)2D3, calcitriol; VD3) [61, 68]. VD3 is obtained from dietary 
sources, mainly fish and meat, dietary supplements and, mostly, conversion of 7-
dehydrocholesterol to colecalciferol by the action of solar UV-B radiation (280-320 nm) in 
the skin [61]. Colecalciferol is then hydroxylated in the liver to 25-hydroxyvitamin D3 (25-
hydroxycholecalciferol, califediol) by vitamin D3 25-hydroxylase [61]. Subsequently, the 
intermediate is again hydroxylated to render 1α,25-dihydroxyvitamin, the most active 
metabolite of vitamin D, in the kidney and several cell types, by the actions of 25-
hydroxyvitamin D3 1α-hydroxylase [Figure 10] [61, 68]. Besides the active form of vitamin 
D and several vitamin D analoges like calcipotriol or tacalcitol, a variety of molecules 
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igure 10: Chemical structure, biosynthesis and actions of Vitamin D. See text for further explanations. 
rect structural 
lationship to the molecule, e.g. LG190119 [64]. Recently, our group could demonstrate that 
also the SCFA butyrate is able to activate and to up-regulate the expression of VDR in CRC 
cells [69, 70].  
Like other nuclear hormones, VD3 is a lipophilic compound that easily passes 
F
[adapted from [68]]  
 
modulate VDR by mimicking many of the activities of VD3  without a di
re
biological membranes and enters the nucleus [71]. Most of the known biological effects of 
VD3 are genomic effects, mediated through specific and high affinity binding to VDR [63, 
67]. Moreover, rapid, non-genomic actions of VD3 are known which have been suggested to 
function via putative membrane receptors [63, 67]. They have been reported to involve 
activation of Ca
2+ channels, G-protein-coupled receptors (GPCR), and downstream protein 
kinase C (PKC) and MAPK pathways [63, 67, 72]. 
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2.3.3  Tissue distribution of VDR 
 
VDR was first discovered in chicken intestine, and subsequently in a wide variety of cells and 
tissues [62]. In human, VDR is not only found in the classic target organs such as the 
intestinal tract, kidney and bone, but also in many other epithelial and mesenchymal cells. 
Moreover, high levels of VDR have been reported in several types of malignant cells like 
leukemic and osteosarcoma, as well as in colon, breast, lung, and prostate carcinoma cells 
[62, 73]. In addition, VDR is expressed by cells of the immune system like monocytes and 
activated B and T lymphocytes [73]. 
Numerous studies have demonstrated variable levels of VDR expression in epithelial 
and human CRC cells [74]. VDR expression is low in normal colon tissue, mainly in 
differentiated luminal crypt cells [74]. In addition, in mice studies, VDR expression has been 
found to be higher in the proximal than in the distal colon [75]. Examination of VDR 
expression in the CRC cell line Caco-2 showed that the expression of the receptor was 
an malignant colonic tissue and normal mucosa of the same 
level of differentiation [72, 74]. 
 
-carcinogenic, -invasive, -angiogenic, and 
nti-metastatic activities have been well established [62, 77].   
VD3 and its analogues are potential therapeutics in diverse disease states of 
inflammation like rheumatoid arthritis, psoriatic arthritis, IBD; dermatological indications like 
psoriasis, photoaging and skin rejuvenation; osteoporosis; cancers like breast, prostate, CRC, 
increased when the cells became confluent and differentiated in culture [76]. Subsequent 
studies corroborated that VDR is associated with a high degree of cell differentiation [72]. 
parison between hum The com
patient revealed significant higher VDR expression in tumoral than in normal tissue [72]. 
However, VDR expression is only enhanced in low grade tumor tissue, whereas in advanced 
carcinomas, it diminishes or disappears completely, - suggesting that CRC cells express VDR 
as long as they retain a certain 
2.3.4  Cellular functions of the VDR 
 
Tissue responsiveness to VD3 depends mainly on the expression levels of VDR and the 
hydroxylases regulating calcitriol synthesis and degradation [64]. Besides the major roles of 
VDR, mainly caused by VD3, in calcium homeostasis and bone metabolisms, immune-
modulatory functions as well as anti-inflammatory, 
a
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leukemia and myelodysplastic syndrome; and autoimmune diseases as multiple sclerosis, type 
I diabe [64, 73]. However, the use of VD3 in above 
entioned indications as well as in the oral therapy for psoriasis and even in the topical 
erate in combination and the predominant effect varies 
from o
loping CRC [77]. In addition, 
tudies in wild-type mice have demonstrated that a high-fat diet, with low levels of VD3, 
increases the risk of CRC. In long-term studies, these mice showed hyperproliferation in 
colonic epithelial cells [77] ented with calcium and VD3 these 
ffects were suppressed, suggesting that neoplasia could be prevented by increasing dietary 
ral studies have demonstrated 
that po
tes and systemic lupus erythematosus 
m
therapy for severe psoriasis is hampered by its associated toxicity, namely hypercalcemia 
[64]. New VDR ligands have been synthesized which exhibit greater specificity by retaining 
desirable properties, but with reduced hypercalcemic potential . 
The anti-cancer activity of VD3, especially in colon cells, stems from the inhibition of 
proliferation and the induction of apoptosis and differentiation. This not only maintains 
normal growth of the colonic crypt, but potentially can prevent the progression into pre-
malignancy [72]. The actions can op
ne to another cell [72]. The growth inhibitory actions of VD3 have been observed in 
many human CRC cell lines and also in cultured primary human colon adenoma- and 
carcinoma-derived cells and xenograft models [72].  
 
2.3.5  Role of VDR in colorectal cancer and inflammatory inflammatory 
bowel disease 
 
One of the earliest observations suggesting that VD3 may play a role in CRC prevention and 
treatment was that people, who lived at northern latitudes and therefore received less solar 
radiation, had an increased risk for dying due to this disease [77]. Moreover it was shown that 
low serum levels of VD3 correlated with a higher risk of deve
s
. When the diet was supplem
e
calcium and VD3 [77]. To examine the direct functional role of VDR in CRC, VDR deficient 
mice have been further analyzed. These mice display hyperproliferation and increased DNA 
damage, mainly in the colon [75]. Although they do not have high rates of spontaneous CRC, 
the results implicate the action of VD3 in the prevention of hyperproliferation and oxidative 
DNA damage, at least in the distal colon [75]. Moreover, seve
lymorphisms of the VDR gene may influence the development of CRC [78, 79]. 
Besides the participation of VDR in inhibition of the development of CRC, the critical 
role of the receptor in the control of IBD has also been established [80, 81]. There is 
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mounting evidence for a link between VD3 availability either from sunshine or diet and the 
prevalence of IBD [81]. In several experimental models, VD3 deficiency has been linked to 
IBD, e.g. absence of VD3 has been shown to exacerbate chronic IBD in IL-10 KO mice [82, 
83]. Treatment of these mice with VD3 resulted in the suppression of IBD symptoms [82]. 
Moreover, VDR-deficiency in mice resulted in an acceleration of the progress of severe IBD 
[84]. In addition, polymorphisms of the VDR gene have been implicated in susceptibility for 
CD in
2.4  Drugs with promising characteristics to treat colorectal cancer 
and inflammatory bowel disease 
2.4.1 
rt of 
sulfasa
 patient studies [85]. Direct effects on T cells and innate immune cells and the 
suppression of TNFα are mechanisms underlying the efficacy of VD3 in vivo [86]. In the gut it 
is likely that the targets of VD3 will include epithelial cells, innate as well as acquired immune 
cells [81]. Furthermore, the modulation of the NFκB pathway by VD3 has been postulated [87, 
88]. 
 
Mesalazine 
 
5-Aminosalicylic acid (5-ASA, 5-AS, 5-aminosalicylate, 5-aminosalicylic acid), including its 
derivates sulfasalazine, olsalazine and balsalazine are the most commonly described anti-
inflammatory drugs in patients with IBD which have been used extensively in the treatment of 
IBD for more than 50 years [89]. Moreover, a series of epidemiological investigations and 
preliminary clinical trials have affirmatively suggested that regular intake of oral mesalazine 
may have anti-neoplastic and potentially prophylactic properties reducing the occurrence of 
CRC in patients with IBD, in particular UC and colonic CD [90]. Furthermore, MSI and CIN 
as well as dysplasia were found to be reduced after long-term mesalazine therapy [91, 92]. 
Oral administration of simple 5-ASA tablets or capsules is ineffective because, 
although absorption is poor, the surface area and transit time through the small bowel is not 
sufficient for most of the drug to be absorbed whilst passing through the small bowel [93]. As 
a result, therapeutic concentrations are not reached in the distal gut [93]. The development of 
pH-dependent, delayed-release formulations of 5-aminosalicylic acid, olsalazine and 
balsalazine not only abolishes the toxicity associated with the sulfapyridine pa
lazine but also delivers 5-ASA in therapeutic concentrations to the large bowel [93]. 
The effectiveness of these drugs depends on the splitting of the diazo-bond of the molecule by 
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Figure 11 aminosalicylates (5-AS). See text for further explanations. [adapted from 
[93]] 
 
the 
lipoxyg
________________________________________
: Chemical structures of 5-
the action of bacteria in the large bowel, releasing the pharmacologically active moiety, 5-AS 
[Figure 11] [93]. 
Although mesalazine has been identified as a candidate chemopreventive agent in 
CRC prophylaxis and in the treatment of IBD caused by its anti-proliferative and pro-
apoptotic effects, the precise mechanisms of action are not fully understood [94]. The 
widespread mechanisms leading to its actions include the inhibition of inflammatory cascades 
and reactions involved in cell growth and proliferation, such as the COX pathways (COX-1 
and COX-2) which regulate cell proliferation through the formation of prostaglandins; 
enase pathway; direct DNA stabilizing effects; the transcription factor NFκB, 
responsible for the subsequent expression of pro-inflammatory molecules; MAPKs and the 
Bcl-2 family, as well as the activation of apoptotic processes via caspase-3 signalling [94]. In 
addition, recently Rousseaux et al. demonstrated that the PPARγ receptor is the key receptor 
for mesalazine [34, 95]. The drug increased the expression of the receptor, promoted its 
translocation from the cytoplasm to the nucleus and induced a modification of its 
conformation permitting the recruitment of coactivators and the activation of a PPRE driven 
gene, thereby affecting the anti-inflammatory actions of the drug [34, 93, 95]. Activation of 
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PPARγ may also have anti-tumorogenic effects, which manifests as anti-proliferative, pro-
differentiation, and pro-apoptotic activities, inhibition of the formation of aberrant crypts foci 
and inhibition of the development of colon tumors [93]. Therefore it is possible that 
mesalazine also acts directly as a PPARγ ligand to suppress tumor formation, rather than 
directly by suppressing inflammation. 
 
2.4.2  Dietary Histone Deacetylase inhibitors  
2.4.2.1  Butyrate 
 
Butyrate (butyric acid) [Figure 12], a SCFA and normal constituent of the colonic luminal 
content, is formed by anaerobic bacterial fermentation of undigested carbohydrates and 
dietary fibre in the colon, where it is present at millimolar concentrations [96]. Besides its role 
as the major energy source for the colonocyte, there is increasing evidence that butyrate also 
proliferation of neoplastic colonocytes in vitro and in vivo ( butyrate paradox) [96]. In 
on of cell cycle arrest and apoptosis, through interaction with the caspase 
signalli
acts as a critical factor in the physiological turnover of the colonic epithelium [96, 97]. 
Although butyrate increases proliferation of normal colonic epithelium, it decreases 
addition, roles of butyrate have been established for cell differentiation, morphology, motility, 
as well as inducti
ng cascade [96, 98, 99]. Moreover, butyrate exerts immune-modulatory effects and 
anti-inflammatory properties in the gastrointestinal tract, i.e. several studies have 
demonstrated that butyrate stimulates the release of the APs cathelicidin and β-defensin-2 and 
influences cytokine-activated gene expression in colonic epithelial cells via inhibition of 
NFκB signalling [100-104]. 
Although human data are still inconsistent, at least in rodents, evidence has been 
provided that alimentary fibres exert a protective role with regard to colorectal carcinogenesis 
[105, 106]. The benefits of a high intake of dietary fibre can be attributed to their fermentation 
in the colonic lumen [96]. In addition, deficiencies in luminal butyrate production have been 
linked to chronic bowel inflammation, such as diversion colitis and pseudomembranous 
colitis [96, 107, 108]. Moreover, a series of experimental results corroborates the role of 
butyrate in the pathogenesis of UC [96]. It has been postulated that UC is due to either 
exogenous or endogenous starvational factors limiting fatty acid oxidation in colonocytes; the 
latter is maybe associated with a mucosal defect [96].  
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Figure 12: Ch
 
emical structure of butyric acid 
lium are mainly relied due to its 
function as a HDAC inhibitor, opening the chromatin structure of the DNA, thereby possibly 
enhancing the transcriptional activity of several genes [Figure 13] [96, 109]. Moreover, 
utyrate has been revealed both to phosphorylate and to methylate DNA-histone complexes, 
 
Mechanisms of butyrate affecting the colonic epithe
b
to influence the expression of various oncogenes (c-myc, c-myb, c-ras), and to reduce 
urokinase activity [96]. Additionally, several studies have demonstrated that butyrate up-
regulates and activates the nuclear hormone receptors, PPARγ and VDR, in colonic epithelial 
cells, indicating the possible involvement of both receptors in butyrate-mediated actions on 
the colonic epithelium [42, 69, 70].  
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Figure 13: Possible working mechanism for dietary HDAC inhibitors like butyrate. HDAC/co-repressor 
complexes maintain a tightly restricted chromatin configuration, which limits access of transcription factors to 
DNA, and the repression of genes. HDAC inhibition by dietary agents enables histone 
acetyltransferase/coactivator (HAT/CoA) complexes to add acetyl groups to histone tails, loosening 
DNA/chromatin interactions, and allowing access of transcription factors to the promoters of genes. [depicted 
modified from [109]] 
 
2.4.2.2  Sulforaphane 
 
Sulforaphane (SFN, [1-isothiocyanato-4-(methyl-sulfinyl)butane]) is one of the most 
promising dietary chemopreventive agents and is present at high concentrations in some 
cruciferous vegetables, especially broccoli, broccoli sprouts, cauliflower and cabbage 
(Brassica oleracea) [98, 110, 111]. SFN is an isothiocyanate derived from hydrolysis of the 
glucosinolate glucoraphanin [Figure 14] [110]. The hydrolytic reaction is catalyzed by the 
endogenous myrosinase which is related by disruption of the plant during harvesting, 
processing, or chewing [110, 111]. The mercapturic acid pathway then concerts SFN 
sequentially to the metabolites SFN-glutathione, SFN-cysteine, SFN-N-acetylcysteine [112]. 
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Figure 14: Enzymatic conversion of glucoraphanin to sulforaphane. [adapted from [110]] 
 
SFN has received a great deal of attention because of its ability to simultaneously 
modulate multiple targets involved in cellular protection, including DNA protection by 
ith the actions of the transcription factor NFκB, modulating the production of pro- and anti-
inflammatory cytokines, and by interacting with the COX system [113, 114]. The exact 
molecula se regulations are not entirely clear. The chemopreventive 
ffects of SFN, similar to butyrate (see 2.4.1), may be achieved mainly through its function as 
inducing carcinogen-metabolising enzymes of Phase II and by blocking the action of 
mutagens [111]. Moreover, in human CRC cells, SFN has been reported to be involved in the 
inhibition of cell proliferation, tumor progression, and neoangiogenesis as well as in the 
initiation of cell growth arrest and apoptosis [98, 111]. In addition, several studies indicate 
that SFN also exhibits immune-modulatory and anti-inflammatory capacities by interfering 
w
r mechanisms behind the
e
a HDAC inhibitor by altering histone structures including acetylation, methylation, 
phosphorylation, ubiquination and biotinylation [109, 112]. This results in chromatin 
relaxation and increased transcription of target genes [109, 112]. A recent study demonstrated 
that direct application of SFN parent compound and SFN-glutathione to nuclear extracts in 
vitro did not effect on HDAC activity, whereas SFN-cysteine and SFN-N-acetylcysteine 
attenuated HDAC activity significantly, indicating that incubation with cells is necessary to 
allow for metabolism [112].  
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2.5  Targets for nuclear hormone receptors involved in inflammation 
and cell cycling 
 
In the following chapter, basics of the caspase cascade, of APs and of NFκB signalling are 
described. Within the scope of this thesis, the interaction of butyrate, mesalazine and SFN 
with these signalling pathways and molecules was scrutinized. Moreover, the putative role of 
the nuclear hormone receptors PPARγ and VDR involved in these regulatory mechanisms 
was elucidated. 
 
2.5.
 
Apop
amily and is engaged in response to cytokines, especially of the 
NF family, and extracellular signals, leading to activation of caspase-8 [115]. The intrinsic 
or mitochondrial pathway is activated in response to intracellular signals and cytotoxic insults 
at the level of mitochondria [115]. After activation by an apoptotic stimulus, mitochondria 
1  The caspase cascade  
tosis is a physiological suicide program that is critical for the development of healthy 
tissues [115]. Dysregulation of cell death pathways leading to increased cellular growth and 
decreased death occurs e.g. in autoimmune and immunodeficiency diseases, reperfusion 
injury after ischemic episodes, in neurodegenerative disorders and in several types of cancer, 
in particular CRC [115]. Although over the past years major advances have increased the 
understanding of the molecular mechanisms triggering apoptosis, the regulation of apoptotic 
cell death has yet not been fully uncovered. Major pathways of apoptosis include the caspase-, 
proteasome- and the autophagic-induced cell death, which frequently occur in parallel or in 
cross-talk [115-117]. Among these, the caspase cascade pathway is the best characterized one 
[Figure 15]. One key endpoint represents caspase-3, a member of the cysteine aspartyl-
specific protease (caspase) family, specifically involved in the initiation and execution of the 
apoptotic program [115]. Caspase-3 is a downstream effector caspase which is activated by 
upstream caspases, predominantly caspase-8 and -9. Activation of caspase-3 then leads to 
cleavage of cellular substrates, e.g. poly(ADP-ribose) polymerase (PARP), DNA 
fragmentation factor (DFF) and disassembling of the cell [115]. Two pathways operate as 
sensors for caspase-3 activation and can stimulate the cellular death program of apoptosis. 
The extrinsic or death receptor-mediated pathway involves members of the tumor-necrosis-
factor receptor (TNFR) superf
T
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Figure 15: The caspase cascade. Activation of the caspase cascade can be suppressed by the inhibitor of 
apoptosis proteins (IAPs) Survivin and Xiap. See text for further explanations. [adapted from [118]] 
 
releases cytochrome c into the cytosol, where it binds to the apoptotic protease activating 
factor-I (Apaf-1) to form the apoptosome. At the apoptosome, the initiator caspase-9 is then 
activated [115]. However, cross-talk between the death receptor-mediated pathway and the 
mitochondrial pathway has been described [115]. Besides the prototypic caspase-dependent 
apoptosis pathways, there are also molecular less-well defined cell death pathways that do not 
require caspase activation. These pathways share some, but not all, the characteristics of
apoptotic classical pathways [115].   
The balance between apoptotic and anti-apoptotic proteins plays an important role in 
determining the response of cancer cells to chemotherapeutic agents [119]. Various proteins 
regulate the apoptotic process at different levels, e.g. the FLICE-inhibitory protein (FLIP) has 
been shown to interfere with the initiation of apoptosis directly at the level of death receptors 
[115]. Moreover, death initiated at the mitochondrial level is regulated by the members of the 
Bcl-2 family which can be divided into anti-apoptotic and pro-apoptotic proteins [115]. The 
family of the inhibitor of apoptosis proteins (IAP), i.e. Survivin and X linked inhibitor of 
apoptosis (Xiap), is a recently identified, novel category of apoptosis-regulatory proteins 
[120]. IAPs can inhibit the activation of caspases by both the extrinsic and intrinsic pathway 
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[120]. IAPs may thereby set the threshold for apoptosis-activation and play a key role in the 
regulation of apoptotic cell death. 
 
2.5.2  Antimicrobial peptides 
2.5.2.1  Fundamentals 
 
Antimicrobial peptides (APs) are endogenous antibiotic effector molecules of the innate 
immune system [121, 122]. In mammals, they are mainly expressed in the epithelia and in 
blood cells. In the past few years, different lines of investigations have implicated a central 
role of APs in gastrointestinal infections and inflammatory diseases [122, 123]. APs are small 
polypeptides of less than 50 amino acid residues, with the ability to directly kill Gram-
gle amino 
acid substitutions can affect the activity [126]. The net charge of nearly all APs is positive, 
ells [130]. In addition, 28 β-defensin genes have been 
identifi
positive and Gram-negative bacteria as well as fungi and viruses [124]. In addition, these 
peptides modify the local inflammatory response and activate mechanisms of cellular and 
adaptive immunity [125]. The activity spectrum is unique for every peptide and sin
and therefore they are often designated cationic APs. The tertiary structures of the peptides 
are diverse. However, they have an amphiphilic character in common [127]. 
The two main families of APs expressed in mammals are defensins and cathelicidins 
[124]. The defensins are characterised by three disulphide bonds, while the cathelicidin family 
is characterised by a conserved prepro-region [128, 129]. The defensins are subdivided into α, 
β and γ defensins. Four human β-defensin (HBD 1-4) peptides have been characterised. They 
are mainly expressed in epithelial c
ed in the human genome [131]. On the other hand, only one human member of the 
cathelicidin family has been identified, namely LL-37 [132]. The name hCAP18 is often used 
when referring to its proform [132]. The APs known to be produced by the colonic epithelium 
are LL-37 and the β-defensins HBD-1 and HBD-2, contributing to the regulation of the 
intestinal balance [121]. Both LL-37 and HBD-1 are constitutively expressed, while HBD-2 is 
induced during inflammation by pro-inflammatory stimuli [133]. There is increasing 
evidence, that the expression of LL-37 and HBD-2 in the colon is modulated by SCFAs [100, 
104]. 
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2.5.2.2  Mechanisms of antimicrobial activity 
 
APs are mainly membrane active and lyse the target by disrupting the integrity of the 
membr irable features of a novel antibiotic class [134]. In 
particular, they have a broad spectrum of activity, kill bacteria rapidly, are unaffected by 
classical ons, do not easily select antibiotic resistant variants, show 
ynergy with classical antibiotics and neutralize endotoxin [135]. 
gatively charged 
membr
ane. They exhibit many of the des
 antibiotic resistance mutati
s
Several models explaining the mode of action of APs have been proposed, of which 
the barrel-stave pore, toroidal pore, and the carpet model are well established [Figure 16] 
[127]. In the barrel-stave pore model the peptides transverse the membrane with the 
hydrophobic surfaces directed towards the lipid membrane and the hydrophilic surfaces 
inwards forming a pore allowing water and electrolyte leakage [127]. The killing mechanism 
of the toroidal pore model is similar to the barrel-stave pore model. In this model, the peptides 
are suggested to aggregate and induce the lipid monolayers to bend continuously through the 
pore, causing the lipid head groups to be directed towards the water core [127]. In the third 
mechanism, the carpet model, bacterial membrane surface is covered with APs after an 
electrostatic interaction, and the membrane is disrupted in a detergent-like manner [127].  
Caused by their positive charge, APs are more attracted to the ne
anes of bacteria than to the neutral mammalian membranes [136]. This difference in 
the membrane charge is due to a higher level of acidic phospholipids in the bacterial 
membranes, while the eukaryotic membranes have more cholesterol and bipolar 
phospholipids facing the extracellular room [136]. Moreover, these acidic phospholipids are 
positioned at the cytoplasmatic side [136]. Besides the initiation of transmembrane pores, 
there is increasing evidence that APs have other intracellular targets regulating microbial 
killing. Proposed mechanisms include the alteration of cytoplasmatic membrane septure 
formation as well as the inhibition of cell-wall biosynthesis, nucleic-acid synthesis, protein 
synthesis or enzymatic activity [127]. Moreover, non-membrane external targets such as 
autolysis and phospholipases are activated by APs [127]. 
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Figure 16: Mechanisms of action of APs. (A) Barrel-stave pore model of AP-induced killing. (B) Toroidal pore 
of AP-induced killing model. (C) Carpet model of AP-induced killing. [modified from [127]] 
 
2.5.2.3  Additional functions of antimicrobial peptides 
 
Aside from being able to directly kill or inhibit growth of microorganisms, APs exert 
multifunctional roles in the immune system. They have been shown to chemo-attract cells of 
both the innate and adaptive immune system, thereby forming a link between these two 
systems [137]. APs exhibit immune-modulatory properties, such as modulating differentiation 
and enhancing the endocytic capacity of dendritic cells, up-regulating the expression of 
chemokines in epithelial cells and macrophages, neutralising lipopolysaccharides (LPS) 
bioactivity, thereby protecting against endotoxic shock, increasing phagocytosis, inducing 
mast cell degradation, regulating the complement system, stimulating angiogenesis and 
playing part in the re-epithelisation in wounds [121, 138-140]. Moreover, they seem to be 
involved in anti-tumor and mitogen activity, or they may act as signalling molecules [141]. 
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2.5.3  The nuclear factor NFκB 
 
NFκB is an ubiquitously expressed family of transcription factors holding a central role in the 
inducible expression of a high number of genes involved in inflammation, host defence, cell 
survival, proliferation and thus also tumorigenesis [24, 142]. The transcription factor is 
triggered by pro-inflammatory stimuli and genotoxic stress, including cytokines such as 
TNFα and IL-1, bacterial cell-wall components such as LPS, viruses, and DNA-damaging 
agents [24]. Increased NFκB activation is not only associated with IBD, but also with CRC 
[142]. CRC cell lines, as well as nuclei of stromal macrophages in sporadic adenomatous 
polyps, were found to have elevated NFκB activity [24, 142]. NFκB inhibitors might, 
therefore be useful in treating both human diseases [142]. The NFκB family consists of five 
 cytoplasm of 
nstimulated cells and must be translocated into the nucleus to function [24, 142]. The 
subcellul teins called IκBs [24, 
ost important regulators of mammalian NFκB is IκBα. When IκBα binds 
le 
acetylation e.g. protein kinase A (PKA)-mediated phosphorylation of p65 has been shown to 
be important for its transcriptional activity [143]. 
 
different proteins (p50 (NFκB1), p52 (NFκB2), p65 (RelA), RelB and c-Rel) which tend to 
dimerize [24, 142]. The majority of NFκB dimers is composed of the p65 and the p50 or p52 
subunits [24, 142]. In resting conditions, NFκB is sequestered in the
u
ar location of NFκB is controlled by a family of inhibitory pro
142]. One of the m
to the p50/p65 heterodimer complex, it maintains the heterodimer in the cytoplasm and 
prevents activation of NFκB target gene transcription [Figure 17] [24, 142]. In response to 
cell stimulation, IκBα kinase (IKK) is activated and phosphorylates IκBα on two serine 
residues leading to polyubiquitination and 26S proteasome-mediated degradation [24, 142]. 
Degradation of IκBα allows a rapid and transient translocation of NFκB to the nucleus, where 
it activates transcription from a wide variety of promoters, including that of its own inhibitor 
IκBα. The newly synthesized IκBα enters the nucleus and removes NFκB from its DNA-
binding sites and transports it back to the cytoplasm, thereby terminating NFκB dependent 
transcription [24, 142]. In addition, there is accumulating evidence that the activity of NFκB 
is regulated by direct modification of NFκB proteins through phosphorylation and possib
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Figure 17: NFκB activation. Various stimuli induce transcription of NFκB target genes by facilitating nuclear 
import of NFκB and binding to cognate DNA sites. In unstimulated cells, p50/p65 is inhibited by IκB.
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3  Aim of the present investigations 
 
Due to increasing relevance of the nuclear hormone receptor PPARγ in the therapy of CRC 
and IBD, the major purpose of the studies presented in this thesis has been to reveal roles for 
the receptor in the pro-apoptotic, immune-modulatory and anti-inflammatory actions caused 
by butyrate, mesalazine and SFN in colonic epithelium cells. The specific aims have been: 
 
Paper I: Butyrate is known to exert pro-apoptotic effects in CRC cells by inducing 
apoptosis via caspase-3 signalling [144, 145]. However, little is known with respect to 
the underlying events participating in this regulation. There is increasing evidence 
supporting the role of PPARγ as a key player in the induction of cellular apoptosis. 
PPARγ does not only control the expression of genes involved in differentiation, but 
also modulates cell cycling [50, 51]. In addition, recent reports indicate that the pro-
CRC cells [42, 146]. On the basis of the current findings, this study addressed the 
potential role of PPARγ in the regulation of caspase-3 activation caused by 
butyrate in Caco-2 cells. The second aim was to point out the involvement of the 
mitogen-activated protein kinase kinase/extracellular-regulated kinase (MEK-
ERK) signalling pathway in butyrate-mediated up-regulation of PPARγ 
expression and caspase-3 activity. 
 
Paper II: Mesalazine has been demonstrated to reduce the development of CRC in 
patients suffering from IBD by decreasing cell proliferation and inducing apoptosis 
[90, 147]. However the mechanisms of these chemopreventive actions are not yet 
completely elucidated. Moreover, mesalazine has been recently identified to modulate 
the activity and expression of PPARγ in vitro and in vivo, thereby exerting its anti-
inflammatory effects in the colon [40, 93]. Based on the observations in Paper I, the 
present study was addressed to investigate the possible role of PPARγ in 
mesalazine-induced pro-apoptotic effects in CRC cells along the caspase 
apoptotic action of PPARγ is dependent on caspase-3 activation [56, 58]. Besides 
revealing that the expression of PPARγ is under control of butyrate, our group could 
demonstrate that the receptor is also involved in butyrate-induced growth inhibition of 
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signalling pathway. Moreover, the involvement of PPARγ in the alteration of cell 
se to mesalazine was investigated. 
 
D, 
characterized by breakdown of colon epithelial barrier function [148]. The capacity of 
κB pathway is still lacking. There is increasing 
vidence that PPARγ and VDR are under control of butyrate implying that the 
cycle distribution and cell growth in respon
Paper III and Paper IV: The APs human β-defensin-2 (HBD-2) and cathelicidin 
hCAP18 (LL-37) are molecules of the innate immune system located at epithelial 
surfaces in particular at the surface of the gastrointestinal mucosa [124, 128]. APs 
influence microbial growth and inflammation and may play a role in IB
butyrate to induce HBD-2 and LL-37 in CRC cells has been demonstrated in several 
studies [101, 104]. However the underlying molecular mechanisms are rarely 
understood.  The intention of this study was to determine the role of several 
pathways, e.g. MEK-ERK signalling, and of the two nuclear hormone receptors 
PPARγ and VDR in butyrate-mediated induction of both APs in CRC cells. 
Moreover, in Paper IV, the influence of the dietary HDAC inhibitor SFN on 
HBD-2 expression and signalling was investigated.    
 
Paper V: High levels of circulating and mucosal pro-inflammatory cytokines resulting 
from increased NFκB activity have been reported in the intestinal mucosa of patients 
suffering from IBD [149-151]. Modulating NFκB signalling may therefore be an 
interesting target to suppress inflammation and the development of cancer in IBD. 
Several studies have demonstrated that butyrate antagonises inducible NFκB 
signalling in colonocytes [103, 152, 153]. However, comprehensive knowledge by 
which butyrate interacts with the NF
e
receptors may participate in butyrate-mediated suppression of NFκB activation [42, 
69, 70]. The aim of this study was to elucidate the putative role of both nuclear 
receptors in butyrate-mediated inhibition of inducible NFκB activation. 
Moreover, the involvement of the receptors in basal NFκB signalling was studied. 
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The following CRC cell lines have been used: 
ell line 
 
Paper 
 
 
C
   
 
Caco-2 (COX-1 non-expressing) 
 
 
I-IV 
HT-29 (mutant p53
R273H, COX-2 non-expressing)  II-V 
 (hMLH1 mutant, WT p53) 
gative PPARγ and empty-vector Caco-2 cells   
ative PPARγ and empty-vector HT-29 cells  , V 
 
 
 
HCT-116
 
II 
SW480 (mutant p53/Arg
273His) 
 
IV 
Transfected dominant-ne
 
I-III
Transfected dominant-neg II, IV
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5  Summary of the Results 
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5.1  Paper I: PPARγ is a key target of butyrate-induced caspase-3 
activation in the colorectal cancer cell line Caco-2 
utyrate exerts pro-apoptotic effects 
y inducing apoptosis via activation of caspase-3 [144, 145]. However, the mechanisms by 
azone induce apoptosis via activating caspase-3 [56, 154]. The objective of the study 
as to investigate a possible role of PPARγ in butyrate-induced caspase-3 activity along the 
esults: Challenge of Caco-2 wild-type cells with butyrate (3 mM) resulted in a time-
 elevated up 
 1.5-fold after 48 h of treatment. Moreover, increased caspase-3 activity (2.2-fold) was 
ation of 
ells with butyrate (3 mM) resulted in increased expression of phospho-p38 MAPK (1.6-fold) 
fter 24 h, while p38 MAPK was not affected. Moreover, the expression of ERK1/2 and 
hospho-ERK1/2 was unchanged in response to butyrate treatment. In order to determine the 
involvement of any MAPK in butyrate-induced PPARγ expression and caspase-3 activation, 
specific MAPK inhibitors, the p38 MAPK inhibitor SB203580 and the ERK1/2 inhibitor 
PD98059 were employed. Pre-incubation of Caco-2 wild-type cells with the p38 MAPK 
inhibitor SB203580 (20 μM) for 12 h, followed by stimulation of cells with butyrate for 
 
Background and rationale: Butyrate belongs to a promising new class of chemopreventive 
agents in CRC. Several studies have demonstrated that b
b
which butyrate modulates the caspase cascade are not fully understood. Recently our group 
not only elucidated the capacity of butyrate to up-regulate PPARγ, but also demonstrated the 
involvement of the receptor in butyrate-mediated inhibition of cell growth in the CRC cell 
line Caco-2 [42, 146]. Moreover, several studies indicate that PPARγ agonists like 
troglit
w
caspase cascade in Caco-2 cells. In this context, the involvement of the MEK-ERK signalling 
pathway in butyrate-mediated elevation of PPARγ expression and caspase-3 activity was 
studied. 
 
R
dependent increase of PPARγ mRNA expression. Initial effects were observed after 24 h and 
were boosted up to 1.7-fold after 48 h of treatment. Up-regulation of PPARγ mRNA was 
followed by transient changes on the protein level. PPARγ protein expression was
to
observed after stimulation of cells with butyrate for 24 h. 
To elucidate the role of MEK-ERK signalling in butyrate-induced caspase-3 activity 
and PPARγ expression, the effect of butyrate on p38 MAPK / phospho-p38 MAPK and 
ERK1/2 / phospho-ERK1/2 levels in Caco-2 wild-type cells was examined. Stimul
c
a
p
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additional 48 h, resulted in a 
PPAR
ERK1/2 inh d up-regulation of 
PARγ expression at any time. To corroborate the findings of a signalling link between p38 
iap and Survivin were further examined. Both caspase-8 (1.3-fold) and -9 (1.8-fold) 
ctivities were increased after incubation of cells with butyrate for 24 h, while the expression 
0, described to be a specific target 
gene o
 
significant inhibition of both butyrate-induced up-regulation of 
γ mRNA as well as protein expression. In contrast, the combination of butyrate and the 
ibitor PD98059 (40 μM) did not influence butyrate-mediate
P
MAPK and PPARγ, Caco-2 cells were treated with arsenite (50 μM), a direct stimulator of 
p38 MAPK [155]. Arsenite treatment resulted in a time-dependent augmentation of PPARγ 
protein expression (6 h: 1.4-fold, 24 h: 2.4-fold), indicating the participation of p38 MAPK in 
butyrate-mediated up-regulation of PPARγ expression. Similar to the increase of PPARγ, the 
involvement of both MAPK signalling pathways in butyrate-mediated activation of caspase-3 
activity was examined. Incubation with the p38 MAPK inhibitor resulted in a significant 
inhibition of elevated caspase-3 activity caused by butyrate (−63%). Again, the specific 
ERK1/2 inhibitor PD98059 had no impact on the induction of caspase-3 activity caused by 
butyrate.  
Revealing the transduction pathway leading to increased caspase-3 activity in response 
to butyrate, caspase-8 and -9 activities as well as the expression of the inhibitor of apoptosis 
proteins X
a
of Xiap (−59%) and Survivin (−68%) was reduced simultaneously. In order to identify a 
possible role of PPARγ in butyrate-mediated apoptosis, above scrutinized pro- and anti-
apoptotic markers were also analysed in Caco-2 cells transfected with a dominant-negative 
PPARγ mutant to inhibit wild-type receptor action. For this purpose, at first, PPARγ receptor 
activity in Caco-2 wild-type, empty-vector and dominant-negative PPARγ mutant cells was 
evaluated by determining the expression of cytokeratin 2
f PPARγ  activity in CRC cells [37]. A time-dependent increase of cytokeratin 20 
caused by butyrate could be observed in wild-type and empty-vector cells (2.0-fold, 48 h). As 
expected, cytokeratin 20 was not expressed in both unstimulated and even butyrate challenged 
dominant-negative PPARγ mutant cells, indicating not only that butyrate is able to increase 
PPARγ receptor activity but also demonstrating the functional successful transfection of the 
cell system. In dominant-negative PPARγ Caco-2 cells, butyrate-mediated increased caspase-
3, -8 and -9 activities were almost completely abolished compared to wild-type and empty-
vector cells after 24 h, and down-regulation of Xiap and Survivin expression was significantly 
reduced. 
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Except for the western blot for p38 / phospho-p38 MAPK and ERK1/2 / phospho-ERK1/2 
expression (Figure 1 in Paper I) and transfection of dominant-negative PPARγ and empty-
vector cells, all experiments and results of Paper I were performed by the author of this 
thesis. Above mentioned blots were performed by Nadine Zahn. Transfected cells were 
kindly provided by Sandra Ulrich. Moreover, interpretation and presentation of findings, 
including graphic display of results as well as writing of the scientific manuscript was 
performed by the author of this thesis. 
 
5.2  Paper II: PPARγ is a key target of mesalazine-mediated inhibition 
of cell growth and induction of apoptosis in colon cancer cells 
 
Background and rationale: Recent data identified PPARγ as a target of mesalazine’s anti-
inflamm
e increased the expression of cytokeratin 20 up to 1.4-fold in Caco-2 wild-type and 
mpty-vector cells, while in dominant-negative PPARγ mutant cells the expression of 
atory effects on the colon [34, 40]. Moreover, mesalazine has been recognized as a 
candidate chemopreventive agent in CRC prophylaxis for its pro-apoptotic effects [93, 156]. 
However, the precise mechanisms of these actions are not fully understood. In analogy to 
Paper I, the aims of this study were to investigate the participation of PPARγ in mesalazine’s 
anti-carcinogenic actions in colonocytes along the caspase signalling pathway. In addition, the 
role of the receptor in mesalazine-mediated growth-inhibitory abilities was investigated. 
 
Results: Caco-2, HT-29 and HCT-116 cells were treated with increasing concentrations of 
mesalazine (10-50 mM) for 24, 48 and 72 h. Mesalazine provoked a significant time- and 
dose-dependent decrease in both cell growth and proliferation for all time points at doses of 
10 mM and higher. To establish whether mesalazine also leads to changes in cell cycle 
progression, HT-29 and HCT-116 cells were cultured in presence of the drug (40 mM) for 24 
and 48 h and cell cycle distribution was analysed by flow cytometry. All cell lines showed 
changes in the cell cycle profile within 48 h, with an apparent increase in the number of cells 
in the G0/G1 phase. 
To establish whether mesalazine affects PPARγ signalling, PPARγ protein expression 
and activity was studied. Stimulation of HT-29 cells with mesalazine (30-50 mM) led to a 
time-dependent up-regulation of PPARγ protein expression. In analogy to Paper I, here, 
mesalazin
e
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cytokeratin 20 was not affected. Comparable effects were obtained for direct determination of 
PPARγ transcriptional activity in HT-29 cells. 
In order to investigate the role of PPARγ in mesalazine-induced inhibition of cell 
proliferation and changes in cell cycle distribution, the effect of the drug was studied in 
dominant-negative PPARγ Caco-2 and HT-29 mutant CRC cells. Mesalazine (50 mM) 
treatment led to a significant decrease in cell proliferation in both wild-type and empty-vector 
cells after 72 h of treatment. In the dominant-negative mutant cell lines, the decrease in cell 
roliferation was partially neutralized compared to wild-type and empty-vector cells. In 
dominant-negative PPARγ HT-29 cells, change in cell cycle distribution in response to 
mesal  
compared to
To study further molecular mechanisms responsible for mesalazine’s growth-
ation 
rough cell-cycle arrest in the G0/G1 phase and to induce apoptosis via the caspase cascade 
LISA. Mesalazine (30 mM) increased the expression of activated PARP 
(2.2-fo
In both cell lines, mesalazine-mediated increased expressions of activated PARP, caspase-3 as 
p
azine (40 mM) was partially reversed. Nevertheless, statistical significant effects 
 the wild-type were not reached.  
inhibitory effects, expressions of the oncoprotein c-myc and of the tumor suppressor gene 
PTEN after incubation with the drug were determined. c-myc is known to modulate a variety 
of biological activities including cellular proliferation and cell growth [157]. After stimulation 
of HT-29 cells with mesalazine (40 mM) for 4 h, the expression of c-myc was decreased in a 
PPARγ-independent mechanism. On the other hand, treatment of HT-29 wild-type and empty-
vector cells with mesalazine (40 mM) up to 8 h provoked a significant increase in the 
expression of the tumor suppressor gene PTEN, well-established to decrease cell prolifer
th
[158, 159]. In dominant-negative PPARγ HT-29 cells, expression of PTEN in response to 
mesalazine was unchanged, suggesting that the tumor suppressor gene takes part in 
mesalazine-mediated PPARγ-dependent growth-inhibitory and pro-apoptotic actions.  
To unravel whether growth inhibition and changes in cell cycle distribution in 
response to mesalazine were accompanied by a modification of the caspase cascade, the pro-
apoptotic markers PARP, caspase-8, caspase-9 as well as the anti-apoptotic proteins Survivin 
and Xiap were examined by western blot analysis in Caco-2 cells. Direct caspase-3 activity 
was determined by E
ld), caspase-3 (1.4-fold) and caspase-8 (1.5-fold) after incubation of cells for 48 h, 
whereas the expression of Xiap (−32%) and Survivin (−22%) was decreased simultaneously. 
In contrast, no influence on the expression of activated caspase-9 could be observed. Similar 
results were obtained in the CRC cell line HT-29. In order to scrutinize any involvement of 
PPARγ, experiments were performed in dominant-negative PPARγ Caco-2 and HT-29 cells. 
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well as the down-regulation of Survivin and Xiap were almost reversed. Moreover, cleavage 
of caspase-8 could not be observed in dominant-negative Caco-2 cells in response to 
mesala
 II:
zine treatment. 
 
All experiments and results, published in this manuscript, were performed by the author of 
this thesis. Transfected cells were provided by Stefan Loitsch. Moreover, interpretation and 
presentation of findings, including graphic display of results as well as writing of the 
scientific manuscript was performed by the author of this thesis. 
 
5.3  Additional results to Paper  Enhanced anti-proliferative and 
e anti-
prolifer
pro-apoptotic effects of mesalazine and butyrate in the colorectal 
cancer cell line Caco-2 
 
Except for determining the role of PPARγ in mesalazine-mediated anti-carcinogenic actions 
[Paper II], it was further examined whether mesalazine and butyrate exert synergistic effects 
in regard to growth inhibition and apoptosis in Caco-2 cells: 
 
Mesalazine and butyrate act additive on the inhibition of cell count and cell proliferation 
 
Cells were challenged with mesalazine (30 mM), butyrate (3 mM) or the combination of both 
substances for 24, 48 or 72 h. Both mesalazine, butyrate and their combination resulted in a 
time-dependent decrease of cell count and proliferation. Figure 18 demonstrates th
ative effect of Caco-2 cells in response to mesalazine (−19%, p < 0.001) and butyrate 
(−32%, p < 0.001) after 72 h. Co-incubation of both substances had an additive effect on the 
inhibition of cell proliferation (−48%, p < 0.001). Similar effects could be observed after 24 
and 48 h of treatment and the same tendency was seen for cell counts. 
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Figure 18: Additional results to Paper II. Cell proliferation measurement for Caco-2 wild-type cells after 
cubation with mesalazine (30 mM), butyrate (3 mM) or co-incubation of both substances for 72 h compared to 
dditive effect on cleavage of PARP and caspase-8 caused by co-incubation of mesalazine 
, p < 0.01). In contrast, 
o cleavage of caspase-9 was observed [Figure 19 B]. Co-incubation of mesalazine with 
butyrate increased cleavage of caspase-8 (3.2-fold, p < 0.001, Figure 19 C) and also induced 
cleavage of caspase-9 [Figure 19 B]. 
 
in
control level. n = 8, ***p < 0.001. Bromodeoxyuridine (BrdU) test and statistics was performed as described in 
Paper II. 
 
A
and butyrate 
 
Challenge of Caco-2 cells with mesalazine (30 mM) and butyrate (3 mM) resulted in an 
increase of cleaved PARP (Figure 19 A, butyrate: 7.9-fold, mesalazine: 3.2-fold) after 48 h. 
Co-incubation of both substances led to an additive effect and up-regulated cleaved PARP 
protein levels up to 10.5-fold [Figure 19 A]. To further unravel the responsible elements in 
the caspase pathway leading to increased cleavage of PARP, cleavage of caspase-8 and -9 
were examined [Figure 19 B, C]. As shown in Figure 19 C, incubation with mesalazine (30 
mM) for 48 h led to elevated cleavage of caspase-8 (1.5-fold of control
n
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Figure 19: Additional results to Paper II. (A) Effect of mesalazine (30 mM), butyrate (3 mM) or the 
combination of both drugs on cleaved PARP protein expression after 48 h of treatment in Caco-2 wild-type cells. 
he band at 89 kDa corresponds to the cleaved PARP protein. Densitometric data are corrected for β-actin 
(30 mM), butyrate (3 mM) or the co-incubation of mesalazine with butyrate in Caco-2 wild-type 
48 h. Western-blotting and statistics was performed as described in Paper II. 
T
levels. ***p < 0.001 (B,C) Western Blot for cleaved caspase-9 (B) and cleaved caspase-8 (C) after treatment 
with mesalazine 
cells for 
 
Synergistic effect of mesalazine and butyrate on the attenuation of the inhibitor of 
apoptosis protein Survivin 
 
To specify the molecular mechanism of mesalazine-induced apoptosis, changes in Xiap 
[Figure 20  A] and Survivin [Figure 20  B] were examined. Levels of both proteins were 
reduced in Caco-2 wild-type cells in response to mesalazine (50 and 30 mM) and butyrate (3 
mM). The decrease in Survivin [Figure 20 B] was even more pronounced after co-incubation 
with butyrate, whereas no cumulative effect on the down-regulation of Xiap was observed 
[Figure 20 A].  
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ll experiments and results, in this additional part of Paper II, were performed by the 
as performed by the author of this thesis. 
Figure 20: Additional results to Paper II. Xiap (A) and Survivin (B) expression in response to mesalazine (30 
mM), butyrate (3 mM) or the combination of both drugs in Caco-2 wild-type cells after 48 h of treatment. One 
representative western blot of three independent experiments is shown. Densitometric data are corrected for β-
actin levels. ***p < 0.001, **p < 0.01, **p < 0.05. Western-blotting and statistics was performed as described in 
Paper II. 
 
A
author of this thesis. Moreover, interpretation and presentation of findings, including 
graphic display of results w
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5.4  Paper III: Role of nuclear hormone receptors in butyrate-
mediated up-regulation of the antimicrobial peptide cathelicidin 
in epithelial colorectal cells                    
                            
Paper IV: The dietary histone deacetylase inhibitor sulforaphane 
induces human beta defensin-2 in intestinal epithelial cells   
 
Background and rationale: APs like human β-defensin-2 (HBD-2) and cathelicidin hCAP18 
(LL-37) play an important role in the non-specific immune system protecting the intestinal 
mucosa against bacterial invasion [124, 128]. Recent studies have demonstrated that butyrate 
induces HBD-2 and LL-37 in colonic epithelial cells [101, 104]. However the precise 
aper III + IV]. Similar 
sults were observed after incubation of colonocytes with SFN (1-20 µM) [Paper IV + 
Figure 21]. 
underlying molecular mechanisms have not yet been elucidated. The objective of this study 
was to investigate several pathways, e.g. the MEK-ERK signalling pathway, and the two 
nuclear hormone receptors PPARγ and VDR, involved in the up-regulation of both peptides in 
response to butyrate [Paper III + IV]. In addition, the influence of the dietary HDAC inhibitor 
SFN on HBD-2 expression and signalling was studied [Paper IV]. 
 
Results: Stimulation of the colorectal carcinoma cell lines Caco-2 and HT-29 with increasing 
concentrations of butyrate (1-5 mM) up to 48 h, resulted in a time-dependent up-regulation of 
both LL-37 and HBD-2 mRNA expression compared to control level [P
re
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Figure 21: Additional results to Paper IV. Dose-dependent effect of sulforaphane (1-20 µM) on LL-37 mRNA 
expression in HT-29 cells after 24 h of treatment. LL-37 mRNA expression was measured by semi-quantitative 
RT-PCR with the fluorescent dye Pico Green. All values for mRNA levels are normalized to corresponding 
mRNA amounts for Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). One representative gel of three 
independent experiments is shown. Induction of LL-37 mRNA is displayed as relative percentage to solvent 
treated control cells. ***p  < 0.001, n.s. = not significant. Semi-quantitative RT-PCR and statistics was 
performed as described in Paper III. 
 
Increased expression of HBD-2 mRNA was accompanied by a comparable up-
regulation on the protein level as measured by ELISA. HBD-2 protein levels were elevated by 
butyrate (3 mM) up to 2.6-fold and by SFN (20 µM) up to 2.0-fold after 48 h of exposure with 
the substances [Paper IV]. To further analyse the subcellular localisation of HBD-2 and LL-
37, Caco-2 cells were treated with butyrate (3 mM) up to 48 h and APs were detected via 
immunofluorescence analysis. Both control and butyrate-treated cells showed intense HBD-2 
and LL-37 staining mainly in the cytosol. Moreover, both peptides were increased in response 
to butyrate stimulation for 48 h [Paper III + IV]. 
To determine the potential role of the nuclear hormone receptors PPARγ and VDR in 
butyrate- and SFN-mediated up-regulation of LL-37 and HBD-2 mRNA expression, induction 
of mRNA levels were analysed in PPARγ dominant-negative cells to inhibit wild-type PPARγ 
function and by use of the specific VDR inhibitor ZK191732, respectively. In dominant-
negative PPARγ mutant Caco-2 cells, an equal time-dependent increase of LL-37 mRNA 
compared to wild-type cells was observed after stimulation with butyrate (2-3 mM) [Paper 
III]. Similarly, equivalent amount of augmented HBD-2 mRNA in dominant-negative PPARγ 
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Figure 22: Additional results to Paper IV. Western blot for PPARγ expression after treatment of Caco-2 cells 
with SFN (10-20 µM) for 24 h. One representative blot of three independent experiments is shown. Western-
blotting and statistics was performed as described in Paper I. 
and PPARγ expression in colonocytes in response to butyrate 
as been demonstrated recently [42, 69, 70]. To elucidate whether the receptors are also 
targets 
lls for 5 h with the two specific MEK-ERK 
inhibito
 
and wild-type HT-29 cells in response to butyrate (3 mM) or SFN (10 µM) was obtained 
[Paper IV]. In contrast, pre-incubation of Caco-2 cells with the VDR antagonist ZK191732 
(10 µM) for 5 h followed by stimulation with butyrate (3 mM) or SFN (10 μM) for 24 h, 
significantly reduced the induction of the APs on mRNA level, indicating the essential role of 
VDR in the signalling pathway. 
Up-regulation of VDR 
h
of SFN signalling, protein expression of VDR and PPARγ in response to this HDAC 
inhibitor was also determined in colonoytes. Incubation of HT-29 and Caco-2 cells with SFN 
(10-20 µM) for 24 h resulted in a dose-dependent augmentation of VDR protein expression in 
both cell lines [Paper IV]. Moreover PPARγ protein expression was increased by SFN as 
determined in Caco-2 cells [Figure 22]. 
In order to establish the involvement of MEK-ERK signalling in LL-37 and HBD-2 
mRNA, the p38 MAPK inhibitor SB203580 (20 µM) and the ERK1/2 inhibitor PD98059 (40 
µM) were employed. Pre-treatment of Caco-2 ce
rs prior to stimulation with butyrate (3 mM) up to 24 h diminished the up-regulation 
of LL-37 mRNA expression with the strongest effects seen by inhibiting the p38 MAPK trail 
[Paper III]. Moreover, the induction of LL-37 mRNA in response to butyrate was 
counteracted by the application of the transforming growth factor TGF-β1 inhibitor 
SB431542 (10 µM) [Paper III]. However, different results were obtained by inhibition of 
MEK-ERK signalling pathways in SFN-mediated induction of HBD-2 mRNA expression for 
this point in time. In this in vitro model, pre-treatment with the ERK1/2 inhibitor PD98059 
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reduced the up-regulation of HBD-2 mRNA expression [Paper IV] in response to SFN after 
24 h. In contrast, co-incubation with the p38 MAPK inhibitor SB203580 did not influence 
SFN-induced HBD-2 levels [Paper IV]. These data are in accordance to the findings on the 
phosphorylation pattern. Exposure of Caco-2 cells with SFN (10-20 µM) resulted in a rapid 
expression of phospho-ERK1/2 after 8 h, while the amount of the ERK1/2 protein was not 
affected. The expression of phospho-p38 MAPK and p38 MAPK proteins were unchanged by 
SFN in Caco-2 cells [Paper IV]. 
presentation of findings, including graphic display of results as well as writing of the 
 
 [42, 69, 70]. The purpose of this study was to 
examin
 
All experiments and results, published in the manuscripts, were performed by the author of 
this thesis. Transfected cells were provided by Stefan Loitsch. Moreover, interpretation and 
scientific manuscripts was performed by the author of this thesis.  
 
5.5  Paper V: Involvement of different nuclear hormone receptors in 
butyrate-mediated inhibition of inducible NFκB signalling 
Background and rationale: NFκB plays a major role in the control of immune and 
inflammatory responses [160]. Recently, it has been demonstrated that butyrate suppresses 
inducible NFκB activation in CRC cells [103, 152, 153]. However, the underlying molecular 
mechanisms are yet not fully understood. Ligands for PPARγ and VDR receptor have been 
shown to interfere with the activity of NFκB and thus to influence the ability of colonocytes 
to express immunmodulatory cytokines
e a possible role of PPARγ and VDR in butyrate-mediated inhibition of NFκB 
activation induced by TNFα and LPS. Besides, the involvement of both receptors in basal 
NFκB signalling was explored. 
 
Results: Treatment of HT-29 wild-type cells with butyrate (4 mM) for 24 h reduced basal p50 
dimer NFκB DNA binding activity in the nucleus (−45%). In contrast, basal p65 dimer 
activity was not affected. Incubation of cells with TNFα for 30 min (100 ng/mL) led to a 
strong increase of both NFκB DNA binding activities (p50: 1.7-fold, p65: 4.9-fold). A 
comparable up-regulation of NFκB DNA binding activity was observed after stimulation with 
LPS (10 ng/mL) for 30 min (p50: 1.5-fold, p65: 3.0-fold). However, TNFα- and LPS-
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mediated increased activities of NFκB were significantly attenuated in response to butyrate 
(TNFα: p50: −54%; p65: −52%; LPS: p50: −63%; p65: −49%). Cytosolic expression of the 
NFκB inhibitor protein IκBα was reduced by butyrate (−60%) and TNFα (−37%) but not by 
LPS. Moreover, combined treatment of butyrate and TNFα enhanced the decrease of IκBα 
(−83%).  
To elucidate the potential involvement of PPARγ and VDR in the activation of NFκB 
in resting HT-29 and also after treatment with butyrate, NFκB activity was studied by 
pplication of the VDR inhibitor ZK191732 (10 μM), the PPARγ antagonist GW9662 (5 μM) 
gations on the expression 
f cytokeratin 20 in Caco-2 cells in Paper I, butyrate (4 mM) provoked a direct up-regulation 
of PP
PPARγ mutant cell line,
of HT-29 wild-type cells with Z
ombination with butyrate (p50: 1.6-fold, p65: 1.8-fold) led to an increase of basal NFκB 
ent with ZK191732 in presence of TNFα 
lmost reversed the inhibitory effect caused by butyrate on both p50 and p65 NFκB dimer 
activities, while the effects on NF B activation in dominant-negative PPARγ mutant HT-29 
a
or in transfected PPARγ dominant-negative cells to inhibit PPARγ wild-type action. To 
scrutinize the functional effective transfection of the cell system, at first, PPARγ receptor 
activity was determined in HT-29 wild-type, empty-vector and dominant-negative PPARγ 
mutant cells via a transcriptional factor assay. Similar to the investi
o
ARγ activity in both HT-29 wild-type and empty-vector cells. In the dominant-negative 
 PPARγ activity was unchanged in response to butyrate. Stimulation 
K191732 (p50: 1.6-fold, p65: 1.8-fold) alone or in 
c
DNA binding activity, while the expression of IκBα was attenuated simultaneously. On the 
contrary, treatment of cells with the PPARγ antagonist GW9662 did neither affect basal 
NFκB activity nor the expression of IκBα. Co-incubation of GW9662 did also not influence 
butyrate’s actions on NFκB activity and IκBα expression. Comparable results were obtained 
by the use of dominant-negative PPARγ mutant cells. 
In order to investigate the putative role of PPARγ and VDR in butyrate-mediated (4 
mM) suppression of inducible p50 and p65 activity caused by LPS (10 ng/mL) or TNFα (100 
ng/mL), experiments were performed in presence of the VDR inhibitor ZK191732 (10 μM) or 
in the PPARγ mutant HT-29 cell line. Pre-treatm
a
κ
cells were comparable to the wild type. Reversed effects were obtained after stimulation of 
cells with LPS. Hence, inhibition of VDR did not affect butyrate-mediated suppression of 
LPS-induced NFκB activity, while inhibition of LPS-induced NFκB activity caused by 
butyrate was almost abolished in the PPARγ mutant cell line. Thus, butyrate-mediated 
inhibition of NFκB activation via LPS seems to be modulated by PPARγ, while VDR is 
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involved in the suppression of TNFα-induced NFκB activity caused by butyrate. Moreover, 
stimulation of HT-29 wild-type cells with LPS led to a time-dependent up-regulation of 
PPARγ expression, confirming the role of the receptor in LPS signalling. Regarding IκBα 
expression, comparable down-regulation of the protein in response to butyrate (4 mM), TNFα 
(100 ng/mL) or their combination was observed in all three cell lines. In addition, the 
decrease in IκBα caused by co-treatment of TNFα and butyrate was reduced in response to 
ZK191732.  
 
All experiments and results, published in this manuscript, were performed by the author of 
this thesis. Transfected cells were provided by Stefan Loitsch. Moreover, interpretation and 
presentation of findings, including graphic display of results as well as writing of the 
scientific manuscript was performed by the author of this thesis. 
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6  Discussion 
6.1  Importance of PPARγ in mesalazine’s and butyrate’s pro-
apoptotic abilities 
 
Apoptosis is a key component in the development and maintenance of tissues within 
ulticellular organisms, providing a tightly regulated and selective mechanism for the 
g ionizing radiation or 
hemotherapeutic drugs to damage DNA and to induce selective apoptosis of rapidly growing 
cells [115]. Apoptosis can be initiated either through the death receptor or the mitochondrial 
pathway (see 2.5.1) [115]. Caspases that cleave cellular substrates leading to characteristic 
biochemical and morphological changes are activated in both pathways [115]. Caspases are a 
family of aspartyl specific cysteine proteases. They exist within the cell as inactive pro-
caspases or zymogenes. The pro-domain is usually removed during the process of activation. 
Their initiation in turn triggers other caspases, resulting in a sequence of events instructing the 
cell to undergo programmed death [115]. 
The functional role of the nuclear hormone receptor PPARγ contributing to apoptosis 
and especially to the involvement in CRC has been implicated at several levels (see 2.2.5). 
There is increasing evidence that the receptor can be modulated by mesalazine and the dietary 
HDAC inhibitor butyrate e.g. by increasing its expression [42, 95]. Moreover, mesalazine was 
recently shown to be a new functional synthetic ligand for PPARγ in colonic epithelial cells 
[95]. In a variety of in vivo studies it has been indicated that long-term use of mesalazine in 
patients suffering from IBD may significantly reduce the risk for the development of CRC by 
decreasing cell proliferation and inducing apoptosis via the caspase cascade [147, 162, 163]. 
Similarly, the protective effect of butyrate reducing the hazard for CRC in the long-term 
therapy of UC has been indicated in vivo [164]. However, detailed molecular knowledge in 
this regulation is still missing. Therefore, in the first part of this thesis the involvement of 
PPARγ in the anti-carcinogenic abilities of mesalazine [Paper II] and butyrate [Paper I] was 
enlightened.  
m
deletion of superfluous, infected, mutated or aged cells. Dysregulation of apoptosis 
contributes to a variety of pathologic conditions, including cancer [161]. As tumor cells show 
a disturbed equilibrium between proliferation and apoptosis, conventional cancer therapies 
take advantage of this apoptotic mechanism by employin
c
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To elucidate the participation of PPARγ in the pro-apoptotic properties of both drugs, 
PPARγ cell system was developed [Paper I + II]. Therefore, colonocytes 
were transfected with
highly
LBD are mutated to alanine. As a consequence, this cell mutant retains PPARγ ligand and 
NA binding, but exhibits markedly reduced transactivation due to impaired coactivator 
 Survivin and Xiap simultaneously [Paper I + II] 
[166]. 
mechanisms have been reported for mesalazine’s apoptotic processes, 
a dominant-negative 
 a mutant receptor to inhibit wild-type PPARγ action. In this mutant the 
 conserved hydrophobic and charged residues (Leu468 and Glu471) in helix 12 of the 
D
recruitment [165]. To assure the functional successful transfection of this in vitro system, 
cells were challenged with mesalazine or butyrate, and PPARγ activity was determined by the 
expression of cytokeratin 20 or transcription factor assay, respectively [Paper I + II]. 
Cytokeratin 20 has been described to be a specific target gene of PPARγ activation in CRC 
cells [37]. As expected in wild-type and empty-vector cells, the activity of the receptor was 
increased, while in the dominant-negative PPARγ cell lines, up-regulation of PPARγ activity 
in response to both substances was suppressed. In accordance with recent studies, 
augmentation of PPARγ protein expression in wild-type CRC cells caused by butyrate or 
mesalazine was shown [42, 95]. Moreover, increased transcriptional PPARγ activity in 
response to mesalazine has been demonstrated by Rousseaux et al. [95].  
To reveal the influence of butyrate [Paper I] and mesalazine [Paper II] along the 
caspase cascade in this in vitro model, several characteristic signalling molecules were 
examined. Both substances led to a significant increase of activated caspase-3 and caspase-8 
by decreasing the expression of the IAPs
Survivin and Xiap have been well-characterized in mammalians and are known to 
inhibit caspases of the death receptor and of the mitochondrial pathway [161] (see 2.5.1). 
However, butyrate increased the cleavage of caspase-9 [Paper I], while activation of the 
enzyme was not affected by mesalazine [Paper II]. In addition, exaggerated expression of 
cleaved PARP in response to mesalazine was observed [Paper II]. Cleavage of PARP 
facilitates cellular disassembly and apoptosis, and cleavage products are commonly used 
markers for activation of the effector caspase-3 [167, 168]. Regarding the interference of 
mesalazine with the caspase cascade [Paper II], the findings of the experiments are in line 
with previous studies demonstrating increased cleavage of PARP and caspase-3 activity after 
mesalazine treatment in HT-29 and colo205 cells, respectively [169, 170]. The increase of 
levels in cleaved caspase-8 by mesalazine in the present study indicates that the death receptor 
pathway plays part in caspase-3 activation. In addition, both caspase-dependent and caspase-
independent 
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demon
ssential role in the 
regulat
strating that the drug activates multiple cell death signalling pathways, e.g. caspase-9, 
Bcl-2, intestinal sphingomyelinase and the induction of intracellular peroxides [94, 169]. The 
initiated mechanism of cell death in response to the drug seems to be cell type specific. 
Accordingly, a similar down-regulation of IAPs as obtained for mesalazine in this study, has 
been demonstrated for the NSAID sulindac and also for PPARγ ligands e.g. troglitazone and 
pioglitazone in colorectal carcinoma cells [171-173]. Moreover, increased activation of 
caspase-3 by butyrate has also been demonstrated in a variety of malignant cancer cell lines 
including CRC cells [144, 145]. Up-regulation of caspase-8 and -9 activity in response to the 
drug [Paper I] indicates that both, the death receptor, and the mitochondrial trail share in 
caspase-3 activation. This finding is confirmed by previous studies [144, 174]. A comparable 
down-regulation of Survivin and Xiap by butyrate for this in vitro setting has recently been 
shown in human glioma and neuroblastoma cells [175, 176]. 
To establish the involvement of MEK-ERK signalling in butyrate-mediated induction 
of caspase-3 activity and PPARγ expression, specific inhibitors against p38 MAPK and 
ERK1/2 were applied [Paper I] [Figure 23]. p38 MAPK belongs to a group of protein 
serine/threonine kinases which has been demonstrated to play an e
ion of several cellular processes including controlling inflammation, growth, apoptosis 
and differentiation [177-179]. p38 MAPK can be activated in response to inflammatory 
cytokines, but also by hormones, ligands for GPCR, cell stress and heat shock [178]. ERK1/2 
signalling has been implicated as a key regulator of cell survival and proliferation [179]. 
ERKs are mainly activated by growth factors, cytokines, virus infection, transforming agents, 
and also by activators of GPCR [178]. The data of this study demonstrate that inhibition of 
p38 MAPK counteracts both the induction of caspase-3 activity and the up-regulation of 
PPARγ caused by butyrate [Paper I]. In contrast, blocking of ERK1/2 did not affect both 
processes [Paper I]. Moreover, butyrate increased the expression of phospho-p38 MAPK, 
while ERK1/2 activity was not affected [Paper I]. In addition, stimulation of cells with the 
direct p38 MAPK stimulator arsenite resulted in an augmentation of PPARγ protein 
expression [Paper I], demonstrating that p38 MAPK plays a key role in PPARγ signalling. 
Nevertheless, butyrate-mediated apoptotic effects were not completely reversed by the p38 
MAPK inhibitor SB203580 [Paper I], indicating that transduction pathways other than p38 
MAPK take part in the activation of caspase-3 by butyrate. Indeed, expression of bak, a 
member of the bcl2-gene family which has been shown to be involved in the regulation of
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Figure 23: MAPK phosphorylay system. Abbreviation: GPCR, G-protein-coupled receptor. MAPKs are 
regulated by an up-stream relay of three protein kinases, i.e. MAPKKK – MAPKK – MAPK, which 
phosphorylate and subsequently activate another. See text for further explanations. 
 
apoptotic signalling, was found to be significantly increased in butyrate-stimulated Caco-2 
cells [180]. Bak was also shown to be a potent activator of the caspase cascade [181]. 
However, since butyrate is known to affect the expression of several genes potentially 
involved in the regulation of programmed cell death [180], other targets such as cJun N-
terminal kinase (JNK) [182, 183] and PKC-δ [184] may also be involved in butyrate-induced 
stimulation of caspase-3 and in the regulation of PPARγ expression in Caco-2. In addition, 
butyrate has been shown to activate p38 MAPK in several cancer cell lines including Caco-2 
[155, 182, 184]. Moreover, activation of p38 MAPK is an important molecular signalling 
event in butyrate-mediated activation of the caspase cascade [182, 184]. Summarising 
experiments hitherto, a signal transduction pathway leading to increased cell death via p38 
MAPK - PPARγ - caspase-3 in response to butyrate was unveiled [Paper I], which is depicted 
in Figure 24. The following investigations in dominant-negative PPARγ cells in this study 
provide further evidence for this proposed model.   
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Figure 24: Model of butyrate-induced cell death. Butyrate activates p38 MAPK, which in turn up regulates 
PPARγ  pression and receptor activity. PPARγ decreases the expression of Survivin and Xiap and activates 
Moreover, dysplasia of colonocytes in UC is also associated with increased expression of the 
oncoprotein [55, 157]. c-myc is known to modulate a broad range of biological activities 
ex
caspase-8 and -9 leading to increased caspase-3 activity, eventually resulting in cell death. 
 
Challenge of CRC cells with mesalazine resulted in a reduction of cell growth and 
proliferation and in the accumulation of cells in the G0/G1-phase of the cell cycle [Paper II]. 
Several  in vivo and in vitro studies have pointed out the anti-proliferative features of 
mesalazine in colon carcinoma cell lines [163, 169, 170, 185]. A number of NSAIDs like 
indomethacin and sulindac, but also the PPARγ agonists rosiglitazone and pioglitazone have 
been demonstrated to induce a G1 arrest in CRC cell [154, 186-188]. These observations 
differ from further studies, illustrating a S- or G2-Phase arrest in response to mesalazine, 
whereas the discrepancy compared to other NSAIDs was not explained [170, 185].  
To unravel further mechanisms contributing to mesalazine’s growth-inhibitory 
abilities in colonocytes, expressions of the oncoprotein c-myc and of the tumor suppressor 
gene PTEN were determined [Paper II]. c-myc is overexpressed in nearly 70% of CRC. 
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including cellular proliferation and cell growth [55, 157]. Deregulated c-myc has been shown 
to increase apoptosis, genomic instability and to block differentiation [55, 157]. In 
colonocytes including HT-29, it was recently shown that mesalazine decreased the expression 
of c-myc [157]. These data are in accordance with the findings in the present study [Paper II], 
reflecting the participation of the oncoprotein in the growth-inhibitory effects caused by the 
drug. On the other hand, PTEN is a tumor suppressor gene involved in the regulation of cell 
survival signalling through the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway [189]. 
PI3K/Akt signalling has been shown to be required for an extremely diverse array of cellular 
activities mainly involved in cell growth, proliferation, apoptosis and survival mechanisms 
[189, 190]. Activated Akt protects cell from apoptotic death by inactivating compounds of the 
cell-death machinery such as pro-caspases [189]. PTEN exercises its role as a tumor 
suppressor by antagonising the PI3K/Akt pathway [189]. Stimulation of HT-29 wild-type 
cells with mesalazine in this in vitro setting increased the expression of PTEN [Paper II]. 
Augmented expression of PTEN in CRC cells, e.g. by NSAIDs, has been demonstrated to 
decrease cell proliferation through cell-cycle arrest in the G0/G1 phase and to activate the 
caspase cascade [159, 190, 191], which is in line with the findings obtained in this study.   
drug was reversed [Paper II]. Altogether these 
results suggest the participation of PPAR
like 15-PGJ , rosiglitazone and troglitazone exhibit inhibitory effects on the proliferation of 
ystem in 
study demonstrates a PPARγ-independent down-regulation of the oncprotein c-myc, known to 
In the dominant-negative PPARγ cell system, mesalazine- and butyrate-mediated 
effects of all investigated apoptotic markers of the caspase cascade were annihilated [Paper I 
+ II]. Moreover, the anti-proliferative effects caused by mesalazine were partially reduced and 
the up-regulation of PTEN in response of the 
γ in mesalazine- [Paper II] and butyrate- [Paper I] 
mediated anti-carcionogenic effects. In contrast, a PPARγ-independent decrease of c-myc in 
response to mesalazine was obtained [Paper II]. Mesalazine’s anti-carcinogenic effects 
obtained in this study are summarized in Figure 25. With regard to the interaction of cell 
growth and PPARγ, in several studies it could be demonstrated that agonists for the receptor 
2
CRC cell lines [154, 172, 188]. This growth inhibitory effect was partially reversed by use of 
the PPARγ inhibitor GW9662 [172, 188], supporting the findings for the partial reduction of 
cellular proliferation caused by mesalazine in the dominant-negative PPARγ cell s
this study [Paper II]. However, incomplete inhibition of cell proliferation indicates that other 
mechanisms besides PPARγ must be involved in this regulation [172]. Recently it was 
demonstrated that mesalazine also interferes with the colonic cell growth by disrupting 
epidermal growth factor signalling via enhanced SH-phosphatase-2 [192]. Moreover, this 
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Figure 
proliferation i
25: Possible molecular mechanism of mesalazine-induced apoptosis and inhibition of cell 
n colorectal carcinoma cells. See text for further explanations. 
 
modulate cell growth [Paper II]. This finding is supported by previous studies. Although 
PPARγ agonists have been demonstrated to inhibit the expression of the oncoprotein [55, 
193], the effects seem to be PPARγ-independent because no PPRE sequences have been 
found in its promoter [193]. Thus, in this study, c-myc seems to contribute to the modulation 
of the PPARγ-independent growth-inhibitory effects caused by mesalazine.    
Several observations propose an interaction between PTEN and PPARγ. Except for the 
ability of PPARγ agonists like rosiglitazone to increase the expression of PTEN, corroborated 
by inhibitor and antisense experiments, PPARγ has also been demonstrated to bind two 
PPREs in the genomic sequence upstream of PTEN [194-196], which is in accordance with 
the present investigations. The PPARγ-dependent increase of PTEN caused by mesalazine in 
these experiments does not only indicate that the tumor suppressor gene contributes to the 
growth-inhibitory activities of the drug, but also may trigger its pro-apoptotic actions.  
Increased caspase-3 activity resulting in apoptosis has been shown by several PPARγ 
ligands like 15-PGJ2 and troglitazone in a variety of cell types including CRC cells [56, 58, 
154]. With regard to the action by which PPARγ controls caspase signalling, the molecular 
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mechanisms are not fully enlightened. It may be speculated that PPARγ activates the caspase 
pathway via modulation of the IAPs e.g. via a spermidine/spermidine N
1-acetyltransferase 
(SSAT) dependent mechanism [197, 198]. Indeed, several NSAIDs have been demonstrated 
to induce the transcription of SSAT via activation of PPARγ and to inhibit the expression of 
IAPs [173, 198]. Other factors known to modulate the expression of the IAPs such as JNK, 
epithelial growth factor (EGF) and STAT-3 may also be involved [166, 199-201]. Only 
recently, a direct interaction of PPARγ with the death receptor signalling pathway was 
disclosed, demonstrating the ability of PPARγ ligands to down-regulate FLIP, an apoptosis-
suppressing protein that blocks early events in death receptor signalling pathway [202]. 
However, decreased expressions of Survivin and Xiap by the PPARγ ligands troglitazone and 
pioglitazone were unveiled as important apoptotic-inducing mechanisms [172, 203].  
 
Conclusions: These data further elucidated the molecular events involved in butyrate- [Paper 
I] and mesalazine- [Paper II] mediated apoptosis in CRC cells, clearly demonstrating the key 
role of PPARγ in this sequential process. Upon activation by p38 MAPK in response to 
contrast, mesalazine-mediated apoptosis appears to be merely modulated by the caspase-8 
 
iety of 
epithel
butyrate, PPARγ triggers the regulation of several pro- and anti-apoptotic markers finally 
followed by activation of caspase-3 eventually resulting in cell death [Paper I, Figure 24]. In 
signalling pathway and the IAPs [Paper II, Figure 25]. Moreover, the data of this thesis 
provide evidence that mesalazine acts via PPARγ-dependent and -independent mechanisms to 
induce growth-inhibitory effects and apoptosis in colonocytes which may in part be triggered 
by the modulation of the oncoprotein c-myc and the tumor suppressor gene PTEN, 
respectively [Paper II, Figure 25].  
6.2  Crucial role of VDR in HDAC-mediated induction of the anti-
microbial peptides HBD-2 and LL-37 
 
The innate immune system modulates a number of biological processes
 so as to properly 
defend against pathogens [204]. The APs LL-37 and HBD-2 are secreted by a var
ial cells, belonging to the innate immune system and are potential factors contributing 
to infection control [124]. In the gastrointestinal tract, these peptides regulate the composition 
and number of colonizing microbes and protect the host from food-borne and water-borne 
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pathogenesis [123]. In many cases they are effective against pathogens which are resistant to 
conventional antibiotics [205]. Hence, APs have been proposed as natural templates for the 
design of novel antimicrobial drugs [205].    
Aberrances in the expression of AP expression have not only been observed in IBD 
but also during infections caused by pathogens including several Helicobacter strains, 
Shigella, Salmonella und Campylobacter jejuni [124, 206, 207]. The site-specific disruption 
of the critical balance between epithelial APs and luminal bacteria might explain adherent 
bacteria to the mucosa, as well as different disease locations, such as found in colonic CD 
compared with UC [123]. In the pathology of UC, epithelial expression of HBD-2 and LL-37 
is enhanced [123]. When stratified according to disease activity, the induction is clearly 
restricted to the inflamed mucosa [208]. However, the difference in the expression of HBD-2 
between non-inflamed mucosa in UC and healthy controls is not significant [208]. In contrast, 
nues [210].  
Cross-talk between nuclear hormone receptors, such as VDR and PPARγ, and the 
innate immune system
  may influence multiple biological functions during an immune 
response [2
responses a  been extensively established [81, 
04, 211]. The dietary SCFA butyrate is able to modulate the activity and expression of the 
HDAC inhibitors butyrate and SFN by the nuclear hormone receptors PPARγ and VDR.   
a slight but significant induction of LL-37 in non-inflamed UC was observed [123]. 
Regarding colonic CD, the state of innate immune affairs is dramatically different [123]. 
There is a broad lack or at least attenuation of HBD-2 and LL-37 response during severe 
inflammation [123]. A model of antimicrobial defence of APs in the normal mucosa and in 
colonic CD is demonstrated in Figure 26 [123]. The expression of HBD-2 and LL-37 shows a 
strong degree of correlation, especially in case of inflammation [123]. This defective 
regulation of HBD-2 could inter alia be explained by a genetic predisposition through 
diminished gene copy numbers in the HBD-2 gene cluster. In contrast, the gene copy number 
of HBD-2 is normal in UC, allowing full transcriptional response [209]. Elucidating the 
underlying molecular mechanisms involved in the complex regulation and biology of these 
APs could open new therapeutic ave
04]. Moreover, the function of nuclear hormone receptors in innate
  immune 
nd inflammation of the gastrointestinal tract has
2
nuclear hormone receptors PPARγ and VDR and can also interact with the innate immune 
system by regulating the expression of APs [70, 100, 104, 212, 213]. In several in vivo studies 
of IBD and experimental Shigelloses butyrate has been demonstrated to decrease 
inflammation [212, 214], probably caused by an induction of APs. The aim of this study was 
therefore to investigate a possible modulation of AP expression in response to the dietary 
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Figure 26: Proposed model for the role of APs in IBD, especially colonic CD. In the healthy gut, the microbes 
can not invade the mucosa because of an effective antimicrobial barrier. In CD of the colon and small intestine 
(lower panel), different components of this antimicrobial barrier are disturbed and bacteria can invade the 
mucosa. According to this hypothesis, a bacterial invasion due to AP deficiency is the primary cause for a 
secondary inflammation. [adapted from [123]] 
 
Stimulation of several CRC cell lines with butyrate in this in vitro study led to a time- 
and dose-dependent up-regulation of HBD-2 and LL-37 mRNA expression, reflecting a 
common mechanism in CRC cells [Paper III + IV]. The results are in line with the 
observations found in a variety of epithelial cell types including colon epithelial cells, 
gastrointestinal cells and lung cells [100, 101, 104, 215]. Moreover, the data provide evidence 
that the CRC cell lines used in this study express basal levels of LL-37 and HBD-2 mRNA 
which is in accordance with the findings in HT-29 and Caco-2 cells [100, 216], but differs 
from the observations in the lung epithelial cell line EBD-1 for LL-37 mRNA expression and 
from the human gastric epithelial cell line AGS for HBD-2 [217]. Moreover, protein 
expression of both APs in response to the HDAC inhibitors was increased as detected by 
immunostaining [Paper III + IV] and ELISA [Paper IV], respectively. In conformity with 
previous studies [100, 104], both peptides were expressed in the cytoplasm of the cells. 
Moreover, the induction of HBD-2 on mRNA and protein level in response to SFN has been 
demonstrated in this thesis for the first time [Paper IV].  
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To elucidate the putative participation of PPARγ and VDR in butyrate and SFN-
mediated induction of LL-37 and HBD-2 mRNA, experiments were performed in CRC cells 
transfected with a dominant-negative PPARγ mutant to inhibit wild-type PPARγ action or by 
application of the specific VDR antagonist ZK191732, respectively [Paper III + IV]. 
Challenge of cells with ZK191732 reversed the expression of the APs in response to both 
HDAC inhibitors [Paper III + IV]. In contrast, in the dominant-negative PPARγ cell lines, the 
induction of the APs was not affected [Paper III + IV]. The findings for the role of VDR in 
butyrate-mediated induction of the APs are supported by the presence of a consensus VDRE 
in the promoters of the human HBD-2 and LL-37 genes [218]. Moreover, induction of LL-37 
by VD3 has been observed in cell lines from various tissue types, e.g. several carcinoma cell-
types of the tongue, lung cancer, CRC, hematopoetic cell lines, primary tissues, bone marrow 
cells and in keratinocytes [104, 219, 220]. Likewise, increased HBD-2 mRNA in response to 
VD3 has been shown in human cell lines and primary cultures [218]. In addition, the up-
ay controls a huge variety of physiological processes 
[178]. In general, these enzymes are regulated by an up-stream relay of three protein kinases, 
i.e. MA
ere not involved [222]. Conflicting 
regulation of VDR protein expression after challenge of cells with butyrate [69, 70] and SFN 
[Paper IV] refers to the involvement of the receptor in the signalling pathway of APs. On the 
other hand, the PPARγ agonist troglitazone was unable to induce the expression of LL-37 in 
U937 cells [219], indicating that PPARγ doesn’t contribute to the signal transduction pathway 
of the AP. 
The MEK-ERK signalling pathw
PKKK – MAPKK – MAPK, which phosphorylate and subsequently activate another 
[178] [see 6.1; Figure 23]. Since p38 MAPK and ERK1/2 have already been indicated in 
HDAC-mediated functions on cellular physiology [155, 221], their role in butyrate- and SFN-
mediated induction of LL-37 and HBD-2 was determined [Paper III + IV]. Pre-treatment with 
two MEK-ERK inhibitors diminished the induction of LL-37 mRNA expression caused by 
butyrate with strongest effects observed for the p38 MAPK inhibitor SB203580 [Paper III]. 
Conversely, inhibition of the ERK1/2 pathway by PD98059 in this study prevented the 
induction of HBD-2 mRNA caused by SFN and butyrate, while blocking of the p38 trail had 
no impact on this regulatory process [Paper IV]. The participation of MEK-ERK signalling in 
butyrate-mediated up-regulation of LL-37 [Paper III] found in these experiments is in 
accordance with data in human lung epithelial cells, demonstrating reduced LL-37 mRNA 
after pre-incubation with inhibitors for the ERK1/2, JNK and p38 MAPK signalling pathway 
[215]. Moreover, inhibition of p38 MAPK in human keratinocytes led to decreased LL-37 
gene expression, whereas JNK and ERK1/2 pathways w
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results 
over, SFN was shown to increase phospho-ERK1/2 in various cell lines including 
Caco-2
have been obtained in SW620 cells. In this cell line, inhibition of the ERK1/2 pathway 
suppressed butyrate-mediated LL-37 mRNA expression, while blocking the p38 MAPK trail 
boosted the expression of the gene [101]. Regarding the influence of the MEK-ERK 
signalling pathway on the induction of HBD-2 caused by SFN [Paper IV], the data from this 
study are in line with middle ear epithelial cell transcriptional activation of the HBD-2 gene 
caused by IL-1α which is mediated through an Raf-MEK1/2-ERK1/2 signalling pathway 
[223]. Different results were obtained in the lung epithelial cell line A549, in which IL-1β-
induced up-regulation of HBD-2 was partly attenuated by inhibiting the p38 MAPK but not 
by the ERK1/2 signalling pathway [224]. Taken together, all these different observations 
indicate a cell specific and stimulus dependent kinase pathway leading to the induction of 
both APs. However, the importance of the MEK-ERK signalling pathway in this regulation 
was underscored by the present findings. The results in this study are further supported by the 
phosphorylation pattern of MEK-ERK signalling obtained after treatment with butyrate 
[Paper I] and SFN [Paper IV]. In this in vitro setting, butyrate was shown to increase the 
expression of phospho-p38 MAPK, while phosphorylation of ERK1/2 was not affected [Paper 
I]. Reversed effects were obtained after stimulation of cells with SFN [Paper IV]. Increased 
phosphorylation of p38 MAPK by butyrate has been demonstrated in several studies [155, 
213]. More
 cells, while the amount of ERK1/2 protein was not affected. SFN treatment had no 
impact on p38 MAPK activation [225, 226].  
The  transforming growth factor TGF-β1 is a multifunctional peptide that controls 
cellular proliferation, differentiation, migration, embryonic development, wound healing and 
other functions in diverse cell types [227, 228]. During active inflammation of IBD, TGF-β1 
was found to be increased in the affected mucosa [227]. To further elucidate the participation 
of the peptide in butyrate-mediated induction of LL-37, cells were pre-treated with a specific 
inhibitor against the TGF-β1 receptor kinase. Stimulation with the inhibitor prior to butyrate 
treatment diminished the up-regulation of LL-37 mRNA [Paper III]. Previous investigations 
reporting the necessity of TGF-β1 in butyrate-induced Caco-2 cell differentiation [229] as 
well as the increase of LL-37 expression in spontaneously differentiating Caco-2 cells [100] 
are supporting these findings of this study. Moreover, in keratinocytes a TGF-β1-dependent 
induction of LL-37 mRNA in response to VD3 has been demonstrated, also reflecting the 
requirement for VDR in the signalling pathway of the AP. This effect was counteracted by 
application of the VDR antagonist ZK159222 [230]. Furthermore, direct cross-talk between 
VDR and TGF-β1 has been reported [231]. 
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Figure 27: Established signalling molecules in HDAC-mediated induction of APs. See text for further 
explanations. 
 
Conclusion: These findings provide evidence for the involvement of the nuclear hormone 
receptor VDR in butyrate and SFN-mediated induction of the APs LL-37 and HBD-2 in 
colonocytes [Figure 27]. Moreover, the participation of MEK-ERK signalling in the 
expression of both peptides was revealed. On the contrary, the participation of PPARγ in this 
regulatory process could be debarred. 
 
6.3  Stimuli-dependent participation of PPARγ and VDR in butyrate-
mediated suppression of cytokine-induced NFκB activation 
 
Most NFκB target genes have been intensively studied for their participation in immune and 
inflammatory responses. However, the transcription factor also regulates cell proliferation, 
apoptosis and cell migration [142]. A causal connection between inflammation and cancer has 
been assumed for a long time. Nevertheless, the mechanistic link between inflammation and 
tumorigenesis is not well understood [142]. Since NFκB becomes activated in response to a 
variety of inflammatory stimuli and environmental stressors and since the constitutive 
activation of the transcription factor has been associated with cancer of several types, NFκB 
might be a missing link between the two processes [142, 232-234]. Moreover, NFκB mediates 
the production of many factors playing an active role in the pathology of IBD and in 
inflammation-driven tumor progression [234]. High levels of circulating and mucosal pro-
inflammatory cytokines resulting from increased activity of NFκB have been reported in the 
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intestinal mucosa of patients with IBD, especially UC and CD [149, 150]. Hence, targeting 
NFκB may be a possibility to suppress inflammation and also the development of cancer in 
IBD. Current studies have demonstrated that the SCFA butyrate suppresses NFκB signalling 
in resting and cytokine stimulated epithelial cells [103, 152, 153]. Moreover, it was shown 
that the nuclear hormone receptors VDR and PPARγ can inhibit NFκB activity, representing 
an important link between the endocrine and immune systems [87, 235]. However, activation 
and increased expression of PPARγ and VDR in response to butyrate has been demonstrated 
recently [42, 69, 70, 213]. Based on these observations, the involvement of both receptors in 
e are two main key receptor families that can activate NFκB, Toll-Like Receptors 
LRs) and TNFRs [Figure 28]. TLRs recognize LPS, a cell wall component of Gram-
50 and p65 NFκB dimer DNA binding activities, while 
is activation was attenuated in response to butyrate [Paper V]. These findings are in line 
with numerous investigations in colonocytes, murine macrophages and adenocarconoma cells, 
indica t
239]. Furth 5 basal 
FκB DNA binding activity was reduced in response to butyrate [Paper V]. The study of Inan 
the modulation of butyrate-mediated suppression of NFκB signalling as well as in basal NFκB 
activation in the CRC cell line HT-29 was scrutinized [Paper V]. 
Ther
(T
negative bacteria. TNFRs are triggered by their ligand TNFα [236-238]. Each of the different 
groups of receptors activate NFκB utilizing a specific signalling cascade [238]. Thus, the 
differences assigned to NFκB functions can be ascribed to specific cell surface receptors 
recognizing a variety of unrelated ligands [238]. Stimulation of HT-29 cells with TNFα or 
LPS increased the expression of both p
th
ting  he efficacy of butyrate to attenuate increased NFκB signalling [103, 152, 153, 
ermore, the data in this study provide evidence that only the p50 but not p6
N
et al. demonstrated by using supershift analysis that the constitutive complex of NFκB in HT-
29 cells is the p50 dimer, although p65 NFκB activation was observed upon cytokine 
stimulation [103]. Exposure to butyrate lead to a selective reduction of p50 NFκB DNA 
binding activity as observed in the present experiments [103]. Cytosolic levels of IκBα 
investigated in this thesis were decreased after stimulation with butyrate, TNFα but not in 
response to LPS [Paper V]. However, conflicting results have been obtained in previous 
studies. In regard to stimulation with TNFα, Inan et al. could not detect any change in the 
expression of IκBα after exposure of the cytokine and even not in the presence or absence of 
butyrate up to 1 h [103]. In further experiments, the same research group demonstrated 
reduced levels of IκBα in TNFα treated cells caused by butyrate, which is in accordance with 
the present experiments [103]. In contrast, Yin et al. established that IκBα was completely 
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degradated in response to TNFα after 15 min in HT-29 cells, whereas its degradation was 
dampened in butyrate-conditioned cells [153]. However, after 30 min the protective effect of 
butyrate on IκBα was completely reversed. The data obtained for exposure of cells to LPS in 
this study differ from previous studies. Stimulation of human intestinal microvascular 
endothelial cells with LPS decreased the expression of IκBα, while the degradation was not 
affected by pre-treatment with butyrate [107]. In contrast, in THP-1 cells a decrease in IκBα 
expression only 4 h after stimulation with LPS was obtained [108]. In presence of butyrate 
this effect was abolished. Altogether, these findings refer to a cell type, concentration and 
time point specific mechanism in the expression of IκBα. Nevertheless, it is unlikely that the 
prevention of IκBα degradation is the only mechanism influencing NFκB activity. Other 
mechanisms or other members of the IκB family may also be responsible for the inhibitory 
effects of butyrate on NFκB actions.  
To elucidate a possible role for PPARγ and VDR in basal NFκB activity and after 
challenge of cells with butyrate, experiments were performed in HT-29 cells transfected with 
a dominant-negative PPARγ mutant to inhibit wild-type PPARγ action or by use of the 
specific PPARγ receptor antagonist GW9662 or the VDR antagonist ZK191732, respectively 
[Paper V]. Challenge of cells with ZK191732 or in combination with butyrate increased both 
p50 and p65 basal NFκB dimer activities, while reducing the expression of IκBα 
simultaneously. However, the PPARγ antagonist GW9662 did not affect butyrate-mediated 
actions on basal NFκB activity and IκBα expression. Basal NFκB activities were not 
influenced either. Comparable results for these observations were obtained in dominant-
negative PPARγ mutant HT-29 vector cells. To further scrutinize any involvement of the 
receptors in butyrate-induced suppression of cytokine-mediated activation of NFκB, 
experiments were additionally performed in the presence of the VDR inhibitor ZK191732 or 
in the PPARγ mutant HT-29 cell line. Co-incubation of cells with the VDR antagonist 
ZK191732 prior to stimulation of cells with TNFα abolished the inhibitory effect of butyrate 
on NFκB activity, while in this in vitro model inhibition of PPARγ signalling did not affect 
the suppressive activity of butyrate. In contrast, the participation of PPARγ but not of VDR 
could be observed after stimulation of cells with LPS. Thus, these findings refer to the 
involvement of different signalling pathways responsible for the reduction of inducible NFκB 
activity caused by butyrate. Butyrate-mediated suppression of inducible NFκB activity in 
response to LPS seems to be modulated via PPARγ and therefore via TLR signalling. 
68 DISCUSSION 
 
 
 
___________________________________________________________________________ 
Figure 28: Proposed model of butyrate-mediated inhibition of inducible NFκB activation dependent on the 
stimulated signalling pathway caused by TNFα or LPS. Abbreviation: NFκB, nuclear factor κB; PPAR, 
peroxisome proliferators-activated receptor; PPRE, peroxisome proliferator response element; RXR, retinoid X 
receptor; TLR4, toll-like receptor 4; TNFR, tumor-necrosis-factor receptor; VDR, vitamin D receptor, VDRE, 
vitamin D response element. See text for further explanations. 
 
Conversely, VDR affects the TNFR signalling pathway leading to increased NFκB activation. 
A proposed model of this interaction is depicted in Figure 28. 
There is little consensus about the precise molecular mechanisms affected by nuclear 
hormone receptors to inhibit NFκB activity. Different mechanisms for this cross-talk, 
influencing the activity of the transcription factor have been indicated [235]. Proposed 
mechanisms can be divided generally into two categories, nuclear and cytoplasmatic models. 
Modes of nuclear models include e.g. physical interaction between NFκB and nuclear 
hormone receptors, interference with the basal transcription machinery and cofactor-based 
activation. Cytoplasmatic interaction is mainly induced by cytoplasmatic sequestration of 
NFκB and the interference of the transcription factor with other signal transduction pathways 
[235]. However, the dynamic nature of the protein shuttling events make it likely that such 
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strict boundaries do not exist in the real setting. Multi-targeting mechanisms have rather been 
considered [235]. Several mechanisms have been reported by which PPARγ can inhibit the 
actions of NFκB activity. The transcription factor can not only physically interact with the 
NFκB subunits p65, subunit p50, or both, but can also inhibit degradation of the inhibitory 
protein IκB [240, 241]. In addition, up-regulation of IκB levels and a frequent interaction of 
PPARγ with cyclic AMP response element binding protein (CREB), a coactivator interacting 
with p65 have been described [240, 241]. A precise interaction between NFκB and the VDR 
receptor has not been elucidated yet. However, integration of p65 in the VDR transcription 
complex has been indicated [242].  
Revealing the participation of PPARγ in butyrate-mediated inhibition of TLR-
mediated NFκB signalling, the following observations found in literature support the data of 
the present study. In a rat model of acute UC caused by TNBS, the PPARγ agonist 
rosiglitazone has been shown to modulate inflammation by reducing increased levels of NFκB 
[243]. In addition, the ability of LPS to up-regulate PPARγ levels has been demonstrated in 
vitro and in vivo [34, 40, 244] which is in accordance with the data of this thesis. Moreover, 
the involvement of TLR4 in PPARγ signalling caused by LPS has been shown by a weak 
expression of PPARγ in the colon of mice with non-functional TLR4 due to a naturally
. 
The discovery for the participation of VDR in basal and in butyrate-mediated 
DR and NFκB signalling. In a 
variety
 
occurring mutation within the TLR4 gene [34, 40]. These data were further supported by the 
transfection of Caco-2 cells with the constitutive active form of TLR4 leading to increased 
induction of PPARγ expression [40]. In general, the up-regulation of PPARγ has been 
ultimately considered as a negative feedback resulting in attenuation of the pro-infammatory 
NFκB signalling pathway induced by LPS [244, 245]
inhibition of TNFα-stimulated NFκB activity by the present study, is underpinned by several 
in vitro and in vivo studies, demonstrating cross-talk between V
 of cell types it was shown that the active metabolite of vitamin D, VD3 counteracts 
NFκB activation [246-249]. This suppressive effect of VD3 on NFκB activation therefore 
appears to be a general effect that occurs in various cell types and immune processes [249]. In 
peripheral blood mononuclear cells of healthy and patients with CD, the vitamin D analogue 
TX 527 not only decreased basal and TNFα-induced activation of NFκB, but also increased 
IκBα protein levels, even in association with TNFα [87]. In a mouse model lacking the VDR 
receptor, a reduction of IκBα was observed [88]. The degradation of IκBα induced by TNFα 
was inhibited by VD3 in normal but not in VDR lacking cells [88]. In human keratinocytes 
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VD3 is able to reduce NFκB DNA binding activity by increasing IκBα protein levels [247]. 
Moreover, in murine macrophages, VD3  up-regulates IκBα levels by increasing mRNA 
stability and decreasing IκBα phosphorylation. The increase in IκBα levels reduces nuclear 
translocation of NFκB and thereby downgrades its activity [249]. Finally, in mouse 
embryonic fibroblasts lacking the VDR receptor, basal IκBα protein levels were markedly 
decreased probably caused by the lack of VDR-mediated stabilization of IκBα by VD3. 
However, degradation of IκBα and its phosphorylation were not altered. Moreover, these 
mutants appear to be more pro-inflammatory due to the increased intrinsic NFκB activity 
[250]. 
 
Conclusion: The data presented in this paper provided evidence for the participation of the 
nuclear hormone receptors PPARγ and VDR in butyrate-mediated inhibition of inducible 
NFκB activation dependent on stimulated signalling pathway caused by TNFα or LPS [Figure 
28]. In addition, the inhibitory role of VDR in basal NFκB signalling was demonstrated. 
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7  Summary - Achievement of this work and outlook 
 
Disruption of the complex gastrointestinal ecosystem between the resident microflora and the 
colonic epithelial cells has been associated with increased inflammation and altered cell 
growth. Possible endpoints of this disturbance are IBD and CRC. The data presented in this 
thesis, entitled “PPARγ as molecular target of epithelial functions in the gastrointestinal 
tract”, shed further light on the underlying molecular mechanisms contributing to the well 
ordered homeostasis of this gastrointestinal ecosystem. Except for elucidating important roles 
for me lazine and the dietary HDAC inhibitors butyrate and SFN in a) the modulation of 
 and 
therapy of gastrointestinal diseases. 
Within the scope of this work, in Paper I and II it could be demonstrated that butyrate 
and mesalazine act via PPARγ to induce their anti-proliferative and pro-apoptotic actions 
along the caspase signalling pathway. Activation of the intrinsic and extrinsic signalling trail 
and the down-regulation of anti-apoptotic proteins are responsible for increased caspase-3 
activity caused by butyrate. In contrast, mesalazine merely activates this cascade via the 
extrinsic trail and the IAPs. Moreover, a signal transduction pathway leading to increased cell 
death via p38 MAPK - PPARγ - caspase-3 in response to butyrate was unveiled. In addition, 
there is strong evidence that mesalazine-mediated pro-apoptotic and growth-inhibitory 
abilities are controlled by PPARγ-dependent and -independent mechanisms which appear to 
be triggered at least in part by the modulation of the tumor suppressor gene PTEN and the 
oncoprotein c-myc, respectively. 
In Paper III and IV the induction of the APs HBD-2 and LL-37 in response to the 
dietary HDAC inhibitors butyrate and SFN was pinpointed. Regarding the molecular events 
of this regulation, the data presented in this thesis provide strong evidence for the 
involvement of VDR in HBD-2- and LL-37-induced gene expression, while the participation 
of PPARγ was excluded. Moreover, the role for p38 MAPK and TGF-β1 in the up-regulation 
of LL-37 caused by butyrate was established. In contrast, SFN-mediated induction of HBD-2 
is modulated via ERK1/2 signalling.  
sa
cellular growth, b) the induction of APs, and c) the control of NFκB signalling in CRC cells, 
the involvement of the nuclear hormone receptors PPARγ und VDR as “gatekeepers” in these 
intricate regulatory mechanisms were established. Future work will be engaged in analysing 
whether these in vitro findings are also physiologically relevant in regard to prevention
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The findings in Paper V clearly refer to the involvement of the nuclear hormone 
NFκB activation 
ependent on the stimulated signalling pathway caused by LPS or TNFα. Moreover, an 
receptors PPARγ and VDR in butyrate-mediated suppression of inducible 
d
inhibitory role for VDR in the regulation of basal NFκB activation was revealed. On the 
contrary, a modulating role for PPARγ on basal NFκB could be debarred. 
Altogether the data presented in this thesis not only provide new insights in the 
understanding of the fundamental gastrointestinal physiology regulated by nuclear hormone 
receptors, but also may offer opportunities for the development of potential drug targets and 
therapeutic strategies in the treatment of IBD and CRC. 
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8  Zusammenfassung 
 
Schlüsselworte: Peroxisome Proliferator-Activated Rezeptor (PPARγ), Vitamin D Rezeptor 
(VDR), nukleäre Hormonrezeptoren, kolorektales Karzinom, gastrointestinale 
Zellreg
ARγ und VDR an der intestinalen 
Zellregulierung ist in zahlreichen in vivo und in vitro Studien hinreichend belegt. Ferner 
konnte der Einfluss der beiden Rezeptoren an der Pathogenese des kolorektalen Karzinoms 
sowie der chronisch entzündlichen Darmerkrankungen (CED), Morbus Crohn und Colitis 
ulcerosa, aufgezeigt werden. In einer Reihe von Zellkultur-, Tier- und Humanstudien wurde 
außerdem eine Verminderung des Tumorwachstums sowie eine Remission von CED durch 
Modulierung der PPARγ- und VDR-Rezeptoraktivitäten beobachtet.  
Die Mukosa des Gastrointestinaltraktes befindet sich in einem komplexen 
dynamischen Gleichgewicht. Schon kleinste Störungen dieses epithelialen Systems können zu 
einer veränderten Expression von antimikrobiell wirkenden Peptiden sowie zur Aktivierung 
des Transkriptionsfaktors NFκB verbunden mit der Freisetzung zahlreicher Entzündungs-
parameter führen. Diese Faktoren begünstigen die Entstehung gastrointestinaler 
Erkrankungen. In der gesunden Darmschleimhaut stehen außerdem proliferierende Zellen und 
deren geregelter Zelltod (Apoptose) in einem Fließgleichgewicht. Der Zelltod wird dabei 
klassischerweise durch die Caspase-Kaskade reguliert. Bei der Tumorentwicklung geht diese 
Kontrolle durch Hemmung der Apoptose verloren; hieraus resultiert ein unkontrolliertes 
Zellwachstum. Die nukleären Hormonrezeptoren PPARγ und VDR tragen vermutlich zur 
Regulation all der hier aufgeführten Prozesse bei. 
Mesalazin sowie die natürlich vorkommenden Histondeacetylase (HDAC)-Inhibitoren 
Butyrat und Sulforaphan (SFN) haben in der letzten Zeit aufgrund ihrer chemopräventiven 
und anti-inflammatorischen Wirkungen in Hinblick auf die Prävention des kolorektalen 
Karzinoms und von CED zunehmend an Bedeutung gewonnen. Im Rahmen dieser Arbeit 
sollte eine potentielle Wirkung dieser Substanzen auf die oben aufgeführten 
Signaltransduktionswege und Moleküle sowie eine mögliche Beteiligung der nukleären 
Rezeptoren aufgezeigt werden. Dazu wurde die Arbeit in 3 Teile gegliedert: 
ulierung, Butyrat, Mesalazin, Sulforaphan, Caspase-Kaskade, antimikrobielle Peptide, 
Cathelicidin, Beta-Defensin-2, NFκB-Signaltransduktionsweg 
 
Die Beteiligung der nukleären Hormonrezeptoren PP
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en dass sowohl Butyrat als auch Mesalazin pro-apoptotische 
und anti-proliferative Eigenschaften aufweisen. Diese werden vorwiegend durch die 
itere Regulationsvorgänge in 
iesem Zusammenhang untersucht [Paper I, II]. Dazu wurden die Aktivitäten bzw. die 
uchen, welche in einer 
verstär
ubation mit Butyrat wurden synergistische 
Effekte
bitors SB203580 
Zahlreiche Studien beleg
Aktivierung der Caspase-Kaskade mittels gesteigerter Caspase-3-Aktivität und 
Zellzyklushemmung eingeleitet. Außerdem ist bekannt, dass beide Substanzen in die PPARγ- 
Signaltransduktion involviert sind. Im ersten Teil dieser Arbeit wurde der Einfluss von 
Butyrat und Mesalazin auf die Caspase-Kaskade sowie we
d
Proteinexpressionen von charakteristischen Signalmolekülen dieser Kaskade in kolorektalen 
Karzinomzellen mittels Western-Blot-Analyse und ELISA ermittelt. Sowohl Mesalazin 
[Paper II] als auch Butyrat [Paper I] steigerten die Aktivität der Effektor-Caspase-3, was zu 
einem apoptotischen Zelltod über sekundäre Zielproteine führt. Darüber hinaus verursachte 
die Mesalazin-Behandlung eine gesteigerte Aktivität der Poly(ADP-Ribose)-Polymerase 
(PARP), einem indirekten Marker für aktive Caspase-3 [Paper II]. Um den Einfluss sowohl 
des extrinsischen als auch des intrinsischen Signalweges zu unters
kten Caspase-3-Aktivität resultieren, wurde die Aktivierung der jeweiligen 
Schlüsselenzyme dieser Signalwege, Caspase-8 und -9, nach Behandlung der Zellen mit 
Butyrat [Paper I] bzw. Mesalazin [Paper II] bestimmt. Darüber hinaus wurde die Wirkung 
dieser Substanzen auf die inhibitorischen Apoptoseproteine (IAP) Survivin und Xiap ermittelt 
[Paper I, II]. Mesalazin [Paper II] und Butyrat [Paper I] führten koinzident zu einem Anstieg 
von aktivierter Caspase-8 bei gleichzeitiger Hemmung der beiden IAP. Die Caspase-9 
Aktivität wurde hingegen lediglich durch Butyrat gesteigert [Paper I]. Mesalazin führte 
außerdem zu einer zeit- und dosisabhängigen Reduktion der Zellzahl und -proliferation, 
einem Zellzyklusarrest mit einer Akkumulation der Zellen in der G0/G1-Phase, einer 
Expressionsminderung von c-Myc, sowie in einer gesteigerten Proteinexpression des Tumor-
Suppressor-Gens PTEN [Paper II]. Durch Co-Ink
 auf die durch Mesalazin-vermittelten anti-proliferativen Wirkungen sowie auf 
sämtliche apoptotischen Marker erzielt. Lediglich die Expression von Xiap blieb unverändert 
[zusätzliche Daten]. 
Um die Beteiligung des MEK-ERK-Signalweges an der durch Butyrat gesteigerten 
PPARγ-Expression sowie Caspase-3-Aktivität zu ermitteln, wurden Caco-2 Zellen mit der 
Kombination aus Butyrat und des p38-MAPK Inhibitors SB20350 bzw. des ERK1/2-
Inhibitors PD98059 stimuliert [Paper I]. In Gegenwart des p38-MAPK-Inhi
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blieben ie durch Butyrat vermittelten Effekte nahezu vollständig aus, hingegen wurde durch 
Inhibie
 PPARγ-abhängige und -unabhänige Regulierungsmechanismen an 
den durch Mesalazin-induziert
 d
rung des ERK1/2-Transduktionsweges keine antagonisierende Wirkung beobachtet. 
Butyrat steigerte außerdem die p38-MAPK-Aktivität, nicht jedoch die Aktivität von ERK1/2 
[Paper I]. Die Behandlung der Zellen mit dem direkten p38-MAPK-Induktor Arsenit 
induzierte zudem zeitabhängig die PPARγ-Expression. Diese Beobachtungen lassen auf eine 
Beteiligung von p38-MAPK an der durch Butyrat induzieren PPARγ- und Caspase-3-
Aktivität schließen [Paper I]. 
In weiteren Experimenten wurden sämtliche apoptotische Marker zudem in 
transfizierten kolorektalen Karzinomzellen mit unterdrückter PPARγ-Funktion untersucht, um 
eine potentielle Beteiligung von PPARγ an den durch Butyrat [Paper I] und Mesalazin [Paper 
II] vermittelten pro-apoptotischen und anti-proliferativen Wirkungen zu ermitteln. Zunächst 
wurde durch Bestimmung der PPARγ-Aktivität nach Butyrat- [Paper I + V] und Mesalazin-
Behandlung [Paper II] mittels Detektion der Expression von Cytokeratin-20, einem indirekten 
Marker für PPARγ-Aktivität, bzw. mittels Transkriptionsfaktorassays ein funktionsfähiges 
Zellsystem sichergestellt. Sowohl Butyrat [Paper I + V] als auch Mesalazin [Paper II] 
steigerten die Aktivität des PPARγ-Rezeptors in Wildtypzellen, indessen blieb, wie erwartet, 
eine gesteigerte Aktivität in dem dominant-negativ PPARγ-transfizierten Zellsystem aus. 
Butyrat [Paper I] und Mesalazin [Paper II] induzierten außerdem die PPARγ-Expression in 
Wildtypzellen. Alle Wirkungen auf die untersuchten apoptotischen Marker der Caspase-
Kaskade waren unter Stimulation von dominant-negativ PPARγ-transfizierten Zellen mit 
Butyrat [Paper I] sowie Mesalazin [Paper II] nicht mehr nachweisbar. Lediglich die 
Expressionsminderung von c-Myc blieb unverändert. Ebenso wurden die durch Mesalazin-
vermittelten anti-proliferativen Effekte partiell aufgehoben; eine durch Mesalazin-verursachte 
Expressionssteigerung von PTEN blieb aus [Paper II].  
Zusammenfassend belegen diese Daten erstmals die Bedeutung von PPARγ als 
zentrales zwischengeschaltetes Signalmolekül an den durch Butyrat und Mesalazin 
induzierten pro-apoptotischen Wirkungen entlang der Caspase-Kaskade. Zudem konnte ein 
durch Butyrat-vermittelter p38-MAPK-PPARγ-Caspase-3 Signaltransduktionsweg etabliert 
werden. Ferner wurden
en pro-apoptotischen und anti-proliferativen Wirkungen 
nachgewiesen. Diese Vorgänge werden u.a. über die modulierende Funktion von Mesalazin 
auf das Tumor-Suppressor-Gene PTEN bzw. auf das Onkoprotein c-Myc vermittelt. 
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Im zweiten Teil dieser Arbeit wurde der Einfluss der HDAC-Inhibitoren Butyrat und 
SFN auf die antimikrobiell wirkenden Proteine Cathelicidin (LL-37) [Paper III] und β-
Defensin-2 (HBD-2) [Paper IV] sowie die zugrunde liegenden molekularen Regulations-
vorgänge untersucht. Antimikrobielle Peptide sind Bestandteil des angeborenen 
Immunsystems, die zur Aufrechterhaltung der schützenden Mukosabarriere im Rahmen 
infektiöser Prozesse beitragen. Mittels semiquantitativer RT-PCR konnte eine zeit- und 
dosisabhängige Induktion der LL-37- [Paper III + zusätzliche Daten] und HBD-2-mRNA-
Expres
 
γ [zusätzliche 
Daten]
7-mRNA 
aus [Paper III]. Umgekehrte Effekte der Inhibitoren waren nach SFN-Behandlung auf die 
sion [Paper IV] nach Inkubation kolorektaler Karzinomzellen mit Butyrat bzw. SFN 
beobachtet werden. Parallel zur Steigerung der Expression von HBD-2-mRNA induzierten 
Butyrat und SFN auch die HBD-2-Proteinexpression [Paper IV]. Mithilfe einer Immuno-
fluoreszenz-Analyse konnte außerdem eine überwiegende Lokalisation von HBD-2 [Paper 
IV] und LL-37 [Paper III] im Zytosol ermittelt werden.  
Um den Einfluss der nukleären Rezeptoren PPARγ und VDR auf die Induktion der 
mRNA-Expression der antimikrobiellen Peptide durch HDAC-Inhibitoren zu untersuchen, 
erfolgte die Bestimmung der Expression unter dem Einfluss des VDR-Antagonisten 
ZK191732, sowie in PPARγ dominant-negativ transfizierten HT-29 Zellen [Paper III, IV]. 
Die durch Butyrat- und SFN-induzierten LL-37- bzw. HBD-2-mRNA-Level wurden jeweils 
durch die Co-Inkubation mit dem VDR-Antagonisten partiell aufgehoben [Paper III, IV]. Die 
Behandlung von PPARγ dominant-negativen Zellen übte hingegen keinen Einfluss auf die 
Induktion von LL-37- [Paper III] bzw. HBD-2-mRNA [Paper IV] im Vergleich mit dem 
Wildtyp aus. Ferner deutet die unter SFN-Behandlung gesteigerte VDR-Expression auf eine 
Beteiligung des Rezeptors in der durch SFN induzierten Signalkaskade hin [Paper IV]. Eine
vergleichbare Induktion der VDR-Expression nach Butyrat-Behandlung ist in der Literatur 
hinreichend belegt. Zudem steigerte SFN die Proteinexpression von PPAR
. 
Darüber hinaus wurde die Beteiligung des MEK-ERK-Signalweges an der 
induzierbaren LL-37- und HBD-2-mRNA-Expression bestimmt [Paper III, IV]. Hierzu 
wurden die Zellen mit spezifischen Inhibitoren gegen p38-MAPK (SB203580) bzw. ERK1/2 
(PD98059) vorinkubiert und anschließend mit Butyrat bzw. SFN behandelt. Durch Co-
Inkubation mit dem p38-MAPK-Inhibitor wurde die durch Butyrat induzierte LL-37-mRNA 
nahezu vollständig aufgehoben [Paper III]. Co-Stimulierung von Butyrat mit dem ERK1/2-
Inhibitor übte hingegen nur eine partielle Reduktion auf die Expression von LL-3
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Expres
n der Zellen mit TNFα und Butyrat erniedrigt, jedoch nicht nach LPS-Stimulation. 
Um ein
sion von HBD-2-mRNA zu beobachten [Paper IV]. SFN induzierte zudem die 
Aktivierung von ERK1/2; hingegen wurde die p38-MAPK-Aktivität nicht beeinflusst [Paper 
IV]. Durch Blockierung der TGF-β1-Rezeptorkinase mittels des spezifischen Antagonisten 
SB431542 wurde die durch Butyrat induzierte LL-37-mRNA-Expression teilweise 
aufgehoben [Paper III]. 
Allgemein weisen diese Daten darauf hin, dass eine durch die natürlichen HDAC-
Inhibitoren Butyrat und SFN induzierbare Expression der antimikrobiellen Peptide LL-37 und 
HBD-2 von einer Vielzahl von Signalkaskaden und Rezeptoren reguliert wird. In diesem 
Regulationsprozess spielen sowohl VDR als auch der MEK-ERK-Signaltransduktionsweg 
eine bedeutende Rolle. Im Gegensatz dazu kann eine Beteiligung des PPARγ-Rezeptors 
ausgeschlossen werden.  
 
Die supprimierende Wirkung von Butyrat auf die induzierbare NFκB-Aktivität ist 
hinreichend belegt. Ferner konnte eine Modulierung der NFκB-Aktivität durch nukleäre 
Rezeptoren aufgezeigt werden. Im letzten Teil der Arbeit wurde daher eine mögliche 
Beteiligung der beiden nukleären Rezeptoren PPARγ und VDR am basalen NFκB-
Signaltransduktionsweg sowie an der Butyrat-vermittelten Hemmung von TNFα- bzw. LPS- 
induzierter NFκB-Aktivität untersucht [Paper V].  
Mittels Transkriptionsfaktorassays konnte nach Stimulierung von HT-29 Zellen mit 
TNFα sowie mit LPS eine erhöhte p50- und p65-NFκB-Dimer-Aktivität gemessen werden. 
Die Prä-Inkubation mit Butyrat führte zu einer signifikanten Hemmung der basalen p50- 
sowie der Zytokin-induzierten p50- und p65-NFκB-Aktivität. Im Gegensatz dazu konnte 
keine hemmende Wirkung auf die basale p65-Untereinheit nach Butyrat-Behandlung 
beobachtet werden. Die cytosolische Expression des NFκB-Inhibitors IκBα wurde nach 
Inkubatio
e potentielle Beteiligung von PPARγ und VDR an der supprimierenden Wirkung von 
Butyrat auf die basale sowie Zytokin-vermittelte NFκB-Aktivität zu bestimmen, wurden die 
Experimente in transfizierten HT-29 Zellen mit unterdrückter PPARγ-Funktion sowie unter 
dem Einfluss von rezeptorspezifischen VDR- (ZK191732) und PPARγ-Antagonisten 
(GW9662) durchgeführt. Die Co-Inkubation mit ZK191732 nach Inkubation mit TNFα hob 
die supprimierende Wirkung von Butyrat auf die NFκB-Aktivität partiell auf; eine 
regulatorische Beteiligung von PPARγ konnte in diesem Modell dagegen ausgeschlossen 
werden. Im Gegensatz dazu wurde nach Behandlung mit LPS eine Beteiligung von PPARγ, 
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nicht jedoch von VDR beobachtet. Die basale NFκB-Aktivität wurde durch Inkubation des 
VDR-Antagonisten bei gleichzeitiger Reduktion von IκBα im Zytoplasma signifikant erhöht; 
der PPARγ-Inhibitor GW9662 übte hingegen keinen Einfluss auf die basale NFκB-Aktivität 
und die IκBα- Expression aus. Die unterschiedlichen Effekte der supprimierenden Wirkung 
von Butyrat auf die durch TNFα- oder LPS-induzierbare NFκB-Aktivität lassen sich durch die 
Beteilig
 belegen diese Daten erstmals die Bedeutung von PPARγ und VDR 
als zwischengeschaltete Signalmoleküle der inhibitorischen Wirkung von Butyrat auf die 
NFκB-
de Funktion von Mesalazin, Butyrat und 
SFN a
ung von unterschiedlichen Signaltransduktionskaskaden erklären. TNFα aktiviert 
NFκB dabei vornehmlich über den TNF-Repeptor, hingegen interagiert LPS mit dem Toll-
Like-Rezeptor-Signaltransduktionsweg. Eine erhöhte PPARγ-Expression nach Behandlung 
der Zellen mit LPS deutet ferner auf PPARγ als Signalmolekül im Toll-Like-Rezeptor-
Signaltransduktionsweg hin.  
Zusammenfassend
Aktivität in Abhängigkeit von dessen Triggerung durch pro-inflammatorische Stimuli. 
Darüber hinaus konnte eine Beteiligung von VDR an der basalen NFκB-Aktivität aufgezeigt 
werden.  
 
Mit den vorliegenden Resultaten in kolorekatalen Tumorzellen wird das Spektrum der 
intestinalen Zellregulierung durch die modulieren
uf die Caspase-Kaskade, auf antimikrobielle Peptide sowie auf den NFκB-
Signaltransduktionsweg erweitert. Ferner konnte eine Beteiligung der nukleären 
Hormonrezeptoren PPARγ und VDR an den genannten Signaltransduktionsprozessen 
aufgezeigt werden. Die vorliegende Arbeit unterstreicht somit nicht nur die allgemeine 
zellbiologische Bedeutung der nukleären Hormonrezeptoren PPARγ und VDR an 
gastrointestinalen Regulierungsvorgängen, sondern impliziert auch deren Potential zur 
Entwicklung neuer therapeutischer Ansätze in der Behandlung des kolorektalen Karzinoms 
und von CED. Die prinzipielle Relevanz der gefundenen Daten muss jedoch durch weitere 
grundlagenwissenschaftliche  und intensive klinische Forschungsbemühungen untersucht 
werden. 
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Abstract Background: Butyrate, a potent histone deacety-
lase inhibitor, belongs to a promising new class of antineo-
plastic agents with the capacity to induce apoptosis of can-
cer cells. However, the underlying mechanisms of action
have yet not been elucidated. Aim: To further investigate
the molecular events involved in butyrate-induced caspase-3
activation in Caco-2 wild-type, empty-vector and dominant-
negative PPARγ mutant cells along the signalling pathway.
Inthiscontext,theinvolvement andup-regulationofPPARγ
was examined. Results: Stimulation of cells with butyrate
resulted in increased expression of PPARγ mRNA, pro-
tein, and activity as well as phospho-p38 MAPK protein
expression and caspase-3 activity. Arsenite, a direct stimu-
lator of p38 MAPK, also led to an increased PPARγ ex-
pression, thereby mimicking the effects of butyrate. In con-
trast, butyrate-mediated up-regulation of PPARγ was coun-
teracted by co-incubation with the p38 MAPK inhibitor
SB203580. Treatment of cells with butyrate resulted in both
increased caspase-8 and -9 activity and reduced expression
of XIAP and survivin. However, butyrate-mediated effects
on these apoptosis-regulatory proteins leading to caspase-
3 activation were almost completely abolished in Caco-2
dominant-negative PPARγ mutant cells. Conclusions: Our
data clearly unveil PPARγ as a key target in the butyrate-
inducedsignallingcascadeleadingtoapoptosisviacaspase-3
in Caco-2 cells.
Keywords Apoptosis . Butyrate . Caspase-3 . p38 MAPK .
PPARγ
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Abbreviations
DFF DNA Fragmentation Factor
DMEM Dulbecco’s modiﬁed Eagle’s medium
DMSO Dimethyl sulfoxide
ECACC European Collection of cell cultures
EGF Epithelial growth factor
ERK Extracellular signal-regulated kinase
FCS Foetal calf serum
FLIP FLICE-inhibitory protein
HDAC Histone deacetylase
IAP Inhibitor of apoptosis protein
JNK cJun N-terminal kinase
LDH Lactate dehydrogenase
MAPK Mitogen-activated protein kinase
PARP Poly(ADP-ribose) Polymerase
PBS Phosphate buffered saline
PKC-δ Protein kinase C-δ
PPARγ Peroxisome proliferator-activated receptor γ
SCFA Short chain fatty acid
STAT3 Signal transducer and activator of
transcription-3
TBS-T Tris-buffered saline containing 0.05% Tween 20
TNF Tumor necrosis factor
XIAP X linked inhibitor of apoptosis
Introduction
Althoughhumandataarestillinconsistent,atleastinrodents
evidencehasbeenprovidedthatalimentaryﬁbresexertapro-
tective role with regard to colorectal carcinogenesis [1]. The
beneﬁts of a high intake of dietary ﬁbre can be attributed to
their fermentation in the colonic lumen to short chain fatty
acids (SCFA), including butyrate. Besides its role as the ma-
jor energy source for the colonocyte [2], there is increasing
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evidence that butyrate also acts as a critical factor in the
physiological turnover of the colonic epithelium [3]. Roles
for butyrate have been established for cell proliferation [4],
differentiation [5], morphology [6], motility [7], as well as
induction ofcellcyclearrest[8]andapoptosis[9].Therefore
butyrate may be considered as a chemopreventive agent in
colorectal cancer [10, 11].
Although over the past years major advances have in-
creased our understanding of the molecular mechanisms that
trigger apoptosis, the regulation of apoptotic cell death has
yet not been fully uncovered. Major pathways in butyrate-
inducedapoptosisincludethecaspase-[12,13],proteasome-
[14] and the autophagic-induced [13] cell death, which fre-
quently occur in parallel or in cross talk [13, 14]. Among
these, the caspase cascade pathway is the best characterized
one in butyrate-mediated apoptosis. One key endpoint rep-
resents caspase-3, a member of a cysteine protease family,
speciﬁcally involved in the initiation and execution of the
apoptotic programme [12, 13]. Activation of p38 Mitogen-
activated protein kinase (MAPK) seems to be a critical up-
stream event in butyrate-induced caspase-3 activity [15].
Moreover, caspase-3 is a downstream effector caspase that
is activated by upstream caspases, predominantly caspase-8
and -9. Activation of caspase-3 then leads to cleavage of cel-
lular substrates e.g. Poly(ADP-ribose) Polymerase (PARP)
[16], DNA Fragmentation Factor (DFF) [17] and disassem-
bling of the cell [18]. Two pathways operate as sensors for
caspase-3activationandcanstimulatethecellulardeathpro-
gram of apoptosis. The extrinsic or receptor-mediated path-
way involves members of the Tumor necrosis factor (TNF)
receptorsuperfamilyandisengagedinresponsetocytokines
and extracellular signals leading to activation of caspase-8
[19]. The intrinsic pathway is activated in response to in-
tracellular signals and cytotoxic insults and is mediated by
members of the Bcl-2 family at the level of mitochondria
resulting in activation of caspase-9 [20].
The family of inhibitor of apoptosis proteins (IAP) is a
recently identiﬁed, novel category of apoptosis-regulatory
proteins. IAPs can inhibit the activation of caspases by both
the extrinsic and intrinsic pathway. IAPs are of particular
interest as they are up-regulated in many cancer cells and are
decreased by several histone deacetylase (HDAC) inhibitors
[21].
Previously, we have uncovered for the ﬁrst time the de-
cisive role of the peroxisome proliferator-activated receptor
γ (PPARγ) in butyrate-induced growth inhibition of colon
cancer cells [22, 23]. There is also a body of evidence indi-
cating that PPARγ may interact with both p38 MAPK and
caspase-3 [15, 24], which makes this nuclear receptor an in-
triguing target in butyrate-mediated apoptosis. On the basis
of these current ﬁndings, our study addressed the potential
role of PPARγ in the regulation of apoptosis by butyrate in
the colorectal adenocarcinoma cell line Caco-2.
Materials and methods
Cell culture
The human colorectal cancer cell line Caco-2 was obtained
from the European Collection of cell cultures (ECACC).
Cells were cultured in a humidiﬁed incubator at 37◦Ci n
an atmosphere of 95% air and 5% CO2. Caco-2 cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM),
supplemented with 10% foetal calf serum (FCS), 1%
non-essential amino acids, 1% sodium pyruvate and 1%
penicillin/streptomycin. Medium of the dominant-negative
PPARγ mutant and empty-vector Caco-2 cells was sup-
plied with 400 µg/ml Geneticin 418 sulphate (G418, Gibco-
BRL, Eggenstein, Germany). Cells were regularly screened
for mycoplasma contamination using the VenorGem
Mycoplasma detection kit (Minerva Biolabs, Berlin,
Germany).
For experiments, cells were seeded in plastic cell cul-
ture wells and were cultivated in DMEM at 80% conﬂuency.
Medium was then removed and replaced by a medium con-
taining either the solvent or butyrate (3 mmol/l), arsenite
(50 µmol/l), p38 MAPK inhibitor SB203580 (20 µmol/l),
extracellular signal-regulated kinase (ERK) 1/2 inhibitor
PD98059 (40 µmol/l) or the combination of butyrate and
one of the inhibitors. Butyrate (Merck-Schuchardt, Ho-
henbrunn, Germany) and arsenite (Fluka, Sigma Aldrich-
Chemie,Steinheim,Germany)weresolubilizedinphosphate
buffered saline (PBS) and added to the medium (ﬁnal max-
imum concentration of PBS in medium was 0.1% (v/v)).
PD98059 and SB203580 (Calbiochem, Schwalbach/Taunus,
Germany) were dissolved in dimethyl sulfoxide (DMSO,
Fluka, Sigma-Aldrich-Chemie, Steinheim, Germany, ﬁnal
maximum concentration of DMSO in medium was 0.1%
(v/v)). The medium was changed every day. Cells were then
harvested at the times indicated in the ﬁgure legends.
Transfection assay
The following plasmids were used for transfection: pcDNA3
(Invitrogen), as an empty-vector for control transfection
and the plasmid pcDNA3-PPARγ L468A/E471A, a dominant-
negative PPARγ double-mutant, that was kindly provided
by VK Chatterjee (Department of Medicine, University of
Cambridge, Addenbrooke’s Hospital, Cambridge, UK) [25].
These constructs were transfected into subconﬂuent Caco-
2 cells with lipofectamine 2000 (Invitrogen) in serum-free
conditions. After 6 h, the cells were supplied with fresh
medium containing 10% FCS. 24 h later, the cells were sup-
plied with medium containing G418 (400 µg/ml) and cul-
ture medium supplemented with G418 was replaced twice a
week. G418-resistant colonies were collected and used for
further analysis.
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Cytotoxicity
Cytotoxicity was excluded by lactate dehydrogenase (LDH)
release assay using a commercial kit (LDH kit, Roche,
Mannheim, Germany).
Cellular extraction
Caco-2 cells were stimulated with indicated substances at
80% conﬂuency. Cellular extraction was performed using
the Active Motif Nuclear cell extraction kit according to the
manufacturer’s instructions (Active Motif Nuclear extract
kit, Rixensart, Belgium). Protein content was determined
via Bio-Rad colorimetric assay according to the method of
Bradford (Bio-Rad Laboratories, Munich, Germany).
SDS-polyacrylamide gel electrophoresis
and immunoblot analysis
Equal amounts of total protein lysates were separated on a
10% SDS-polyacrylamide gel for PPARγ and cytokeratin
20 protein and on a 12.5% SDS-polyacrylamide gel for p38
MAPK, phospho-p38 MAPK, XIAP and survivin protein,
respectively. Proteins were transferred to a nitrocellulose
membrane (Schleicher & Schuell, Dassel, Germany). Sub-
sequently, membranes were blocked overnight at 4◦C with
3% (w/v) nonfat dried milk in Tris-buffered saline contain-
ing 0.05% Tween 20 (TBS-T). Membranes were then incu-
bated for one hour with 1:2000 dilutions of human PPARγ-
antibody(Calbiochem,LaJolla,CA),phospho-p38MAPK-,
XIAP- and survivin-antibody (all from Cell signaling, Bev-
erly, MA) or with a 1:500 dilution of human cytokeratin
20-antibody (Santa Cruz Biotechnologies, Santa Cruz, CA),
respectively. After washing, the blots were incubated for
half an hour with corresponding horseradish peroxidase-
conjugated antibodys (all from Santa Cruz Biotechnolo-
gies, Santa Cruz, CA, dilution 1:2000) in 0.05% TBS-T
and 3% (w/v) nonfat dried milk. The washing steps were
repeated, and subsequently enhanced chemoluminescence
detection was performed according to the manufacturer’s
instructions (ECL, Amersham Pharmacia Biotech, Bucking-
hamshire, UK) on Hyperﬁlm-MP (Amersham International
plc, Buckinghamshire, UK). Blots were then reprobed with
β-actin antibody (Santa Cruz Biotechnologies, Santa Cruz,
CA). For quantitative analysis, bands were detected by scan-
ning densitometry, using a Desaga CabUVIS scanner and
Desaga ProViDoc software (Desaga, Wiesloch, Germany).
Semiquantitative RT-PCR
Cells were cultivated in 6-well plates and were treated at
80% conﬂuency with butyrate, any inhibitor or one of the
combinationsbutyrate +SB203580orbutyrate +PD98059
for 24 and 48 h, respectively. Total RNA was iso-
lated from cells by RNA isolation reagent (TRIR, Ab-
gene, UK), followed by phenol extraction and ethanol
precipitation. Reverse transcription of total RNA was
performed using Superscript II RNase H reverse tran-
scriptase (Invitrogen, Karlsruhe, Germany) and random
hexanucleotide primers (Applied Biosystems, Weiterstadt,
Germany). PCR was conducted using the following sense
and antisense primers, respectively (Biospring, Frankfurt,
Germany): PPARγ-forward: 5 -atg-ggt-gaa-act-ctg-gga-gat-
tct-cct-a-3 ;P P A R γ-reverse: 5 -ggt-cat-ttc-ttg-tga-tat-gtt-
tgc-aga-cag-t-3 ; thermal cycling conditions: 30 cycles, de-
naturation at 94◦C for 30 s, annealing at 55◦C for 60 s, and
extension at 72◦C for 60 s. Cycles were selected as optimal
ampliﬁcationconditionstoproducealong-linearrelationship
between the amount of each mRNA and the intensity of the
PCRproduct.ThePCRreactioncontained0.2mmol/ldNTPs
(Eurogentec, Seraing, Belgium), 1 µmol/l primers, 0.3 µl
Taq DNA Polymerase (1.5 U) and 1.5 mmol/l MgCl2 per
30 µl reaction. PCR products were separated electrophoret-
ically using a 2% agarose gel containing ethidium bromide
and visualized by UV illumination. For semi-quantitative
analysis of ampliﬁed PCR products, the ﬂuorescent dye
PicoGreen (Molecular Probes, Eugene, OR) was used ac-
cording to the manufacturer’s instructions. In brief, two mi-
croliters of ampliﬁed DNA in 100 µl TE buffer were mixed
with an equal volume of diluted PicoGreen reagent (1:200,
v/v in TE buffer). Samples were incubated for 5 min at room
temperature protected from light in a microtiter plate. The
ﬂuorescence was measured (λex = 485 nm; λem = 538 nm)
in the ﬂuorescence microplate reader Tecan SpectraFluor
PLUS (Tecan GmbH Crailsheim, Germany). The standard
curve for the quantitative analysis was obtained with λ DNA
standard in TE buffer and was linear from 1 to 200 ng/well.
Measurement of caspase-3 activity
The EnzCheck caspase-3 assay kit #2 (Molecular Probes,
Leiden, The Netherlands) was used according to the man-
ufacturers instructions. Caco-2 cells were grown to 80%
conﬂuency and then stimulated with indicated substances.
In inhibitor experiments, cells were pretreated with the in-
hibitorsfor12h,followedbychallengeofcellswithbutyrate
for 24 h. Cells were trypsinized and counted. For each sam-
ple106 cellswerepelleted and storedat −80◦Cuntil further
preparation.Pelletswerethenthawedoniceandresuspended
in lysis buffer. After complete lysis of the cells, the particu-
late material was sedimented by centrifugation at 2000×g
for 5 min. Protein concentration of the supernatant was mea-
sured by Bio-Rad colorimetric assay and equal amounts of
protein were diluted in lysis buffer for each reaction. The
normalized supernatant was incubated with the Z-DEVD-
R110 substrate for 30 min. Fluorescence was measured
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(λex = 492 nm; λem = 535 nm) with the ﬂuorescence mi-
croplate reader Tecan SpectraFluor PLUS.
Measurement of caspase-8 and -9 activity
The FLICE/Caspase-8 Colorimetric Assay Kit (BioVision
Mountain View, CA) and the caspase-9 Colorimetric As-
say Kit (Calbiochem, La Jolla, CA) were used to de-
termine enzymatic activity of caspase-8 or -9 class of
proteases in apoptotic cells by colorimetric reaction. The
three cancer cell lines Caco-2 wild-type, Caco-2 dominant-
negative PPARγ, and Caco-2 empty-vector were treated
with butyrate (3 mmol/l) for 24 h. After trypsinisation,
cells (5×106/sample) were collected in PBS and pelleted.
100µgoftotalproteinwasloadedintoeachwellofa96-well
ﬂat bottom microplate and adjusted to 50 µl with dilution
buffer. Subsequently, 50 µlo f2× reaction buffer contain-
ing 10 mmol/l of dithiothreitol was added. After adding 5 µl
of caspase colorimetric substrate, the plate was incubated at
37◦C for 2 h. Caspase-8 and -9 activity was determined us-
ing IETD-pNA and LEHD-pNA as substrate, respectively.
Optical density was determined by a microplate reader
(λex = 405 nm). Results were expressed as the percent of
control.
Statistics
If not otherwise stated, data are expressed as means ± SEM
fromthreeindependentexperimentsperformedinduplicates.
Student’s t test was used for statistical comparison (Sigma-
Stat, SPSS, Chicago, IL). P value <0.05 was considered to
be signiﬁcant.
Results
Phospho-p38 MAPK is involved in butyrate-induced
caspase-3 activation
To establish a possible role of MAPKs in butyrate-induced
apoptosis in colonic epithelial cells, we ﬁrst examined the
effect of butyrate on p38 MAPK and ERK1/2 expression
in the Caco-2 cell line. As shown in Fig. 1, incubation of
cells with butyrate at a concentration of 3 mmol/l for 24 h
signiﬁcantly increased phospho-38 MAPK as compared to
control. In contrast, expression of phospho-ERK1/2 was not
affected by treatment of the Caco-2 cell line with butyrate
(data not shown).
In order to unveil the involvement of any MAPK in
butyrate-inducedapoptosis,weemployedspeciﬁcMAPKin-
hibitors,thep38MAPKinhibitorSB203580andtheERK1/2
inhibitorPD98059,andinvestigatedtheireffectsonbutyrate-
induced caspase-3 activation. Incubation of Caco-2 cell with
butyrate (3 mmol/l) for 24 h signiﬁcantly increased caspase-
3 activity up to +215 ± 45% compared to control level
(p < 0.01) as determined by cleavage of Z-DEVD-R110. In
contrast, pretreatment of the Caco-2 cell line with the p38
MAPK inhibitor SB203580 (20 µmol/l) for 12 h, followed
by treatment of cells with butyrate for additional 24 h, re-
sultedinasigniﬁcantinhibitionofbutyrate-inducedcaspase-
3 activity (−63 ± 10%, p < 0.05). The speciﬁc ERK1/2
inhibitor PD98059 (40 µmol/l) had no impact on the in-
duction of caspase-3 activity caused by butyrate (data not
shown).
PPARγ plays a pivotal role in p38 MAPK-mediated
caspase-3 activation by butyrate
Stimulation of the colorectal carcinoma cell line Caco-
2 with butyrate (3 mmol/l) resulted in a time-dependent
increase of PPARγ mRNA. Signiﬁcant effects were ﬁrst
observed after 24 h (data not shown) and reached its
maximum at 48 h of treatment with a 1.7-fold increase
in PPARγ mRNA. Whereas the combination of butyrate
and the ERK1/2 inhibitor PD98059 did not inﬂuence
butyrate-induced PPARγ mRNA expression at any time,
co-incubation of butyrate with the p38 MAPK inhibitor
SB203580 (20 µmol/l) signiﬁcantly reversed the butyrate-
induced up-regulation of PPARγ mRNA expression at 48 h
of treatment (Fig. 2(A)). Up-regulation of PPARγ mRNA
was followed by transient changes on the protein level. In-
deed, after 48 h of treatment, butyrate signiﬁcantly aug-
mented PPARγ protein expression (+45 ± 14% of con-
trol, p < 0.05, Fig. 2(B)). Again, incubation with the
p38 MAPK inhibitor completely abolished the induction of
PPARγ protein expression by butyrate, whereas the ERK1/2
inhibitor PD98059 had no impact on PPARγ expression
levels.
To corroborate our ﬁndings of a signalling link between
p38 MAPK and PPARγ, Caco-2 cells were treated with ar-
senite (50 µmol/l), a known direct stimulator of p38 MAPK.
As shown in Fig. 3, arsenite augmented PPARγ protein ex-
pression in a time-dependent manner, already beginning at
6 h of stimulation (+44 ± 18% of control, p < 0.05) with a
maximumof +135 ± 10%vs.controlat24hofincubation,
indicating that p38 MAPK is involved in butyrate-induced
up-regulation of PPARγ expression.
In order to conﬁrm the pivotal role of PPARγ in butyrate-
mediated apoptosis, activation of caspase-3 by butyrate was
also analysed in Caco-2 cells transfected with a dominant-
negative PPARγ mutant to inhibit wild-type receptor action.
As shown in Fig. 4, no signiﬁcant effects on caspase-3 ac-
tivity could be detected in PPARγ dominant-negative Caco-
2 cells treated with butyrate (3 mmol/l) for 24 h as com-
pared with both Caco-2 wild-type and Caco-2 empty-vector
cells.
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Fig. 1 Effect of butyrate (3
mmol/l) on p38 MAPK and
phospho-p38 MAPK protein
expression in Caco-2 cells after
24 h. One representative gel of
three independent experiments
is shown. Quantitative data are
corrected for β-actin levels. ∗∗p
< 0.01
PPARγ is also involved in caspase-8 and caspase-9
activation and controls the expression of the inhibitor
of apoptosis proteins XIAP and survivin after butyrate
treatment
To investigate the ﬁne tuning in the caspase pathway lead-
ing to elevated caspase-3 activity after butyrate treatment,
the activities of caspase-8 and -9 were examined. Incuba-
tion with butyrate (3 mmol/l) resulted in a signiﬁcant in-
crease in caspase-8 (∼2.3-fold, p < 0.01) and caspase-9
(∼1.7-fold, p < 0.01) activity after 24 h in both, Caco-
2 wild-type and Caco-2 empty-vector cells. In contrast,
up-regulation of caspase-8 (∼1.2-fold, n.s.) and caspase-9
(∼1.2-fold, n.s.) activity in response to butyrate was found
to be almost reversed in PPARγ dominant-negative Caco-2
cells.
To specify the molecular mechanism of butyrate-induced
apoptosis, changes in IAPs, X linked inhibitor of apoptosis
(XIAP) and survivin, were further examined (Fig. 5(A) and
(B)). In Caco-2 wild-type cells, levels of survivin and XIAP
were reduced to −68 ± 8% (p < 0.001) and −59 ± 10%
(p < 0.01) of control in response to butyrate (3 mmol/l)
for 24 h, respectively. Similar effects were obtained in
Caco-2 empty-vector cells. In contrast, butyrate-mediated
down-regulation of both IAP family members was partially
neutralized when incubated in Caco-2 dominant-negative
PPARγ mutant cells.
To evaluate receptor activity of PPARγ in Caco-2 wild-
type and dominant-negative PPARγ mutant Caco-2 cells,
we determined the expression of cytokeratin 20 which has
been described to be a speciﬁc target gene of PPARγ activ-
ityincolorectalcancercells[26].Atime-dependentincrease
Springer1806 Apoptosis (2006) 11:1801–1811
Fig. 2 (A) PPARγ mRNA-expression in Caco-2 cells after treatment
with butyrate (3 mmol/l), p38 MAPK inhibitor SB203580 (20 µmol/l),
ERK1/2 inhibitor PD98059 (40 µmol/l) and the combined treatment
of butyrate and one of the inhibitors for 48 h. Semiquantitative analy-
sis of PCR products was performed using Pico Green. All values for
mRNA levels are normalized to corresponding mRNA amount of the
housekeeping gene GAPDH. ∗p < 0.05, ∗∗p < 0.01, n.s. = not sig-
niﬁcant (B) Effect of the speciﬁc inhibitors SB203580 (20 µmol/l) and
PD98059 (40 µmol/l), respectively, on butyrate-induced PPARγ pro-
tein expression after 48 h of treatment. The band at 60 kDa corresponds
to the PPARγ protein. One representative gel of three independent ex-
periments is shown. Quantitative data are corrected for β-actin levels.
∗∗p < 0.01, n.s. = not signiﬁcant
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Fig. 3 Time-dependent effect
of the chemical p38 MAPK
stimulator arsenite (50 µmol/l)
on PPARγ protein expression
after 6 h (A) and 24 h (B) of
treatment. One representative
gel of three independent
experiments is shown.
Quantitative data are corrected
for β-actin levels. ∗p < 0.05,
∗∗p < 0.01
of cytokeratin 20 could be observed after butyrate incuba-
tion (3 mmol/l) in Caco-2 wild-type cells. Up-regulation of
protein was already detected after 24 h and reached its max-
imum to approximately 2.0-fold as compared with control
after 48 h (p < 0.01, Fig. 5(C)). As expected, cytokeratin
20 was not expressed in both unstimulated and butyrate-
challenged Caco-2 dominant-negative PPARγ mutant cells
(Fig. 5(C)).
Discussion
TheHDACinhibitorbutyrateexertspotentanti-tumoreffects
by inhibition of proliferation, induction of differentiation,
andstimulationofapoptosis[27].Revealingthetransduction
pathwayofbutyrate-mediatedapoptoticcelldeathisnotonly
important to understand fundamental biological processes,
but also may be useful for developing pharmacological tools
fortreatingcancerswithapoptoticdefects.Amongthediffer-
ent apoptotic pathways involved in butyrate-mediated apop-
tosis, activation of the caspase cascade appears to play a
protruding role. Indeed, induction of caspase-3, a down-
stream key member of the caspase pathway, by butyrate
has been demonstrated in a variety of malignant cancer
cell lines including colorectal cancer cells [28–30]. How-
ever, little is known with respect to the underlying up-
stream events participating in the regulation of caspase-3 by
butyrate.
p38 MAPK belongs toa group of protein serine/threonine
kinases which has been demonstrated to play an essential
role in the regulation of several cellular processes includ-
ing apoptosis [31–34]. Moreover, butyrate has been shown
to activate p38 MAPK in several cancer cell lines includ-
ing Caco-2 [15, 32, 35, 36]. Recent data indicate that acti-
vation of p38 MAPK is an important molecular signalling
event in butyrate-mediated activation of the caspase cascade
[15, 32, 37]. Activation of p38 MAPK by butyrate in the
human colorectal adenoma cell line AA/C1 resulted in ac-
tivation of caspase-3 [15]. Furthermore, butyrate-mediated
activation of p38 MAPK appeared to be signalled via
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Fig. 4 Caspase-3 activity of
Caco-2 wild-type, Caco-2
dominant-negative PPARγ,a n d
Caco-2 empty-vector cells 24 h
after incubation with butyrate (3
mmol/l) compared to control.
∗∗p < 0.01, n.s. = not
signiﬁcant
protein kinase C-δ (PKC-δ)[ 15]. Our data corroborate
these ﬁndings by demonstrating that butyrate-induced ac-
tivation of caspase-3 was signiﬁcantly reduced by the spe-
ciﬁcp38MAPKinhibitorSB203580.Nevertheless,butyrate-
mediated apoptotic effects were not completely reversed by
the p38 MAPK inhibitor SB203580 indicating that trans-
duction pathways other than p38 MAPK are involved in
activation of caspase-3 by butyrate at least in Caco-2. In-
deed, expression of bak, a member of the bcl2-gene family
which has been shown to be involved in the regulation of
apoptotic signalling was found to be signiﬁcantly increased
in butyrate-stimulated Caco-2 cells [38]. Moreover, bak ex-
pression does not only correlate positively with apoptosis in
intestinal epithelium [39] but also has been demonstrated to
be a potent activator of the caspase cascade [40]. However,
since butyrate is known to affect the expression of several
genes potentially involved in the regulation of programmed
cell death [38], other targets such as cJun N-terminal kinase
(JNK) [32, 41] and PKC-δ [15] may also be involved in
butyrate-induced stimulation of caspase-3 in Caco-2.
There is increasing evidence supporting the role of
PPARγ, a ligand-activated transcription factor belonging to
the nuclear hormone receptor superfamily, as a key player
in the induction of cellular apoptosis. PPARγ does not only
control the expression of genes involved in differentiation,
but also modulates cell cycling [42, 43]. Indeed, recent re-
ports indicate that the pro-apoptotic action of PPARγ is de-
pendent on caspase-3 activation. Thus, the PPARγ agonists
15-deoxy-delta12,14-prostaglandin J2 and troglitazone were
shown to induce apoptosis via elevated activity of caspase-3
in human neuroblastoma [44] and HepG2 [45] cells, respec-
tively. Finally, an association between loss-of-function mu-
tations of PPARγ and the development of colorectal cancer
inhumans[46]alsosuggeststheinvolvementofthisreceptor
in the regulation of apoptosis.
Previous studies have shown that expression of PPARγ
mRNA and protein [22, 23, 47] is under the control of
butyrate implying that PPARγ may participate in butyrate-
induced caspase-3 apoptotic signalling. To prove such a
possible role for PPARγ, butyrate-mediated pro-apoptotic
properties were investigated in Caco-2 cells, transfected
with a mutant receptor to inhibit wild-type PPARγ action. In
this mutant the highly conserved hydrophobic and charged
residues (Leu468 and Glu471) in helix 12 of the ligand
binding domain are mutated to alanine. As a consequence,
this cell mutant indeed retains PPARγ ligand and DNA
binding, but exhibits markedly reduced transactivation due
to impaired coactivator recruitment [25]. Indeed, butyrate-
mediated activation of caspase-3 was almost completely
abolished in these mutant cells indicating that PPARγ
plays a critical role in signalling the pro-apoptotic effects
of butyrate. Furthermore, our data suggest that PPARγ
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Fig. 5 Western Blot of survivin
(A) and XIAP (B) in Caco-2
wild-type and
dominant-negative PPARγ cells
after incubation with butyrate (3
mmol/l) for 24 h. One
representative gel of three
independent experiments is
shown. Quantitative data are
corrected for β-actin levels. (C)
Induction of cytokeratin 20 in
Caco-2 wild-type and
dominant-negative PPARγ cells
after treatment with butyrate (3
mmol/l) for 48 h. A
representative immunoblot of
three independent experiments
is shown
acts downstream of p38 MAPK as demonstrated by both
up-regulation of PPARγ protein by the direct p38 MAPK
stimulator arsenite and down-regulation of this nuclear
receptor on the mRNA and protein level in presence of the
p38 MAPK inhibitor SB203580.
In addition to the contribution of PPARγ in butyrate-
mediated Caco-2 cell apoptosis, our data provide further in-
sightinthemoleculareventsleadingtoactivationofcaspase-
3 as depicted in Fig. 6. The increase in caspase-8 and -9 ac-
tivity by butyrate indicates that both the extrinsic (caspase-
8) and the intrinsic (caspase-9) caspase pathway share in
caspase-3 activation. This ﬁnding is supported by recent
studies illustrating that both caspase-8 and -9 lead to in-
creased caspase-3 activity after butyrate incubation [29, 48].
Moreover, in our in vitro model butyrate also signiﬁcantly
decreased protein levels of survivin and XIAP, two proteins
known to potently block caspase-3 and -9, thereby inhibiting
apoptosis. Accordingly, a similar down-regulatory effect on
survivin and XIAP by butyrate has been previously shown
in human glioma cells [49]. Again, butyrate-mediated ef-
fects on both pro-apoptotic and anti-apoptotic events were
vigorously diminished in PPARγ dominant-negative Caco-2
cells. The underlying mechanism(s) by which PPARγ con-
trols the caspase signalling pathway are yet not fully en-
lightened. It might be speculated that PPARγ activates both
the intrinsic and extrinsic caspase pathway via modulation
of the IAPs. However, incomplete abolishment in PPARγ
dominant-negative Caco-2 cells suggests that other factors
known to modulate the expression of the IAPs such as JNK,
epithelialgrowthfactor(EGF)andactivator oftranscription-
3 (STAT3) [50–53] might also be involved. A direct interac-
tionofPPARγ andthedeathreceptorsignallingpathwaywas
disclosedonlyrecently.Kimetal.demonstratedthatPPARγ
ligands were able to down-regulate the FLICE-inhibitory
protein (FLIP), an apoptosis-suppressing protein that blocks
early events in death receptor signalling pathway [54]. Ac-
cordingly, reduced levels of FLIP after butyrate treatment
were detected in human colon cancer [55] and pancreatic
cancer cells [48], allowing apoptosis to occur via activation
of caspase-8.
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Fig. 6 Model of butyrate-induced cell death: Butyrate activates p38
MAPK, which in turn up-regulates PPARγ expression and receptor
activity. PPARγ decreases the expression of survivin and XIAP and
activatescaspase-8and-9leadingtoincreasedcaspase-3activity,even-
tually resulting in cell death
Conclusion
Our data shed further light in the underlying mechanisms of
butyrate-mediated apoptosis via caspase-3 in colorectal can-
cer cells. Following the activation of p38 MAPK by phos-
phorylation, up-regulation of PPARγ receives a key role in
mediating death receptor signalling by decreasing the ex-
pression of survivin and XIAP and increasing the activity of
caspase-8 and -9 ﬁnally leading to increased caspase-3 ac-
tivity, eventually resulting in cell death. Further studies are
warranted to elucidate the complex mechanisms underlying
butyrate-mediated apoptosis.
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Abstract 
Purpose: Mesalazine has been identified as a candidate chemopreventive agent in colon 
cancer prophylaxis because of its pro-apoptotic and anti-proliferative effects. However, the 
precise mechanisms of action are not entirely understood. The aim of our study was to 
investigate the involvement of PPARγ in mesalazine’s anti-carcinogenic actions in colorectal 
cancer cells.  
Experimental Design: The effects of mesalazine on cell cycle distribution, cell count, 
proliferation and caspase-mediated apoptosis were examined in Caco-2, HT-29 and HCT-
116 cells used as wild-type, dominant-negative PPARγ mutant and empty-vector cultures. 
We focused on caspase-3 activity, cleavage of PARP, caspase-8, and caspase-9, as well as on 
expression of survivin, Xiap, PTEN and c-Myc. Techniques employed included transfection 
assays, immunoblotting, flow cytometry analysis, colorimetric and fluorometric assays.  
Results: Mesalazine provoked a time- and dose-dependent decrease in both cell growth and 
proliferation. Growth inhibition was accompanied by a G1/G0 arrest, a significant increase 
in PTEN, caspase-3 activity, cleavage of PARP and caspase-8; while the expression of Xiap, 
survivin and c-Myc was decreased simultaneously. Cleavage of caspase-9 was not observed. 
Moreover, PPARγ expression and activity were elevated. The growth-inhibitory effect of 
mesalazine was partially reduced in dominant-negative PPARγ mutant cells, while the 
expression of c-Myc was not affected. Mesalazine-mediated increased caspase-3 activity, the 
expression of PTEN, cleavage of PARP and caspase-8 as well as reduced levels of survivin 
and Xiap were completely abolished in the PPARγ mutant cell lines.  
Conclusions: This study clearly demonstrates that mesalazine-mediated pro-apoptotic and 
anti-proliferative actions are regulated via PPARγ-dependent and -independent pathways in 
colonocytes.     3 
 
 
Introduction 
Colorectal cancer (CRC) is one of the most fearsome complications of inflammatory bowel 
diseases (IBD) mainly ulcerative colitis (UC) but also Crohn’s colitis (1, 2). CRC risk 
increases significantly with extent and duration of the disease (1). Main strategy for CRC 
prevention in chronic UC is currently based on identification of neoplasia by surveillance 
colonoscopy, but there is great interest in the possibility of primary chemoprevention (3). A 
series of epidemiological investigations and preliminary clinical trials have affirmatively 
suggested that regular intake of oral mesalazine (5-ASA, 5-aminosalicylate) may have anti-
neoplastic and potentially prophylactic properties reducing the occurrence of CRC in 
patients with IBD, in particular UC (4, 5). Furthermore, chromosomal and microsatellite 
instability as well as dysplasia was found to be reduced after long-term mesalazine therapy 
(6-8). 
The molecular mechanisms responsible for mesalazine’s chemopreventive effects are 
not entirely understood. The widespread mechanisms leading to its anti-carcinogenic actions 
include the inhibition of inflammatory cascades such as the cyclooxygenase pathway (COX-
1 and COX-2) which regulates cell proliferation through formation of prostaglandins (9). 
Moreover, recent studies suggest that 5-ASA may reduce the cancer risk by mechanisms 
other than simply controlling inflammation, such as increasing apoptosis, decreasing cellular 
proliferation and by activating the Peroxisome-Proliferator-Activated Receptor γ (PPARγ) 
(10, 11). 
In a rodent CRC model, mesalazine inhibits tumor growth and reduces the number of 
aberrant crypt foci while in patients with sporadic polyps or cancer of the large bowel, 
mesalazine induces apoptosis and decreases proliferation in the colorectal mucosa (12). In 
addition, induction of apoptosis through activation of caspase-3 in colon cancer cells has also    4 
 
 
been indicated (13). However, the precise pathway of activating the caspase cascade is still 
unknown.    
Rousseaux et al. demonstrated that PPARγ is a target of mesalazine (11, 14). The 
drug increased PPARγ expression, promoted its translocation from the cytoplasm to the 
nucleus and induced a modification of its conformation permitting the recruitment of 
coactivators and the activation of a PPARγ response element driven gene (11, 14, 15). 
PPARγ is a transcription factor belonging to the nuclear hormone receptor superfamily (11). 
The receptor is highly expressed in the colonic epithelium and can not only be activated by 
natural ligands such as eicosanoids and fatty acids like butyrate, but also by synthetic ligands 
such as thiazolidinediones (16, 17). In the gastrointestinal tract, PPARγ is known to regulate 
cellular proliferation, differentiation, and to induce apoptosis (18, 19). Moreover, reports 
demonstrate that PPARγ ligands lead to tumor suppression (20). The growth of cultured 
human colon tumor cells and of transplanted tumors in nude mice is inhibited by activators 
of PPARγ, including troglitazone, rosiglitazone and 15-deoxy-delta
12,14-prostaglandin J2 (19, 
20).  
Recently, the participation of PPARγ, both in cell growth inhibition and in the 
regulation of several pro- and anti-apoptotic markers of the caspase signalling pathway was 
demonstrated by our group in CRC cells (21, 22). Based on these observations, the present 
study was addressed to elucidate the putative role of PPARγ in mesalazine-mediated anti-
proliferative and pro-apoptotic effects. 
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Materials and methods 
Cell culture 
The human CRC cell lines Caco-2, HT-29 and HCT-116 were obtained from the European 
Collection of cell cultures (ECACC). Cells were cultured in a humidified incubator at 37 °C 
in an atmosphere of 95% air and 5% CO2. Caco-2 cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 10% foetal calf serum (FCS), 1% non-
essential amino acids, 1% sodium pyruvate and 1% penicillin/streptomycin. HT-29 and 
HCT-116 cells were grown in McCoy’s 5A Medium, supplemented with 10% FCS and 1% 
penicillin/streptomycin. Medium of the dominant-negative PPARγ mutant and empty-vector 
Caco-2 and HT-29 cells was supplied with 400 μg/ml Geneticin 418 sulphate (G418, Gibco-
BRL, Eggenstein, Germany). Cells were regularly screened for mycoplasma contamination 
using the VenorGem Mycoplasma detection kit (Minerva Biolabs, Berlin, Germany).  
For experiments, cells were seeded in plastic cell culture wells and were cultivated in 
DMEM until 80% confluency was reached. Medium was then removed and replaced by a 
medium containing mesalazine (10-50 mM). Mesalazine (5-aminosalicylate, 5-ASA, Sigma,
 
Deisenhofen, Germany) was dissolved as a 100 mM stock solution
 in culture medium. The 
pH of the drug solution was adjusted to 7.0
 with NaOH and afterwards, the solution was 
sterile filtrated. All experiments using mesalazine were protected from light. The medium 
was changed every day. Cells were then harvested at the times indicated in the figure 
legends. 
 
Transfection assay 
The following plasmids were used for transfection: pcDNA3 (Invitrogen, Karlsruhe, 
Germany), as an empty-vector for control transfection and the plasmid pcDNA3-   6 
 
 
PPARγL468A/E471A, a dominant-negative PPARγ double-mutant, that was kindly provided by 
VK Chatterjee (Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, 
Cambridge, United Kingdom) (23). These constructs were transfected into subconfluent 
Caco-2 and HT-29 cells with lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) in 
serum-free conditions. After 6 h, the cells were supplied with fresh medium containing 10% 
FCS. 24 h later, the cells were supplied with medium containing G418 (400 μg/mL) and 
culture medium supplemented with G418 was replaced twice a week. G418- resistant 
colonies were collected and used for further analysis.  
 
Cytotoxicity 
Cytotoxicity of mesalazine in concentrations used in our experiments was excluded by 
lactate dehydrogenase (LDH) release assay using a commercial kit (LDH kit, Roche, 
Mannheim, Germany).  
 
Cell counts 
Cells were suspended and cultured on 96-well dishes at a density of 10
4/well (0.28 cm
2). 24 
h after plating, cells were incubated for 24–72 h with mesalazine. At given time points 
following treatment, cell numbers were assessed by crystal violet staining. Medium was 
removed from the plates and cells were fixed with 5% formaldehyde for 5 min. After 
washing with PBS, cells were stained with 0.5% crystal violet for 10 min, washed again with 
PBS and unstained with 33% acetic acid. Absorption, which correlates with the cell number, 
was measured at λex= 620 nm.  
 
Assay for cell proliferation    7 
 
 
The effect of mesalazine on DNA synthesis of cells was assessed using a cell proliferation 
ELISA kit (Roche Diagnostics, Tokyo, Japan). This assay is a colorimetric immunoassay for 
quantification of cell proliferation based on the measurement of bromodeoxyuridine (BrdU) 
incorporation during DNA synthesis, and is a nonradioactive alternative to the [
3H]-
thymidine incorporation assay. Incorporated BrdU was measured colorimetrically. 
 
Caspase-3 activity assay 
Caco-2 and HT-29 cells were stimulated with mesalazine at 80% confluency. Fluorometric 
immunosorbent enzyme assay (FIENA, Roche, Mannheim, Germany) was used according to 
the manufacturers instructions. Protein concentration was analysed and samples were 
normalized in lysis buffer to equal protein concentrations. 
 
PPARγ transactivation assay 
PPARγ activity was assayed using an ELISA-based transactivation
 TransAM
® PPARγ kit 
(Active Motif, Rixensart, Belgium) following the
  manufacturer’s protocol. The PPARγ 
TransAM
® kit contains
  a 96-well plate with immobilized oligonucleotides containing
  a 
peroxisome proliferator response element (5'-AACTAGGTCAAAGGTCA-3'). 
 
Flow Cytometry Analysis 
Cells were starved for 72 h and then treated with mesalazine (40 mM) up to 48 h. Cells were 
harvested by trypsinization, fixed with 80% ethanol and kept at -20°C. Cells were then 
centrifuged for 10 min at 500 × g and resuspended in PBS containing 0.25% Triton-X100 for 
5 min. After washing with PBS, cells were stained with PBS containing propidium iodide 
(20 µg/ml; Sigma Chemicals, Deisenhofen, Germany) and RNAse A (2 mg/ml; Sigma    8 
 
 
Chemicals, Deisenhofen, Germany) at room temperature for 30 minutes. Subsequently, DNA 
content was measured by flow cytometry (FACSCalibur, Becton Dickinson, Heidelberg, 
Germany) and cell cycle distribution was calculated using Cell Quest Software (Becton 
Dickinson Technology, Mountain View, California, USA). 
 
Protein extraction 
Caco-2 and HT-29 cells were stimulated with mesalazine at 80% confluency. Cells were 
washed three times with ice-cold PBS and incubated with cell lysis buffer (Cell signaling, 
Beverly, Massachusetts, USA) containing multiple protease inhibitors (Complete, Roche, 
Mannheim, Germany) for 20 min at 4 °C. Protein extracts were obtained after sonication of 
cell lysates (2 × 5 s) and centrifugation at 10.000 rpm at 4 °C (10 min). Protein content was 
determined via Bio-Rad colorimetric assay according to the method of Bradford (Bio-Rad 
Laboratories, Munich, Germany). 
 
SDS–polyacrylamide gel electrophoresis and immunoblot analysis 
Equal amounts of total protein lysates were separated on a 15% SDS-polyacrylamide gel for 
PARP, Caspase-8, -9 and on a 12.5% SDS-polyacrylamide gel for Xiap, survivin, PPARγ, 
PTEN, c-Myc and cytokeratin 20, respectively. Proteins were transferred onto a 
nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany). Subsequently, 
membranes were blocked for one hour with 5% (w/v) nonfat dried milk in Tris-buffered 
saline containing 0.05% Tween 20 (TBS-T). Membranes were then incubated overnight with 
1:1000 dilutions of PPARγ-, c-Myc (both from Calbiochem, La Jolla, CA), PTEN-, PARP-, 
Caspase-8-, Caspase-9-, Xiap- and survivin- antibody (all from Cell signaling, Beverly, 
Massachusetts, USA) or with a 1:500 dilution of human cytokeratin 20- antibody (Santa    9 
 
 
Cruz Biotechnologies, Santa Cruz, California, USA) in 0.05% TBS-T and 5% (w/v) nonfat 
dried milk, respectively. After washing, the blots were incubated for half an hour with 
corresponding horseradish peroxidase-conjugated antibodys (all from Santa Cruz 
Biotechnologies, Santa Cruz, California, USA, dilution 1:2000) in 0.05% TBS-T and 5% 
(w/v) nonfat dried milk. The washing steps were repeated, and subsequently enhanced 
chemoluminescence detection was performed according to the manufacturer’s instructions 
(ECL, Amersham pharmacia biotech, Buckinghamshire, UK) on Hyperfilm-MP (Amersham 
International plc, Buckinghamshire, UK). Blots were then reprobed with β-actin antibody 
(Santa Cruz Biotechnologies, Santa Cruz, California, USA). For quantitative analysis, bands 
were detected by scanning densitometry, using a Desaga CabUVIS scanner and Desaga 
ProVilDoc software (Desaga, Wiesloch, Germany). 
 
Statistics 
All statistical analyses were performed using GraphPad Prism 4.01 (San Diego, California, 
USA). Analysis of variance (ANOVA) was performed when more than two groups were 
compared and, when significant (P < 0.05), multiple comparisons were performed with the 
Newman-Keuls test. If not otherwise stated, data are expressed as means ± SD from three 
independent experiments. P value < 0.05 was considered to be significant.    10 
 
 
Results 
Mesalazine reduces cell count, inhibits cell proliferation and affects cell cycle progression of 
colorectal cancer cells 
First, we evaluated the effect of mesalazine on cell number and proliferation of Caco-2, HT-
29 and HCT-116 cells. Cells were treated with increasing concentrations of mesalazine (10-
50 mM) for 24, 48 and 72 h. As shown in Fig. 1 A, treatment of CRC cells with mesalazine 
for 48 h significantly reduced the cell count in a dose-dependent manner. Similar effects 
were obtained for 24 and 72 h and for the inhibition of cell proliferation, measured by the 
BrdU test (data not shown). To establish whether the reduction in cell growth and 
proliferation after mesalazine treatment of colon cancer cells was due to changes in cell 
cycle progression, HT-29 and HCT-116 cells were cultured in presence of the drug (40 mM) 
for 24 and 48 h, and cell cycle distribution was analysed by flow cytometry (Fig. 1 B). Both 
cell lines showed changes in the cell cycle profile within 48 h, with an apparent 
accumulation of cells in the G0/G1 phase.  
 
Mesalazine up-regulates the expression and activity of PPARγ 
As depicted in Fig. 2 A, stimulation of HT-29 cells with mesalazine (30-50 mM) for 48 h led 
to a concentration-dependent up-regulation of PPARγ protein expression. To evaluate 
receptor activity of PPARγ in HT-29 wild-type, dominant-negative PPARγ and empty-vector 
HT-29 cells, PPARγ activation was determined via a transcriptional factor assay (Fig. 2 B). 
Treatment of both HT-29 wild-type and empty-vector cells with mesalazine (30 mM) for 48 
h increased the activity PPARγ. As expected, PPARγ activity was not affected in the 
dominant-negative PPARγ cell line. Similarly, treatment of Caco-2 wild-type and empty-
vector cells with mesalazine (30 mM) provoked +1.4-fold increase of cytokeratin 20    11 
 
 
expression (vs. control, p < 0.01, 48 h), a specific target gene of PPARγ activity in CRC 
cells (data not shown) (24). In contrast, the induction of cytokeratin 20 could not be 
observed in dominant-negative PPARγ mutant Caco-2 cells (data not shown).  
 
PPARγ is partially involved in mesalazine-induced inhibition of cell proliferation 
In order to elucidate a potential role for PPARγ in mesalazine-induced inhibition of cell 
proliferation and changes in cell cycle distribution, the effect of the drug was studied in 
dominant-negative PPARγ colon cancer cells. Mesalazine (50 mM) treatment led to a 
significant decrease in cell proliferation in both HT-29 wild-type (-50%, p < 0.001) and 
empty-vector cells (-49%, p < 0.001) after 72 h of treatment (Fig. 3 A). In contrast, in the 
dominant-negative PPARγ cell line, the decrease in cell proliferation was partially reversed 
(-34%, p < 0.001, vs. wild-type and empty-vector). Similar effects were obtained in the cell 
line Caco-2 (data no shown). In dominant-negative PPARγ HT-29 cells, change in cell cycle 
distribution in response to mesalazine (40 mM) was partially neutralised (data no shown). 
Nevertheless, statistical significant effects compared to the wild-type were not reached.   
 
Mesalazine down-regulates the expression of c-Myc in a PPARγ-independent mechanism 
To study further molecular mechanisms responsible for mesalazine’s growth-inhibitory 
effects, expression of the oncoprotein c-Myc after incubation with the drug was determined. 
c-Myc is known to modulate a broad range of biological activities including cell 
proliferation and growth (25). Stimulation of HT-29 wild-type, dominant-negative PPARγ 
and empty-vector (data not shown) cells with mesalazine (40 mM) for 4 h decreased the 
expression of c-Myc, indicating that PPARγ does not contribute to the down-regulation of 
the oncoprotein in response to the drug (Fig. 3 B).     12 
 
 
 
PPARγ is involved in mesalazine-mediated up-regulation of the tumor suppressor gene 
PTEN 
The tumor suppressor gene PTEN modulates several cellular functions, including cell 
survival signalling (26). In particular, it is well established that PTEN decreases cell 
proliferation through cell-cycle arrest in the G0/G1 phase and induces apoptosis via the 
caspase-cascade (27, 28). Treatment of HT-29 wild-type and empty-vector (data not shown) 
cells with mesalazine (40 mM) up to 8 results in a significant increase of PTEN protein 
expression (Fig. 3 C). In dominant-negative PPARγ HT-29 cells, the effect of mesalazine on 
the expression of PTEN was annihilated (Fig. 3 C). 
 
Mesalazine-induced up-regulation of caspase-3 activity by the caspase-8 signalling pathway 
occurs via PPARγ 
Challenge of both, Caco-2 wild-type and empty-vector cells, with mesalazine (30 mM) 
resulted in increased cleavage of the nuclear poly (ADP-ribose) polymerase (PARP) protein 
after 48 h (+2.2-fold, p < 0.001), a marker for caspase-3 activity (Fig. 4 A). In contrast, up-
regulation of cleaved PARP protein expression in response to mesalazine (30 mM) was 
found to be attenuated in dominant-negative PPARγ mutant Caco-2 cells. Analogue effects 
could be observed in HT-29 wild-type, dominant-negative PPARγ and empty-vector cells 
after mesalazine treatment (data not shown). Direct determination of caspase-3 activity with 
a fluorometric immunosorbent enzyme assay (Fig. 4 B) showed a similar pattern of results as 
compared to the cleavage of PARP (Fig. 4 A). Incubation with mesalazine resulted in a 
significant increase in caspase-3 activity after 48 h both, in Caco-2 wild-type and empty 
vector cells (+1.4-fold, p < 0.001). In contrast, up-regulation of caspase-3 activity in    13 
 
 
response to mesalazine was found to be almost reversed in PPARγ dominant-negative Caco-
2 cells. Comparable results were also obtained in the cell line HT-29 (data not shown).  
To further unravel the responsible elements in the caspase pathway leading to 
increased caspase-3 activity after mesalazine treatment, cleavage of caspase-8 and -9 were 
examined. Incubation with mesalazine (30 mM) for 48 h led to elevated cleavage of caspase-
8 (+1.5-fold, p < 0.01) in Caco-2 wild-type and empty-vector cells. In contrast, no cleavage 
of caspase-9 in response to mesalazine could be observed. In dominant-negative PPARγ 
Caco-2 cells, mesalazine-mediated (30 mM) cleavage of caspase-8 was also reversed.  
 
PPARγ controls the expression of inhibitor of apoptosis proteins after mesalazine treatment 
To specify the molecular mechanism of mesalazine-induced apoptosis, changes in protein 
levels of the inhibitor of apoptosis proteins (IAP), survivin (Fig. 5) and X linked inhibitor of 
apoptosis (Xiap) (Fig. 6) were examined. Levels of survivin (5 A) and Xiap (6 A) were 
reduced in HT-29 wild-type and empty-vector cells in response to mesalazine after 48 h. In 
contrast, mesalazine-mediated down-regulation of both IAP family members was completely 
neutralized when incubated in HT-29 dominant-negative PPARγ mutant cells. A similar 
pattern of results was obtained in the cell line Caco-2 (5 B, 6 B). 
    14 
 
 
Discussion 
The increased risk for the development of CRC in patients suffering from UC and Crohn’s 
colitis remains a significant problem in the long-term management of IBD (1). One of the 
first candidate chemopreventive drugs that has specific relevance in IBD patients seems to 
be mesalazine, an anti-inflammatory drug which has been used extensively in the treatment 
of IBD for more than 50 years (29). Several retrospective studies have suggested that long-
term use of 5-ASA in IBD patients may significantly reduce the risk for the development of 
CRC by decreasing cell proliferation and inducing apoptosis (4, 9). However, despite 
comprehensive clinical and experimental experience with the drug, the mechanisms leading 
to its pro-apoptotic actions are largely unknown. Unravelling the signalling pathways behind 
these effects could deliver insights into mesalazine’s mode of action in colon cancer 
prevention.  
There is increasing evidence supporting the role of PPARγ as a regulator of 
proliferation and a modulator of cell growth (21, 30). Recent studies demonstrate that 
activators of PPARγ suppress the growth response of colon cancer cells (19, 20). Thus, 
inhibition of cell growth is partly due to the induction of apoptosis upon PPARγ activation. 
In addition, several reports describe not only an induction of caspase-3 by PPARγ ligands in 
a variety of cancer cells (31, 32), but also an association between loss of function mutations 
of PPARγ and the development of CRC (33). These observations raised the possibility that 
somatic mutations of PPARγ contribute to the carcinogenic process and the receptor 
functions as a tumor suppressor gene by inhibiting cell growth and inducing apoptosis.  
Recent data showed that PPARγ was the major functional receptor mediating the 
common mesalazine activities in IBD and have corroborated involvement of the receptor in 
controlling intestinal inflammation (14). Mesalazine has been identified to act as an agonist    15 
 
 
of PPARγ and was shown to up-regulate the expression and activity of the receptor in HT-29 
cells (14), which is in accordance to the findings in the present study. Moreover, PPARγ has 
also been proposed to mediate the anti-proliferative and pro-apoptotic effects of mesalazine 
(10). In the present study, we shed light on PPARγ as a possible key target in mesalazine-
mediated anti-carcinogenic abilities. For that purpose, mesalazine-induced anti-proliferative 
effects and pro-apoptotic actions along the caspase signalling cascade were examined in 
colonocytes transfected with a dominant-negative PPARγ vector to inhibit wild-type PPARγ 
receptor action (23). The therapeutic effect of 5-ASA depends more on the direct contact of 
the molecule with the colonic epithelium than to tissue concentration in the colon (14). It has 
been demonstrated that stool concentrations in patients conventionally treated with 5-ASA 
are in the median order of 30 mM, ranging from 10 to 100 mM (14). These concentrations 
have been demonstrated in vivo to modulate several cellular functions including inhibition of 
cell proliferation (13, 14). Hence, the concentrations used in the present study are clinically 
and biological relevant.   
In our in vitro model, mesalazine decreased cell proliferation of colonocytes in a 
time- and dose-dependent manner. These anti-proliferative abilities were partially reversed 
in the PPARγ dominant-negative cell lines. However, the inhibition was not complete, 
indicating that other mechanisms besides PPARγ are involved in mesalazine’s anti-
proliferative effects. The anti-proliferative actions of mesalazine on colon carcinoma cell 
lines are in line with several in vivo and in vitro studies (9, 13, 34, 35). In addition, PPARγ 
agonists like rosiglitazone and troglitazone have been shown to decrease proliferation of 
colon cancer cell lines, merely mediated in part by a PPARγ-dependent mechanism (36, 37). 
Moreover, our data clearly demonstrate that mesalazine induced a G0/G1 arrest in colon 
cancer cells which is in line with the robust G1 arrest of other non-steroidal anti-
inflammatory drugs (NSAIDs) e.g. indomethacin, sulindac and direct PPARγ agonists e.g.    16 
 
 
rosiglitazone (38-40). Our results differ from the observations of former studies illustrating a 
S- or G2-Phase arrest in response to mesalazine, however, the authors could not reasonably 
explain the discrepancy compared to other NSAIDs (13, 35). 
To unravel further mechanisms contributing to mesalazine’s growth-inhibitory 
abilities in colonocytes, expressions of the oncoprotein c-Myc and of the tumor suppressor 
gene PTEN were determined. c-Myc is overexpressed in nearly 70% of CRC. Moreover, 
dysplasia of colonocytes in UC is also associated with increased expression of the 
oncoprotein (19, 25). c-Myc is known to modulate a broad range of biological activities 
including cellular proliferation and cell growth (19, 25). Deregulated c-Myc has been shown 
to increase apoptosis, genomic instability and to block differentiation (19, 25). In 
colonocytes including HT-29, it was recently shown that mesalazine decreased the 
expression of c-Myc (25). Although several PPARγ agonists inhibit the expression of the 
oncoprotein (19, 41), the effects seem to be PPARγ-independent because no peroxisome 
proliferator response element (PPRE) has been found in its promoter (41). Therefore, it is not 
surprising that a PPARγ-independent down-regulation of c-Myc in response to mesalazine 
was obtained in our in vitro setting which seems to contribute to the modulation of the 
PPARγ-independent growth-inhibitory effects caused by the drug. 
PTEN is a tumor suppressor gene involved in the regulation of cell survival 
signalling through the phosphatidylinositol 3-kinase/Akt (PI3K/Akt) pathway (42). 
PI3K/Akt signalling has been shown to be required for an extremely diverse array of cellular 
activities mainly involved in cell growth, proliferation apoptosis and survival mechanisms 
(42, 43). Activated Akt protects cell from apoptotic death by inactivating compounds of the 
cell-death machinery such as procaspases (42). PTEN exercises its role as a tumor 
suppressor by antagonising the PI3K/Akt pathway (42). In CRC cells, enforced expression 
of PTEN, e.g. by NSAIDs, has been demonstrated to decrease cell proliferation through cell-   17 
 
 
cycle arrest in the G0/G1 phase and to activate the caspase cascade (28, 43, 44). Stimulation 
of HT-29 wild-type cells with mesalazine in our in vitro model increased the expression of 
PTEN. In contrast, in the dominant-negative PPARγ cell line, the effect of mesalazine on the 
expression of PTEN was reversed. Besides the ability of PPARγ agonists to up-regulate the 
expression of PTEN, confirmed by inhibitor and antisense experiments, two PPREs in the 
genomic sequence upstream of the tumor suppressor gene have been found (26, 45), 
supporting the findings of our investigations. The PPARγ-dependent increase of PTEN 
caused by mesalazine in our experiments not only indicates that the tumor suppressor gene 
contributes to the growth-inhibitory activities of the drug, but also may trigger its pro-
apoptotic actions. 
In addition to the contribution of PPARγ in mesalazine-induced growth inhibition, 
our data provides insight into the molecular mechanisms leading to activation of the caspase 
cascade, demonstrated directly by increased caspase-3 activity and indirectly by augmented 
levels of cleaved PARP. Our findings are supported by former studies demonstrating 
increased cleavage of PARP and caspase-3 activity after mesalazine treatment in HT-29 and 
colo205 cells, respectively (13, 34). Caspase-3 can be activated via two signalling pathways, 
the extrinsic pathway and the intrinsic trail, initiated by caspase-8 or caspase-9 signalling, 
respectively (46). The increase in levels of cleaved caspase-8 by mesalazine in the present 
study indicates that the extrinsic signalling pathway takes part in caspase-3 activation. Both 
caspase-dependent and caspase-independent mechanisms have been reported for 
mesalazine’s apoptotic processes, indicating that the drug activates multiple cell death 
signalling pathways, e.g. caspase-9, Bcl-2, intestinal sphingomyelinase and the induction of 
intracellular peroxides (34, 47). Moreover, in our in vitro model mesalazine significantly 
decreased the protein levels of survivin and Xiap, two anti-apoptotic proteins known to 
potently block caspase-3, thereby inhibiting apoptosis (46). Accordingly, a similar down-   18 
 
 
regulation of IAPs has not only been demonstrated for sulindac, but also for PPARγ ligands 
e.g. pioglitazone in colorectal carcinoma cells (36, 48). Mesalazine-mediated effects on both 
pro-apoptotic and anti-apoptotic markers were almost reversed in PPARγ dominant-negative 
cells. Taken together, these results indicate the involvement of PPARγ in mesalazine-
mediated apoptosis via activating the caspase cascade. The underlying mechanism by which 
PPARγ controls the caspase signalling pathways are not fully explained. It may be 
speculated that the receptor regulates the cascade via modulation of the IAPs by a 
spermidine/spermidine N
1-acetyltransferase-dependent mechanism (49, 50).  
In conclusion, this study provides evidence for the involvement of PPARγ-dependent 
and -independent mechanisms, responsible for mesalazine’s pro-apoptotic and anti-
proliferative abilities which appear to be triggered at least in part by the modulation of PTEN 
and c-Myc, respectively. In addition, activation of caspase-8 and down-regulation of Xiap 
and survivin contribute to elevated caspase-3 activity caused by mesalazine. Revealing this 
transduction pathway is not only important to understand the fundamental biological 
processes, but also may provide new opportunities in the chemoprevention of IBD. 
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Figure Legends 
Fig. 1: (A) Cell counts of Caco-2, HT-29 and HCT-116 cells after incubation with increasing 
concentrations of mesalazine (10-50 mM) for 48 compared to control. n = 8, p value < 0.001 
(vs. control) was obtained for all concentrations and all cell lines. (B) Cell cycle distribution 
in mesalazine-treated cells. HT-29 and HCT-116 cells were treated with mesalazine (40 
mM) up to 48 h. After staining with propidium iodide, the cellular DNA content was 
visualized by flow cytometry, and the cell cycle distribution was analysed. 
 
Fig. 2: (A) Western blot for PPARγ expression after treatment of HT-29 wild-type cells with 
mesalazine (30-50 mM) for 48 h. One representative blot of three independent experiments 
is shown. (B) Effect of mesalazine (30 mM) on PPARγ transcriptional activity in HT-29 
wild-type, PPARγ dominant-negative and empty-vector cells after 48 h of stimulation. ***p 
< 0.001, n.s. = not significant.  
 
Fig. 3: (A) Cell proliferation measurement of HT-29 wild-type, dominant-negative PPARγ 
and empty-vector cells after incubation with mesalazine (50 mM) for 72 h compared to 
control. n = 8, ***p < 0.001, n.s. = not significant (B) Western blot for the expression of c-
Myc after treatment of HT-29 cells with mesalazine (30 mM) for 4 h. One representative blot 
of three independent experiments is shown. (C) Western blot for the expression of the tumor 
suppressor PTEN in HT-29 wild-type and dominant-negative PPARγ cells in response to 
mesalazine (40 mM) up to 8 h. One representative blot of three independent experiments is 
shown. 
    29 
 
 
Fig. 4: (A) Effect of mesalazine (30 mM) on cleaved PARP protein expression after 48 h of 
treatment in Caco-2 cells used as wild-type, dominant-negative PPARγ mutant and empty-
vector cultures. One representative western blot of three independent experiments is shown. 
The band at 89 kDa corresponds to the cleaved PARP protein. Densitometric data are 
corrected for β-actin levels. ***p < 0.001, n.s. = not significant (B) Caspase-3 activity in 
Caco-2 wild-type, dominant-negative PPARγ mutant and empty-vector cells measured via 
fluorometric immunosorbent enzyme assay after stimulation with mesalazine (30 mM) for 
48 h. n = 6, ***p < 0.001, n.s. = not significant  
 
Fig. 5: (A) Effect of mesalazine (30 mM) on the expression of survivin in HT-29 wild-type, 
dominant-negative PPARγ mutant and empty-vector cells after incubation for 48 h. One 
representative western blot of three independent experiments is shown. Quantitative data are 
normalized for β-actin levels. *p < 0.05, n.s. = not significant (B) Effect of mesalazine (30 
mM) on the expression of survivin in Caco-2 wild-type, dominant-negative PPARγ mutant 
and empty-vector cells after incubation for 48 h. One representative western blot of three 
independent experiments is shown. Densitometric data are corrected for β-actin levels. ***p 
< 0.001, n.s. = not significant 
 
Fig. 6: (A) Effect of mesalazine (30 mM) on the expression of Xiap in HT-29 wild-type, 
dominant-negative PPARγ mutant and empty-vector cells after incubation for 48 h. One 
representative western blot of three independent experiments is shown. Densitometric data 
are corrected for β-actin levels. ***p < 0.001, n.s. = not significant (B) Effect of mesalazine 
(30 mM) on the expression of Xiap in Caco-2 wild-type, dominant-negative PPARγ mutant 
and empty-vector cells after incubation for 48 h. One representative western blot of three    30 
 
 
independent experiments is shown. Densitometric data are corrected for β-actin levels. ***p 
< 0.001, n.s. = not significant      
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Abstract
Background and aims: The human cathelicidin (LL-37) is one of the major antimicrobial peptides of the non-speciﬁc innate immune system in
the intestinal tract. Altered expression has been associated with gastrointestinal disease. Recent studies demonstrated that butyrate induces LL-37
mRNA in colonic epithelial cells, however the underlying molecular mechanisms have not been elucidated. The objective of this study was to
investigate the regulatory pathways involved in butyrate-induced up-regulation of LL-37.
Methods and results: Treatment of Caco-2 and HT-29 cells with butyrate led to a time-dependent up-regulation of LL-37 mRNA expression
as determined by semi-quantitative RT-PCR. Up-regulation of LL-37 mRNA by butyrate was subsequently followed by an increase in LL-37
protein expression as observed by immunoﬂuorescence. Co-incubation of butyrate with a VDR, p38 MAPK, ERK 1/2 and TGF-1 receptor kinase
inhibitor all reduced butyrate-mediated LL-37 mRNA up-regulation. In contrast, transfection of Caco-2 cells with a dominant-negative PPAR
mutant vector did not affect butyrate-mediated up-regulation of LL-37 mRNA.
Conclusion: Our results clearly demonstrate that butyrate-mediated up-regulation of LL-37 is inﬂuenced by several signalling pathways and
receptors including MAPKs as well as VDR and TGF-1, but not by PPAR. These data may provide new opportunities in the treatment of
gastrointestinal diseases.
© 2006 Elsevier Ltd. All rights reserved.
Keywords: Butyrate; Cathelicidin; Colon; Innate immunity; LL-37; MAPK; PPAR; TGF-1; VDR
1. Introduction
Antimicrobial peptides, such as cathelicidins, are active
defence molecules in the innate immune system. Several stud-
ies conﬁrm their importance at epithelial surfaces as imme-
diate barrier effectors in preventing gastrointestinal infections
Abbreviations: DAPI, 4 ,6-diamidino-2-phenylindol; DMEM, Dulbecco’s
modiﬁed Eagle’s medium; DMSO, dimethyl sulfoxide; ECACC, European col-
lection of cell cultures; ERK, extracellular signal-regulated kinase; FCS, foetal
calfserum;GAPDH,glyceraldehyde-3-phosphatedehydrogenase;IBD,Inﬂam-
matory bowel disease; JNK, cJun N-terminal kinase; LDH, lactate dehydroge-
nase;MAPK,mitogen-activatedproteinkinase;PBS,phosphatebufferedsaline;
PPAR, peroxisome proliferator-activated receptor ; SCFA, short chain fatty
acid;TGF-1,transforminggrowthfactor1;VDR,VitaminDreceptor;VDRE,
Vitamin D response element
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Frankfurt/Main, Germany. Tel.: +49 69 6301 6204; fax: +49 69 6301 83112.
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(O’Neil et al., 1999; Schauber et al., 2006; Schmid et al.,
2004).
Cathelicidins constitute a family of cationic precursor pro-
teins with a well-conserved cathelin pro-region, followed by a
highly variable C terminal antimicrobial domain (Bals, 2000;
Eckmann, 2005). They are widespread in nature and found in
many mammalian species (Sorensen, 2005). The only human
cathelicidin gives rise to LL-37, a 37-amino acid mature antimi-
crobial peptide, after cleavage from the cathelin propart (De
Smet and Contreras, 2005). LL-37 is present in neutrophils,
lymphocytes and in epithelial cells of the testis, skin, respi-
ratory and the gastrointestinal tract (Sorensen, 2005). In the
colon, the protein is produced constitutively in differentiated
surface and upper crypt epithelial cells. Its expression in these
cells coincides with epithelial cell differentiation and is not
up-regulated in response to inﬂammatory markers, which con-
trasts with the ﬁnding in keratinocytes (Hase et al., 2002). So
far, the molecular mechanisms regulating cathelicidin expres-
sion remain largely unknown. Besides its antimicrobial activity,
0161-5890/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
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cathelicidin exerts a variety of other functions such as chemoat-
tractionofimmunecells,degranulationofmastcells,stimulation
of wound vascularisation and induction of antitumoral effects
(De Smet and Contreras, 2005). Moreover, LL-37 binds and
neutralizes lipopolysaccharide bioactivity and protects against
endotoxic shock (De Smet and Contreras, 2005).
Altered levels of cathelicidin expression are observed in
inﬂammatory bowel disease (IBD) and Shigellosis, indicating
its important role in gastrointestinal host defence (Raqib et al.,
2006; Schauber et al., 2006; Zasloff, 2006a). In IBD, increased
levels of the antimicrobial peptide are measured in patients
with ulcerative colitis but not in patients with Crohn’s disease
(Schauberetal.,2006).Atriggeringfactorhowevercouldnotbe
identiﬁed. In contrast, cathelicidin expression is suppressed in
Shigella infections. Oral treatment with butyrate however, stim-
ulatedthereleaseoftheactivepeptideandpromotedelimination
of Shigella in a rabbit experimental model (Raqib et al., 2006).
Butyrate, a short chain fatty acid (SCFA) and normal con-
stituent of the colonic luminal content, is formed by bac-
terial fermentation of undigested dietary ﬁbre in the colon
(Wachtershauser and Stein, 2000). Besides its role as the major
energy source for the colonocyte (Wachtershauser and Stein,
2000), it exerts profound effects on the colonic physiology
by inﬂuencing colonocyte proliferation and differentiation, gut
motility and mucosal inﬂammation (Klurfeld, 1999). More-
over, recent studies demonstrated an immune modulating role
for butyrate by inducing cathelicidin in human gastrointesti-
nal cells (Hase et al., 2002; Schauber et al., 2003, 2004,
2006). Although the requirement of the mitogen-activated pro-
tein kinase (MAPK) pathway in this up-regulation has recently
beenindicated(Schauberetal.,2003;Zasloff,2006b),theintra-
cellular signalling pathways are mainly unknown.
In the present study we demonstrate for the ﬁrst time the
involvement of several signalling pathways and receptors like
p38 MAPK, extracellular signal-regulated kinase 1/2 (ERK),
Vitamin D receptor (VDR) and transforming growth factor
1 (TGF-1) in butyrate-mediated induction of LL-37. On
the contrary, the participation of the peroxisome proliferator-
activatedreceptor(PPAR)inthisregulatoryprocesscouldbe
excluded.
2. Materials and methods
2.1. Cell culture
Both human colorectal cancer cell lines Caco-2 and HT-29
were obtained from the European collection of cell cultures
(ECACC). Cells were cultured in a humidiﬁed incubator at
37 ◦C in an atmosphere of 95% air and 5% CO2. Caco-2
cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM), supplemented with 10% foetal calf serum (FCS),
1% non-essential amino acids, 1% sodium pyruvate and
1% penicillin/streptomycin. HT-29 cells were grown in
McCoy’s 5A Medium, supplemented with 10% FCS and 1%
penicillin/streptomycin. Medium of the dominant-negative
PPAR mutant and empty-vector Caco-2 cells was supplied
with 400g/ml Geneticin 418 sulphate (G418, Gibco-BRL,
Eggenstein, Germany). Cells were regularly screened for
mycoplasma contamination using the VenorGem Mycoplasma
detection kit (Minerva Biolabs, Berlin, Germany).
Forexperiments,cellswereseededinplasticcellculturewells
and cultivated in DMEM and McCoy’s 5A Medium, respec-
tively, until 80% conﬂuency was reached. Medium was then
removed and replaced by medium containing either the solvent,
butyrate (2 and 3mM), or one of the combinations of butyrate
(3mM) with the Vitamin D receptor inhibitor ZK191732
(10M), the p38 MAPK inhibitor SB203580 (20M), the
ERK1/2 inhibitor PD98059 (40M), or the TGF-1 recep-
tor kinase inhibitor SB431542 (10M), respectively. In these
experiments, cells were pre-treated with the inhibitors for 5h,
followed by challenge of cells with butyrate for up to 48h.
Butyrate (Merck-Schuchardt, Hohenbrunn, Germany) was sol-
ubilized in phosphate buffered saline (PBS) and added to the
medium. SB431542 (Sigma, Saint Louis, Missouri, USA) was
dissolved in ethanol (Merck, Darmstadt, Germany), PD98059,
SB203580 (both Calbiochem, Schwalbach/Taunus, Germany)
andZK191732(suppliedbytheDepartmentofMedicinalChem-
istry at Schering AG, Berlin, Germany) were dissolved in
dimethyl sulfoxide (DMSO, Fluka, Sigma–Aldrich–Chemie,
Steinheim, Germany). Final maximal concentration of solvents
inmediumwaskeptbelow0.1%(v/v).Themediumwaschanged
every day. Cells were then harvested at the times indicated in
the ﬁgure legends.
2.2. Transfection assay
The following plasmids were used for transfection: pcDNA3
(Invitrogen, Karlsruhe, Germany), as an empty-vector for con-
troltransfectionandtheplasmidpcDNA3-PPARL468A/E471A,a
dominant-negative PPAR double-mutant, that was kindly pro-
videdbyVKChatterjee(DepartmentofMedicine,Universityof
Cambridge, Addenbrooke’s Hospital, Cambridge, United King-
dom) (Gurnell et al., 2000). These constructs were transfected
into subconﬂuent Caco-2 cells with lipofectamine 2000 (Invit-
rogen,Karlsruhe,Germany)inserum-freeconditions.After6h,
thecellsweresuppliedwithfreshmediumcontaining10%FCS.
24hlater,thecellsweresuppliedwithmediumcontainingG418
(400g/ml) and culture medium supplemented with G418 was
replaced twice a week. G418-resistant colonies were collected
and used for further analysis.
2.3. Cytotoxicity
Cytotoxicity was excluded by lactate dehydrogenase (LDH)
release assay using a commercial kit (LDH kit, Roche,
Mannheim, Germany).
2.4. Immunoﬂuorescence assay
Caco-2 cells were grown on glass chamber slides (Lab-
Tek, Nunc, Rochester, New York, USA) and allowed to reach
conﬂuency. They were then treated with butyrate (3mM) for
24 and 48h. Cells were ﬁxed in ice-cold ethanol (95%) for
10min and permeabilized by addition of 0.1% Triton X-100M. Schwab et al. / Molecular Immunology 44 (2007) 2107–2114 2109
in PBS for 10min. After washing, unspeciﬁc binding of anti-
bodies was blocked by incubating cells in 8% horse serum
in PBS containing 0.1% Tween-20 for 1h at room tempera-
ture. LL-37 antibody (Santa Cruz Biotechnology, Santa Cruz,
California, USA) was diluted 1:100 in blocking buffer. After
1.5h of incubation, cells were washed three times with PBS
before secondary antibody (cy3 conjugated rabbit-anti-goat,
Sigma, Saint Louis, Missouri, USA) was added for 45min.
Following washing and air-drying, the cells were embedded in
4 ,6-Diamidino-2-phenylindol (DAPI) mounting medium (Vec-
tor Laboratories, Burlingame, California, USA) and evaluated
by immunoﬂuorescence microscopy (Eclipse E 600, Nikon,
Tokyo,Japan)withadigitalcameraDX20H(Kappa,Monrovia,
California, USA).
2.5. mRNA isolation
Cells were cultivated in six-well plates and were treated at
80% conﬂuency with butyrate, or the combination of butyrate
and one of the inhibitors for 24 and 48h, respectively. Total
RNA was isolated from cells by RNA isolation reagent (TRIR,
Abgene, United Kingdom), followed by phenol extraction and
ethanol precipitation.
2.6. Semi-quantitative RT-PCR
RT-PCR was conducted with the Gene Amp RNA PCR
kit (Applied Biosystems, Branchburg, New Jersey, USA)
according to the manufacturer’s protocol, starting from 1g
total RNA. Ampliﬁcation of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) served as control. From the results
of preliminary experiments, 20 PCR cycles for GAPDH and
35 cycles for LL-37 were selected as optimal ampliﬁcation
conditions to produce a log-linear relationship between the
amount of each mRNA and intensity of PCR product. The PCR
reaction contained 0.2mM dNTPs (Invitrogen Corporation,
Carlsbad, California, USA), 0.05Ul−1 AmpliTaqGold DNA
polymerase (Applied Biosystems, Branchburg, New Jersey,
USA), 1.5mM Mg2Cl (Applied Biosystems, Branchburg,
New Jersey, USA) and either 0.2mol/L primers of LL-37
or GAPDH, respectively (Biospring, Frankfurt, Germany).
PCR cycling conditions for LL-37 were: initial denaturation
at 94 ◦C for 1min followed by annealing at 53 ◦C for 1min,
extension at 72 ◦C for 2min and a ﬁnal extension at 72 ◦C
for 7min after the last cycle. The respective annealing tem-
perature for GAPDH was 45 ◦C. Primers for ampliﬁcation
were as follows: LL-37 sense 5 -cggtcctcggatgctaacctcta-
3 , LL-37 antisense 5 -cctgggtacaagattccgcaaa-3 ; GAPDH
sense 5 -gcaccgtcaaggctgagaac-3 , GAPDH antisense 5 -
ccaccaccctgttgctgtag-3 . The expected sizes of LL-37 and
GAPDH were 357 and 803 base pairs, respectively. Aliquots
of the PCR mixtures (10L) were analyzed by electrophoresis
using a 1.5% agarose gel containing ethidium bromide and
visualized by UV illumination.
For semi-quantitative analysis of ampliﬁed PCR products,
the ﬂuorescent dye PicoGreen (Molecular Probes, Eugene, Ore-
gon, USA) was used according to the manufacturer’s instruc-
tions. In brief, 2l of ampliﬁed DNA in 100l TE buffer
were mixed with an equal volume of diluted PicoGreen reagent
(1:200, v/v, in TE buffer). Samples were incubated for 5min at
room temperature and protected from light in a microtiter plate.
The ﬂuorescence was measured (λex =485nm; λem =538nm)
in the ﬂuorescence microplate reader Tecan SpectraFluor
PLUS. A  DNA linear standard curve was applied for each
experiment.
2.7. Statistics
All statistical analyses were performed using GraphPad
Prism 4.01 (San Diego, California, USA). Analysis of variance
(ANOVA) was performed when more than two groups were
comparedand,whensigniﬁcant,multiplecomparisonswereper-
formed with the Tukey’s test. If not otherwise stated, data are
expressedasmeans±S.D.fromthreeindependentexperiments.
A p value <0.05 was considered to be signiﬁcant.
3. Results
3.1. Butyrate up-regulates LL-37 mRNA in colorectal
cancer cells in a time-dependent manner
Challenge of the colorectal carcinoma cell line Caco-2 with
butyrate (3mM) resulted in a time-dependent increase of LL-37
mRNA compared to control (Fig. 1) (24h: +149% versus con-
trol, p<0.001; 48h: +489% versus control, p<0.001). Similar
results were observed in the HT-29 cell line. In these cells, LL-
37 mRNA expression was augmented up to 338% (p<0.001)
after 24h and even up to 770% (p<0.001) after 48h of
treatment.
Fig.1. Time-dependenteffectofbutyrateonLL-37mRNAexpressioninCaco-2
cells after 24 and 48h of treatment. LL-37 mRNA was performed by semiquan-
titative RT-PCR with the ﬂuorescent dye Pico Green. All values for mRNA
levels are normalized to corresponding mRNA amounts for GAPDH. Induction
of LL-37 mRNA is displayed as relative percentage to solvent treated control
cells. ***p<0.001.2110 M. Schwab et al. / Molecular Immunology 44 (2007) 2107–2114
3.2. LL-37 protein exhibits a predominant cytoplasmatic
localisation in Caco-2 cells
The subcellular localisation of LL-37 protein in Caco-2 cells
was determined via immunoﬂuorescence. Caco-2 cells were
treatedwithbutyrate(3mM)for24and48h(Fig.2).Microscopy
analysis revealed that the natural antibiotic is predominantly
expressedinthecytosolofCaco-2cells,bothintreatedandcon-
trolcells.Moreover,butyratechallengeledtoincreasedstaining
of the cytoplasm, which is in line with the results obtained at the
mRNA level.
3.3. The Vitamin D receptor is involved in butyrate-induced
LL-37 mRNA expression
To determine a possible role of the VDR in butyrate-
induced LL-37 mRNA expression, Caco-2 cells were treated
with butyrate (3mM) in presence of the VDR antagonist ZK
191732 for 24h (Fig. 3A) and 48h (Fig. 3B). The antago-
nistic characteristics of the inhibitor have been described pre-
viously by our group (Gaschott et al., 2001). Application of
ZK 191732 signiﬁcantly reversed the LL-37 induction already
after 24h (−54%, p<0.05) of incubation and an even more
pronounced effect was obtained at 48h of treatment (−75%,
p<0.001).
3.4. MAPK and TGF-β1 play a pivotal role in
butyrate-mediated LL-37 mRNA up-regulation
In addition, Caco-2 cells were incubated with butyrate
(3mM) in presence of the p38 MAPK, ERK1/2 or TGF-1
receptor kinase inhibitor to investigate the involvement of TGF-
1 and intracellular signalling pathways in butyrate-regulated
LL-37 mRNA expression.
Combined treatments of butyrate with the p38 MAPK
inhibitor SB203580, the ERK1/2 inhibitor PD98059, and the
TGF-1 receptor kinase inhibitor SB431542 all reduced the
induction of LL-37 mRNA expression caused by butyrate after
24h of treatment (Fig. 4). Largest effects were obtained for co-
incubationofbutyratewiththep38MAPKinhibitorSB203580.
3.5. PPARγ is not involved in butyrate-mediated LL-37
mRNA up-regulation
Butyrate is known to induce the expression of the transcrip-
tionfactorPPAR.ToinvestigatewhetherPPARplaysarolein
the up-regulation of LL-37 mRNA induced by butyrate, expres-
sion of LL-37 mRNA was examined in Caco-2 cells transfected
with a dominant-negative PPAR mutant (Fig. 5). This mutant
still exhibits PPAR DNA binding activity, but lacks transcrip-
tional activation capacity (Gurnell et al., 2000). In this mutant
Fig. 2. Representative immunoﬂuorescence pictures for LL-37 protein in Caco-2 cells. Conﬂuent Caco-2 cells were challenged with butyrate (3mM) for 48h (C)
or were grown in culture medium as control (A). (B and D) Nuclear counterstaining with DAPI mounting medium for each of the adjacent panels. Magniﬁcation,
400×.M. Schwab et al. / Molecular Immunology 44 (2007) 2107–2114 2111
Fig. 3. LL-37 mRNA expression in Caco-2 cells. Medium was supplemented
with(1)thesolvent,or(2)butyrate(3mM),or(3)theVDRinhibitorZK191732
(10M), or (4) the combination of butyrate and ZK191732 for 24 (A) and
48h (B). Semiquantitative analysis of PCR products were performed using Pico
Green. All values for mRNA levels are normalized to corresponding mRNA
amounts of the housekeeping gene GAPDH. One representative gel of three
independent experiments is shown. Induction of LL-37 mRNA is displayed
as relative percentage to solvent treated control cells. ***p<0.001; **p<0.01;
*p<0.05; n.s.: not signiﬁcant.
cell line, no statistical difference compared to wild-type Caco-2
cells in butyrate-induced (3mM) LL-37 mRNA up-regulation
could be observed.
4. Discussion
Cathelicidin is an important natural peptide antibiotic that
actively contributes to the host bactericidal defence system
at mucosal surfaces. Changes in cathelicidin expression have
been associated with gastrointestinal disease. In IBD differ-
ential expression of human cathelicidin was observed. While
inﬂamed and non-inﬂamed colon mucosa in ulcerative colitis
patients showed increased expression of cathelicidin mRNA, in
Crohn’sdiseasenoinductioncomparedtonon-inﬂamedhealthy
Fig. 4. Inﬂuence of the p38 MAPK inhibitor SB203580 (20M), the ERK1/2
inhibitor PD98059 (40M) and the TGF-1 inhibitor SB431542 (10M) on
butyrate-induced (3mM) LL-37 mRNA expression in Caco-2 cells after 24h
of treatment. LL-37 expression was analysed by semiquantitative RT-PCR with
the ﬂuorescent dye Pico Green. All values for mRNA levels are normalized
to corresponding mRNA amounts of GAPDH. One representative gel of three
independent experiments is shown. Induction of LL-37 mRNA is displayed
as relative percentage to solvent treated control cells. ***p<0.001; **p<0.01;
*p<0.05; n.s.: not signiﬁcant.
Fig. 5. Time-dependent effect of butyrate (3mM) on LL-37 mRNA expression
in wild-type and PPAR mutant Caco-2 cells after 24 and 48h of treatment.
LL-37 mRNA was performed by semiquantitative RT-PCR with the ﬂuorescent
dye Pico Green. All values for mRNA levels are normalized to corresponding
mRNAamountsforGAPDH.InductionofLL-37mRNAisdisplayedasrelative
percentage to solvent treated control cells. ***p<0.001; n.s.: not signiﬁcant.2112 M. Schwab et al. / Molecular Immunology 44 (2007) 2107–2114
colon mucosa was seen (Schauber et al., 2006; Zasloff, 2006b).
Furthermore, previous studies found that cathelicidin is down-
regulated in the rectal epithelium of patients during Shigellosis
andthatbutyrateup-regulatestheexpressionofLL-37incolonic
epithelial cells in vitro and decreases severity of inﬂammation
in experimental Shigellosis (Raqib et al., 2006). Comprehen-
sive knowledge of cathelicidin regulation and expression is still
lacking. The SCFA butyrate is known to up-regulate LL-37 in a
variety of human colon cells (Hase et al., 2002; Schauber et al.,
2003,2004).Theaimofthepresentstudywastoshedlightonthe
regulatory pathways by which butyrate induces LL-37. In this
context,theroleoftheVDR,PPARaswellastheERK-MAPK
pathways and TGF-1 were examined.
Stimulation of both Caco-2 and HT-29 cells with butyrate
led to a time-dependent increase of LL-37 mRNA and protein.
TheseﬁndingsareinlinewiththestudyofSchauberetal.(2003),
whoreportedasimilarLL-37expressionpatterninseveralcolon
cells including HT-29. Furthermore, our data provide evidence
that both colorectal cancer cell lines express basal levels of LL-
37, which differs from lung epithelial EBC-1 cells (Kida et al.,
2006).
Butyrate affects the expression of a diverse array of tar-
get genes potentially involved in the regulation of cell death
(Ruemmele et al., 1999) and immune-modulation of the gas-
trointestinal tract and exhibits thereby anti-inﬂammatory prop-
erties (Schauber et al., 2006). Mechanisms that have been pro-
posed for butyrate-induced effects include hyperacetylation of
histonesduetoinhibitionofhistonedeacetylase,leadingtochro-
matin relaxation and increased transcriptional activity and both
phosphorylation and methylation of DNA-histone complexes
(Wachtershauser and Stein, 2000).
PPAR and VDR are target genes for butyrate and are
up-regulated by this substance (Gaschott and Stein, 2003;
Wachtershauser et al., 2000). Both are ligand-activated tran-
scription factors that belong to the nuclear hormone receptor
family and participate in a variety of immunological processes
(Tirona and Kim, 2005). VDR is widely expressed in epithe-
lial tissues, cells of the immune system and several cancer cell
lines including the colon cancer cell line Caco-2 (Giuliano et
al., 1991; Segaert and Bouillon, 1998). PPAR is activated
by natural ligands such as fatty acids and eicosanoids and is
highly expressed in colonic epithelium, indicating an impor-
tant role of the receptor in the physiology of the human colon
(Desvergne and Wahli, 1999). All these characteristics make
both receptors potential targets in butyrate-mediated LL-37
up-regulation. We therefore examined butyrate-induced LL-
37 gene expression through application of the VDR inhibitor
ZK191732andaCaco-2PPARmutantcelllinetoinhibitwild-
type action. Our data indeed demonstrate that VDR activity,
but not PPAR activity, is required for the butyrate-induced
LL-37 expression. The presence of a consensus vitamin D
response element (VDRE) in the promoter of the human cathe-
licidin gene supports our ﬁndings (Wang et al., 2004). Further-
more, LL-37 mRNA levels were up-regulated after treatment
with 1,25-dihydroxyvitamin D3 and its analogues in several
human cell types (Gombart et al., 2005; Wang et al., 2004).
This mechanism seems to be conserved in primates but not
in other mammals as suggested by the absence of the VDRE
in murine and canine cathelicidin promotors (Gombart et al.,
2005).
In addition, the participation of MAPKs in LL-37 regula-
tion was scrutinized. MAPKs, such as ERK1/2 and p38 MAPK,
comprise a group of protein serine/threonine kinases that are
able to modulate the activity of a variety of transcription factors
(Narayanan et al., 2004; Qi et al., 2004). They are activated in
response to a variety of stimuli through dual phosphorylation
at conserved threonine and tyrosine residues (Seger and Krebs,
1995).Thep38MAPKsignallingtransductionpathwayhasbeen
demonstratedtoplayanessentialroleintheregulationofseveral
cellular processes including, cell differentiation (Nagata et al.,
1998), cell growth, apoptosis, as well as inﬂammation (Nebreda
and Porras, 2000). Increased phosphorylation of p38 MAPK by
butyrateindifferentcelltypeshasbeendemonstratedbyseveral
groups including our own (Daniel et al., 2004; Schwab et al.,
2006; Witt et al., 2000). Furthermore, we have recently shown
that p38 MAPK is involved in the up-regulation of the VDR
after butyrate treatment (Daniel et al., 2004), suggesting a pos-
sible role for this signalling pathway also in the regulation of
LL-37 expression. Indeed, pre-treatment with two MAPK-ERK
inhibitors diminished the induction of cathelicidin by butyrate,
thestrongesteffecttherebyobservedforthep38MAPKinhibitor
SB203580, underscoring the importance of the p38 MAPK sig-
nallingpathwayintheinductionprocessofcathelicidininCaco-
2 cells. In accordance to our ﬁndings, butyrate-induced transac-
tivation of the cathelicidin promotor in a human lung epithelial
cell line was reported to be blocked after pre-incubation with
inhibitorsfortheERK1/2,JNKandp38MAPKsignallingpath-
way (Kida et al., 2006). However, conﬂicting results have been
obtained in other cell types. In SW620 cells, inhibition of the
ERK1/2 pathway suppressed butyrate-mediated LL-37 mRNA
expression while blocking the p38 MAPK trail supported the
expression of the gene (Schauber et al., 2003). Moreover, inhi-
bition of p38 MAPK in human keratinocytes led to decreased
cathelicidin gene expression, whereas cJun N-terminal kinase
(JNK) and ERK 1/2 pathways were not involved (Sayama et
al., 2005). Altogether, these ﬁndings suggest the involvement
of cell speciﬁc kinase pathways in the induction of LL-37 by
butyrate.
Transforminggrowthfactors,includingTGF-1,arekeyreg-
ulatory peptides that modulate mucosal cell populations critical
to IBD (Babyatsky et al., 1996). During active inﬂammation of
IBD, TGF-1 was found to be increased in the affected mucosa
modulating epithelial cell restitution and functional features of
cells within the lamina propria (Babyatsky et al., 1996). In addi-
tion, TGF-1 expression was reported to be enhanced in wound
healingandthisgrowthfactorresponseceasedafterregeneration
oftheinjuredtissue,whenthephysicalbarrierprotectingagainst
microbial infections was re-established (Sorensen et al., 2003).
Wethereforereasonedthatgrowthfactorsarelogicalcandidates
as inducers of antimicrobial peptides. Our data demonstrate that
pre-treatment of Caco-2 cells with a TGF-1 receptor kinase
inhibitor diminished LL-37 up-regulation caused by butyrate.
These ﬁndings are supported by former studies reporting the
necessity of TGF-1 in butyrate-induced Caco-2 cell differen-M. Schwab et al. / Molecular Immunology 44 (2007) 2107–2114 2113
tiation (Schroder et al., 1999) and the increase of LL-37 expres-
sion in spontaneously differentiating Caco-2 cells (Hase et al.,
2002).
Insummary,thedatapresentedheregivenewinsightsintothe
regulation of the antimicrobial cathelicidin in the colon cancer
cell line Caco-2. Our results clearly demonstrate that butyrate-
induced up-regulation of LL-37 in Caco-2 cells is inﬂuenced by
several signalling pathways and receptors including MAPKs as
well as VDR and TGF-1. In contrast, PPAR does not par-
ticipate in this cascade. Revealing this transduction pathway is
not only important to understand fundamental biological pro-
cesses, but also may provide new opportunities in the treatment
of gastrointestinal diseases.
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Abstract 
Background and aims: Antimicrobial peptides like human β-defensin-2 (HBD-2) play an 
important role in the innate immune system protecting the intestinal mucosa against bacterial 
invasion. The dietary histone deacetylase (HDAC) inhibitors sulforaphane (SFN) and butyrate 
have received a great deal of attention because of their ability to simultaneously modulate 
multiple cellular targets involved in cellular protection. In this study the influence of SFN and 
butyrate on HBD-2 expression as well as molecular pathways involved in the HBD-2 
regulatory process were scrutinized.  
Methods and Results: Treatment of Caco-2, HT-29 and SW480 cells with SFN led to a time- 
and dose-dependent up-regulation of HBD-2 mRNA expression as determined by semi-
quantitative RT-PCR. Moreover, HBD-2 protein was increased in response to SFN, measured 
by ELISA. Immunofluorescence analysis revealed that the protein is localised in the cytosol. 
Co-incubation of SFN with a vitamin D receptor (VDR) antagonist and a ERK1/2 inhibitor 
reduced HBD-2 mRNA up-regulation. In contrast, transfection of cells with a dominant-
negative peroxisome proliferator-activated receptor γ (PPARγ) mutant vector to inhibit 
PPARγ wild-type action and inhibition of p38 MAPK signalling did not affect SFN-mediated 
up-regulation of HBD-2 mRNA. Similar results for all experiments were obtained after 
butyrate stimulation. Moreover, SFN induced the expression of VDR and phosphorylated 
ERK1/2 but did not affect p38 MAPK activation. 
Conclusion: The data clearly demonstrate for the first time that the dietary HDAC inhibitor 
SFN is able to induce antimicrobial peptides in colonocytes. In this process HBD-2 
expression is regulated via VDR and the MEK/ERK signalling pathway. 
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Introduction 
The gastrointestinal tract is constantly in contact with bulk of commensal microorganisms, 
residing in the colon and distal small intestine. Although the presence of this native flora in 
general is mutually beneficial, the host also requires protection against these microorganisms. 
The role of antimicrobial peptides of the defensin family mediating protective responses has 
been established (Ganz, 2003; Sansonetti, 2004; Wehkamp and Stange, 2006; Zasloff, 2002). 
Disturbances in their expression in the intestinal tract were shown to be linked to 
inflammatory bowel diseases (IBD) (Wehkamp et al., 2005b; Wehkamp et al., 2005c; 
Wehkamp et al., 2005d; Zasloff, 2006).  
Defensins are small cationic peptides with a broad spectrum of antimicrobial activity 
having characteristic pairs of intramolecular disulfide bonds, a beta-sheet structure and a mass 
of 3-5 kDa (Bevins et al., 1999; Eckmann, 2004). They are classified as α- and β-defensins 
based on the position of three disulfide bridges (Eckmann, 2005). The β-defensins are 
ubiquitously expressed throughout the gastrointestinal tract, including the colon (Sansonetti, 
2004). Among the β-defensins, HBD-1 is constitutively expressed (O'Neil et al., 1999; 
Wehkamp et al., 2003), whereas HBD-2 is inducible in response to infection, pro-
inflammatory mediators such as IL-1β, TNF-α, and probiotic bacteria (De Smet and 
Contreras, 2005; Wehkamp et al., 2004). Permeabilization of target membranes is the crucial 
step in defensin-mediated antimicrobial activity and cytotoxicity (Ganz, 2003). The positively 
charged defensin molecules are inserted into the bacterial membranes under the influence of 
cell-generated transmembrane potentials and local electrostatic fields, resulting in the 
cessation of RNA, DNA, and protein synthesis in bacteria (Ganz, 2003; Wehkamp et al., 
2005a). Besides their direct antimicrobial effects, defensins exert further functions related to 
host defence such as the induction of histamine release by mast cells and chemoattraction of 
various cells of the immune system including neutrophils and T cells (Befus et al., 1999; De 4 
Smet and Contreras, 2005). Moreover, they seem to be involved in carcinogenesis (Bullard et 
al., 2008; Markeeva et al., 2005; Papo and Shai, 2005).  
The dietary histone deacetylase (HDAC) inhibitor sulforaphane (SFN) is one of the 
most biologically active phytochemicals in the human diet and is present at high 
concentrations in some cruciferous vegetables, especially broccoli (Brassica oleracea) 
(Fimognari and Hrelia, 2007). SFN has received a great deal of attention because of its ability 
to simultaneously modulate multiple cellular targets involved in cellular protection (Myzak 
and Dashwood, 2006; Myzak et al., 2006). SFN is regarded as a highly promising dietary 
preventative agent because of its capacity to induce apoptosis and to inhibit cell proliferation 
in various tumour cells, including colorectal cancer (Fimognari and Hrelia, 2007; Myzak and 
Dashwood, 2006). In addition, several studies indicate that SFN exhibits immune-modulatory 
capacities by interfering with the actions of the pro-inflammatory transcription factor NFκB 
and by the modulation of the production of pro- and anti-inflammatory cytokines (Bertl et al., 
2006; Heiss et al., 2001; Thejass and Kuttan, 2007). Recent studies including our own report 
that HDAC inhibitors like butyrate and Trichostatin A induce the expression of antimicrobial 
peptides in several colorectal cancer cells (Hase et al., 2002; Schauber et al., 2006; Schauber 
et al., 2004; Schwab et al., 2007b). In analogy, the aim of this work was to explore a possible 
role for SFN in the induction of HBD-2 expression as well as to scrutinize molecular 
pathways involved in this regulatory process.  
 5 
Materials and methods 
Cell culture 
The human colorectal cancer cell lines Caco-2, HT-29 and SW480 were obtained from the 
European Collection of cell cultures (ECACC). Cells were cultured in a humidified incubator 
at 37 °C in an atmosphere of 95% air and 5% CO2. Caco-2 and SW480 cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% foetal calf serum 
(FCS), 1% non-essential amino acids, 1% sodium pyruvate and 1% penicillin/streptomycin. 
HT-29 cells were grown in McCoy’s 5A Medium, supplemented with 10% FCS and 1% 
penicillin/streptomycin. Medium of the dominant-negative PPARγ mutant and empty-vector 
HT-29 cells was supplied with 400 μg/ml Geneticin 418 sulphate (G418, Gibco-BRL, 
Eggenstein, Germany). Cells were regularly screened for mycoplasma contamination using 
the VenorGem Mycoplasma detection kit (Minerva Biolabs, Berlin, Germany).  
For experiments, cells were seeded in plastic cell culture wells and were cultivated in 
DMEM and McCoy’s 5A Medium, respectively until, 80% confluency was reached. Medium 
was then removed and replaced by medium containing either the solvent, SFN (1-20 µM), 
butyrate (1-5 mM) or one of the combinations of SFN (10 µM) or butyrate (3 mM) with the 
vitamin D receptor inhibitor ZK191732 (10 μM), the p38 MAPK inhibitor SB203580 (20 
μM) or the ERK1/2 inhibitor PD98059 (40 μM), respectively. In these experiments, cells 
were pre-treated with the inhibitors for 5 h, followed by challenge of cells with SFN or 
butyrate for up to 48 h. Sodium butyrate (Merck-Schuchardt, Hohenbrunn, Germany) was 
dissolved in phosphate buffered saline (PBS), SFN (Axxora, San Diego, California, USA) 
solubilised in aqua ad iniectabilia (DeltaSelect, Pfufflingen, Germany). PD98059 and 
SB203580 (both Calbiochem, Schwalbach/Taunus, Germany) was dissolved in dimethyl 
sulfoxide (DMSO, Fluka, Sigma-Aldrich-Chemie, Steinheim, Germany), ZK191732 was 
(supplied by the Department of Medicinal Chemistry at Schering AG, Berlin, Germany) 6 
dissolved in ethanol. The maximal concentration of solvents in each medium was kept below 
0.1% [v/v]. The medium was changed every day. Cells were then harvested at the times 
indicated in the figure legends. Concentrations of SFN and butyrate in our experiments 
correspond to appropriate physiologic concentrations (Jakubikova et al., 2005; Traka et al., 
2005; Wachtershauser and Stein, 2000). 
 
Transfection assay 
The following plasmids were used for transfection: pcDNA3 (Invitrogen, Karlsruhe, 
Germany), as an empty-vector for control transfection and the plasmid pcDNA3-
PPARγL468A/E471A, a dominant-negative PPARγ double-mutant, that was kindly provided by 
VK Chatterjee (Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, 
Cambridge, United Kingdom) (Gurnell et al., 2000). These constructs were transfected into 
subconfluent HT-29 cells with lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) in 
serum-free conditions. After 6 h, the cells were supplied with fresh medium containing 10% 
FCS. 24 h later, the cells were supplied with medium containing G418 (400 μg/ml) and 
culture medium supplemented with G418 was replaced twice a week. G418-resistant colonies 
were collected and used for further analysis. The functional successful transfection of the 
dominant-negative PPARγ cell system was demonstrated recently (Schwab et al., 2007a; 
Schwab et al., 2006). 
 
Cytotoxicity 
Cytotoxicity was excluded by lactate dehydrogenase (LDH) release assay using a commercial 
kit (LDH kit, Roche, Mannheim, Germany).  
 
mRNA isolation 7 
Cells were cultivated in 6-well plates and were treated at 80% confluency with SFN (20 µM), 
butyrate (3 mM), or the combination of SFN or butyrate with one of the inhibitors for 24 and 
48 h, respectively. Total RNA was isolated from cells by RNA isolation reagent (TRIR, 
Abgene, United Kingdom), followed by phenol extraction and ethanol precipitation. 
 
Semi-quantitative RT-PCR 
RT-PCR was conducted with the Gene Amp RNA PCR kit (Applied Biosystems, Branchburg, 
New Jersey, USA) according to the manufacturer’s protocol, starting from 1 μg total RNA. 
All RNA samples were subjected to DNase-treatment during the RT-step to remove traces of 
genomic DNA (Shrimp Nuclease, Abgene, United Kingdom). Amplification of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as control. From the results of 
preliminary experiments, 20 PCR cycles for GAPDH and 35 cycles for HBD-2 were selected 
as optimal amplification conditions to produce a log-linear relationship between the amount 
of each mRNA and intensity of PCR product. The PCR reaction contained 0.2 mM dNTPs 
(Invitrogen Corporation, Carlsbad, California, USA), 0.05 U × µl
-1 AmpliTaqGold DNA 
polymerase (Applied Biosystems, Branchburg, New Jersey, USA), 1.5 mM Mg2Cl (Applied 
Biosystems, Branchburg, New Jersey, USA) and either 0.2 µmol/L primers of HBD-2 and 
GAPDH, respectively (Biospring, Frankfurt, Germany). PCR conditions for HBD-2 were: 
initial denaturation at 94°C for 1 min followed by annealing at 58°C for 1 min, extension at 
72°C for 2 min and a final extension at 72°C for 7 min after the last cycle. The respective 
annealing temperature for GAPDH was 45°C. Primers for amplification were as follows: 
HBD-2 sense 5’-ggtggtataggcgatcctgtt-3’, HBD-2 antisense 5’-agggcaaaagactggatgaca-3’; 
GAPDH sense 5’-gcaccgtcaaggctgagaac-3’, GAPDH antisense 5’-ccaccaccctgttgctgtag-3’. 
The expected sizes of HBD-2 and GAPDH were 66 and 803 base pairs, respectively. Aliquots 
of the PCR mixtures (10 µL) were analyzed by electrophoresis using a 1.5% agarose gel 8 
containing ethidium bromide. Gels were placed on a UV transilluminator and digitalized by 
DocuGel V-System (Scananalytics). For semi-quantitative analysis of amplified PCR 
products, the fluorescent dye PicoGreen (Molecular Probes, Eugene, Oregon, USA) was used 
according to the manufacturer’s instructions. In brief, two microliters of amplified DNA in 
100 μl TE buffer were mixed with an equal volume of diluted PicoGreen reagent (1:200, v/v 
in TE buffer). Samples were incubated for 5 min at room temperature and protected from light 
in a microtiter plate. The fluorescence was measured (λex= 485 nm; λem = 538 nm) in the 
fluorescence microplate reader Tecan SpectraFluor PLUS. A λ DNA linear standard curve 
was applied for each experiment. 
 
Immunofluorescence Assay 
Caco-2 cells were grown on glass chamber slides (Lab-Tek, Nunc, Rochester, New York, 
USA) and allowed to reach 80% confluency. Cells were fixed in ice-cold ethanol (95%) for 
10 min and permeabilized by addition of 0,1% Triton X-100 in PBS for 10 min. After 
washing, unspecific binding of antibodies was blocked by incubating cells in 8% horse serum 
in PBS containing 0,1% Tween-20 for 1 h at room temperature. HBD-2 antibody 
(Immundiagnostik, Bensheim, Germany) was diluted 1:25 in blocking buffer. After 1.5 h of 
incubation, cells were washed three times with PBS before secondary antibody (cy3 
conjugated rabbit-anti-goat, Sigma, Saint Louis, Missouri, USA) was added for 1 h. 
Following washing and air-drying, the cells were embedded in 4',6-Diamidino-2-phenylindol 
(DAPI) mounting medium (Vector Laboratories, Burlingame, California, USA) and evaluated 
by immunofluorescence microscopy (Eclipse E 600, Nikon, Tokyo, Japan) with a digital 
camera DX 20H (Kappa, Monrovia, California, USA). 
 
β-defensin-2 ELISA 9 
Caco-2 cells were grown in 6-well plates and were treated at 80% confluency with SFN or 
butyrate for 24 and 48 h, respectively. Cells were washed three times with ice-cold PBS and 
incubated with cell lysis buffer (Cell signaling, Beverly, Massachusetts, USA) containing 
multiple protease inhibitors (Complete, Roche, Mannheim, Germany) for 5 min at 4  °C. 
Protein extracts were obtained after sonication of cell lysates (2 × 5 s) and centrifugation at 
13.000 rpm at 4  °C (10  min). Protein content was determined via a colorimetric assay 
according to the method of Bradford (Bio-Rad Laboratories, Munich, Germany). Cell lysates 
were diluted 1:3 with PBS containing 0,1% bovine serum albumin. 100 µL were used for each 
reaction. HBD-2 ELISA Kit (Immundiagnostik, Benzheim, Germany) was then used 
according to the manufacturers instructions. Protein concentration of HBD-2 was analysed 
and samples were normalized to equal protein concentrations. 
 
SDS–polyacrylamide gel electrophoresis and immunoblot analysis 
Caco-2 and HT-29 cells were stimulated with SFN at 80% confluency. Cells were than 
harvested and protein content was determined via Bio-Rad colorimetric assay (see β-defensin-
2 ELISA). Equal amounts of total protein lysates were separated on a 10% SDS-
polyacrylamide gel for VDR and on a 12.5% SDS-polyacrylamide gel for ERK1/2, phospho-
ERK1/2, p38 MAPK and phospho-p38 MAPK. Proteins were transferred onto a nitrocellulose 
membrane (Schleicher & Schuell, Dassel, Germany). Subsequently, membranes were blocked 
for one hour with 5% (w/v) nonfat dried milk in Tris-buffered saline containing 0.05% Tween 
20 (TBS-T). Membranes were then incubated overnight with a 1:1000 dilution of VDR-, 
ERK1/2-, phospho-ERK1/2-antibody (all from Santa Cruz Biotechnologies, Santa Cruz, 
California, USA) or with p38 MAPK- and phospho-p38 MAPK-antibody (both from Cell 
signalling, Beverly, Massachusetts, USA) in 0.05% TBS-T and 5% (w/v) nonfat dried milk, 
respectively. After washing, the blots were incubated for half an hour with corresponding 10 
horseradish peroxidase-conjugated antibody (Vector Laboratories, Burlingame, California, 
USA, dilution 1:2000) in 0.05% TBS-T and 5% (w/v) nonfat dried milk. The washing steps 
were repeated, and subsequently enhanced chemoluminescence detection was performed 
according to the manufacturer’s instructions (ECL, Amersham pharmacia biotech, 
Buckinghamshire, UK) on Hyperfilm-MP (Amersham International plc, Buckinghamshire, 
UK). Blots were then reprobed with β-actin antibody (Sigma, Saint Louis, Missouri, USA). 
For quantitative analysis, bands were detected by scanning densitometry, using a Desaga 
CabUVIS scanner and Desaga ProVilDoc software (Desaga, Wiesloch, Germany). 
 
Statistics 
All statistical analyses were performed using GraphPad Prism 4.01 (San Diego, California, 
USA). Analysis of variance (ANOVA) was performed when more than two groups were 
compared and, when significant (P < 0.05), multiple comparisons were performed with the 
Tukey’s test. Data are expressed as means ± SD from three independent experiments. P value 
< 0.05 was considered to be significant. 
 
Results 
Sulforaphane is a direct inducer of HBD-2 mRNA expression in colonocytes 
Challenge of HT-29 cells with increasing concentrations of SFN (1-20 µM) provoked a dose-
dependent up-regulation of HBD-2 mRNA after 24 h (Fig. 1) and 48 h of treatment (data not 
shown). Significant effects were seen at concentrations of ≥ 5 µM. Increased expression of the 
HBD-2 gene in response to SFN (20 µM) was also obtained in the colon cancer cell lines 
Caco-2 and SW480 after 24 h (Fig. 1), reflecting a common mechanism in colorectal cancer 
cells. In analogy, stimulation of HT-29 cells with increasing concentrations of the dietary 
HDAC inhibitor butyrate (1-5 mM) also resulted in a dose-dependent up-regulation of HBD-2 11 
mRNA compared to control cells (Fig. 1) after 24 h. A similar up-regulation was seen in 
Caco-2 cells (data not shown).  
 
Sulforaphane elevates HBD-2 protein expression in colonocytes  
Up-regulation of HBD-2 mRNA was accompanied by a similar increase in protein level as 
measured by ELISA. In Caco-2 cells, a time-dependent increase of HBD-2 protein levels was 
observed after exposure with SFN (20 µM) or butyrate (3 mM) (Fig. 2 A: SFN: 24 h: +62%, p 
< 0.05; 48 h: +104%, p < 0.001 / butyrate: 24 h: +47%, p < 0.05; 48 h: +161%, p < 0.001). 
Moreover, the subcellular localisation of HBD-2 protein in Caco-2 cells was determined via 
immunofluorescence analysis (Fig. 2 B). Caco-2 cells were treated with butyrate (3 mM) up 
to 48 h. Both control and butyrate-treated cells showed strong HBD-2 staining predominantly 
in the cytosol. Moreover, butyrate challenge for 48 h led to an increased expression of the 
HBD-2 protein, which is in line with the results obtained by ELISA. Similar results were 
obtained after challenge of cells with SFN used in the concentration of 20 µM (data not 
shown). 
 
The vitamin D receptor (VDR) but not the peroxisome proliferator-activated receptor γ 
(PPAR γ) is involved in sulforaphane-induced β-defensin-2 mRNA expression 
The nuclear receptors vitamin D receptor (VDR) and peroxisome proliferator-activated 
receptor γ (PPARγ) are potent regulators of immune responses. To evaluate the involvement 
of PPARγ in SFN-induced HBD-2 mRNA expression, HT-29 cells transfected with a 
dominant-negative PPARγ mutant to inhibit wild-type receptor action were used (Fig. 3). In 
these mutant cells, an equal time-dependent increase of HBD-2 compared to wild-type and 
empty-vector (data not shown) cells was observed after challenge of SFN, indicating that 
PPARγ activity is not required for HBD-2 regulation. Similar effects were obtained after 12 
challenge of cells with butyrate (data not shown). Moreover, wild-type Caco-2 cells were 
treated with SFN (10 µM) in presence of the VDR antagonist ZK191732. Inhibition of the 
VDR significantly antagonized the SFN-induced HBD-2 mRNA after 24 h of incubation, 
demonstrating its pivotal role in SFN-induced HBD-2 up-regulation (-71% vs. control, p < 
0.001, Fig. 4 A). A similar pattern for HBD-2 mRNA levels was observed after treatment of 
Caco-2 cells with ZK191732 and butyrate (data not shown). To unveil whether VDR is a 
target of the SFN signalling pathway, colonocytes were stimulated with SFN (10-20 µM) for 
24 h. As depicted in Fig. 4 B, SFN increased VDR protein expression in HT-29 cells. A 
similar pattern was observed for the colorectal cancer cell line Caco-2 (Fig. 4 B). 
 
The mitogen-activated protein kinase kinase/extracellular-regulated kinase (MEK/ERK) 
signalling pathway plays a role in sulforaphane-induced HBD-2 mRNA expression 
To determine the involvement of intracellular signal transduction pathways such as p38 
mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK1/2) 
in SFN-mediated HBD-2 expression, Caco-2 cells were pre-incubated for 5 h with specific 
inhibitors prior to stimulation with SFN (10 µM). Combined treatment of SFN with the 
ERK1/2 inhibitor PD98059 reduced the induction of HBD-2 mRNA expression after 24 h 
(Fig. 5 A). On the contrary, co-incubation with the p38 MAPK inhibitor SB203580 did not 
affect elevated HBD-2 mRNA expression caused by SFN for this point in time (Fig. 5 A). 
Similar effects were obtained after challenge of cells with butyrate (data not shown). 
Moreover, exposure of Caco-2 cells with SFN (10-20 µM) resulted in a rapid phosphorylation 
of ERK1/2 after 8 h, while the amount of total ERK1/2 protein was not affected. The 
expression of phospho-p38 MAPK and p38 MAPK proteins were unchanged by SFN in 
Caco-2 cells (Fig. 5 B). 
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Discussion 
The discovery of antimicrobial peptides such as defensins has extended the knowledge of 
unspecific defence mechanisms. A deficiency in the antimicrobial defence system of 
defensins may be a reasonable and plausible explanation for the breakdown of barrier 
functions with increased invasion of infectious pathogens, leading to inflammation or 
deleterious immune responses. Aberrances in defensin expression have not only been 
observed in inflammatory bowel diseases (Wehkamp et al., 2005a; Zasloff, 2006), but also in 
cystic fibrosis where the inactivation of the defensins due to high salt conentrations has been 
linked to recurrent bronchopulmonary infections (Goldman et al., 1997). In contrast to 
ulcerative colitis and ileal Crohn’s disease, colonic Crohn’s disease is characterized by an 
impaired induction of the epithelial HBD-2 (Fellermann et al., 2006; Wehkamp et al., 2002; 
Wehkamp et al., 2005b). This defective regulation could be explained by the lower HBD-2 
gene copy number in the HBD-2 locus in colonic Crohn’s disease (Fellermann et al., 2006). A 
normal HBD-2 copy number distribution was seen in ileal Crohn’s disease and also in 
ulcerative colitis (Fellermann et al., 2006). Eventually, the lack of HBD-2 induction may 
contribute to a defective antimicrobial barrier leading to chronic inflammation in Crohn’s 
disease affecting the large bowel (Fellermann et al., 2006). Detailed knowledge of HBD-2 
expression and regulation is still lacking. The aim of this study was to determine a possible 
role for the dietary HDAC inhibitor SFN in the regulation of the HBD-2. In this context, the 
involvement of the nuclear receptors VDR and PPARγ as well as MEK-ERK pathways were 
examined. Equal experiments were accomplished with the dietary HDAC inhibitor butyrate. 
Accumulating evidence suggests that SFN is a highly promising dietary preventive 
agent, due to its ability to exert anti-inflammatory effects via multiple mechanisms of action 
(Dashwood et al., 2006; Thejass and Kuttan, 2007). The anti-inflammatory effects of SFN and 
butyrate may be achieved via different pathways: The agents can affect the expression of a 14 
diverse array of genes potentially involved in immune modulation through their ability to 
inhibit HDAC activity via histone hyperacetylation (Dashwood et al., 2006). This results in 
chromatin relaxation and increased transcription of target genes (Dashwood et al., 2006). SFN 
and butyrate are able to block TNFα- and LPS-induced NFκB translocation resulting in 
reduced expression of pro-inflammatory cytokines (Heiss et al., 2001; Place et al., 2005; 
Thejass and Kuttan, 2007). Moreover, the involvement of HDAC inhibitors like butyrate and 
Trichostatin A in the modulation of the intestinal antimicrobial peptides make the proteins 
possible targets for SFN’s actions (Schauber et al., 2006; Schauber et al., 2003; Schwab et al., 
2007b). The present study demonstrated for the first time that the dietary HDAC inhibitor 
SFN is a direct inducer of HBD-2 mRNA and protein in colonocytes. Similar results were 
obtained after butyrate treatment. Immunofluorescence experiments showed that the peptide 
exhibits a primarily cytoplasmatic localisation. 
PPARγ and VDR are highly expressed in the colonic epithelium indicating that both 
receptors are important agents in the physiology of the human colon (Desvergne and Wahli, 
1999; Nagpal et al., 2005; Schwab et al., 2006). The receptors partly mediate their anti-
inflammatory actions through negative interference with pro-inflammatory transcription 
factors such as NFκB (Delerive et al., 2001; Schwab et al., 2007a; Sun et al., 2006). 
Moreover, there is great influx of information that PPARγ ligands may influence the 
inflammatory response in IBD and colon cancer (Auwerx, 2002; Bull, 2003). Similarly, the 
active form of vitamin D, 1,25-dihydroxyvitamin D3, was shown to inhibit the development of 
various autoimmune diseases, including IBD (Cantorna et al., 2004). In addition, a VDR gene 
polymorphism has been associated with Crohn’s disease susceptibility (Simmons et al., 2000). 
All these features implicate a possible involvement of both receptors in SFN-mediated HBD-2 
regulation. Using the VDR inhibitor ZK191732 and a Caco-2 dominant-negative PPARγ 
mutant cell line in our experiments, we demonstrated that VDR activity, but not PPARγ 15 
activity, is required for HBD-2 expression induced by SFN or butyrate. The properties of the 
VDR inhibitor and the functional successful transfection of the dominant-negative PPARγ 
mutant cell system has described recently (Schwab et al., 2007a). Our findings are supported 
by the presence of a consensus vitamin D response element (VDRE) in the promoter of the 
human HBD-2 gene (Wang et al., 2004). Accordingly, stimulation of several human cell types 
with 1,25-dihydroxyvitamin D3 resulted in increased expression levels of HBD-2 mRNA 
(Wang et al., 2004). Moreover, our in vitro model demonstrates for the first time the up-
regulation of VDR after SFN stimulation in colonocytes. A similar increase of the receptor 
was observed after butyrate treatment (Gaschott and Stein, 2003; Gaschott et al., 2001). 
SFN stimulation may activate different MAPKs in colorectal cancer cells (Jakubikova 
et al., 2005; Keum et al., 2006; Shen et al., 2006). Kinase pathways act as signal sorters and 
conduct a variety of upstream signals to the nucleus of the eukaryotic cell, where transcription 
of specific target genes will be affected (Seger and Krebs, 1995). To gain insight into the 
regulatory pathways by which SFN augments HBD-2 expression in Caco-2 cells, our in vitro 
model focused on two major MAPKs: p38 MAPK and ERK1/2. These MAPKs are involved 
in a large variety of cellular activities, including cell survival, proliferation and inflammatory 
responses (Ballif and Blenis, 2001; Chang and Karin, 2001; Nebreda and Porras, 2000; Seger 
and Krebs, 1995). Increased phosphorylation of ERK1/2 by SFN in various cell lines 
including human colon adenocarcinoma Caco-2 cells has been demonstrated by several 
groups, although the amount of ERK1/2 protein was not affected. In contrast, SFN treatment 
had no impact on p38 MAPK activation (Jakubikova et al., 2005; Keum et al., 2006). These 
observations are confirmed by our experiments. Moreover, inhibition of the ERK1/2 pathway 
in this study prevented SFN-mediated induction of HBD-2 mRNA expression in Caco-2 cells, 
while blocking of the p38 MAPK trail did not affect HBD-2 levels for this point in time. Our 
data are in accordance with the observations in middle ear epithelial cells, demonstrating 16 
transcriptional activation of the HBD-2 gene caused by IL-1α which is mediated through an 
Raf-MEK1/2-ERK1/2 signalling pathway (Moon et al., 2002). Conflicting results were 
obtained in the lung epithelial cell line A549, in which IL-1β-induced up-regulation of HBD-2 
was partly attenuated by inhibiting the p38 MAPK but not by the ERK1/2 signalling pathway 
(Jang et al., 2004). These different observations indicate a cell specific and stimulus 
dependent kinase pathway leading to induction of HBD-2. However, all these studies 
underscore the importance of the MAPK signalling pathways in innate immunity through the 
regulation of HBD-2 levels. 
Recapitulating our present findings, we could demonstrate for the first time that SFN 
induces the expression of the antimicrobial peptide HBD-2 on mRNA and protein level in 
colorectal cancer cells. Furthermore, we revealed that SFN-mediated induction of HBD-2 is 
modulated via the VDR and the MEK/ERK signalling pathway. Similar effects were obtained 
after butyrate treatment. These data support the potential usefulness of dietary HDAC 
inhibitors in the therapy of colonic Crohn’s disease. Further in vivo studies are required to 
confirmly establish the relevance of these findings. 
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Figure Legends 
Fig. 1: Dose-dependent effect of sulforaphane (1-20 µM) and butyrate (1-5 mM) on β-
defensin-2 mRNA expression in HT-29 cells after 24 h of treatment. Moreover the induction 
of β-defensin-2 mRNA expression in Caco-2 and SW480 cells in response to sulforaphane 
(20 µM) was demonstrated. β-defensin-2 mRNA expression was measured by semi-
quantitative RT-PCR with the fluorescent dye Pico Green. All values for mRNA levels are 
normalized to corresponding mRNA amounts for GAPDH. One representative gel of three 
independent experiments is shown. Induction of β-defensin-2 mRNA is displayed as relative 
percentage to solvent treated control cells. ***p < 0.001, *p < 0.05, n.s. = not significant 
 
Fig. 2: (A) β-defensin-2 protein expression in Caco-2 cells measured via ELISA: Cells were 
starved for 72 h and then stimulated with sulforaphane (10-20 µM) or butyrate (3 mM) for 
24 and 48 h. Proteins were harvested and β-defensin-2 was measured by ELISA. The 
concentration range of all experiments was ng/ml. Induction of β-defensin-2 protein is 
displayed as fold induction relative to solvent treated control cells. ***p < 0.001, *p < 0.05 
(B) Representative immunofluorescence assays for β-defensin-2 in Caco-2 cells: Confluent 
cells were challenged with butyrate (3 mM) for 48 h (III) or grown in culture medium as 
controls (I). (II, IV): Nuclear counterstaining with 4',6-Diamidino-2-phenylindol (DAPI) 
mounting medium for each of the adjacent panels. Magnification, x 400. 
 
Fig. 3: Time-dependent effect of sulforaphane (10 µM) on β-defensin-2 mRNA expression 
in wild-type and PPARγ mutant HT-29 cells after 24 and 48 h of treatment. β-defensin-2 
mRNA was measured by semi-quantitative RT-PCR with the fluorescent dye Pico Green. 
All values for mRNA levels are normalized to corresponding mRNA amounts for GAPDH. 27 
Induction of β-defensin-2 mRNA is displayed as relative percentage to solvent treated 
control cells. n.s. = not significant 
 
Fig. 4: (A) β-defensin-2 mRNA expression in Caco-2 cells. Medium was supplemented with 
the solvent, sulforaphane (10 µM), the VDR inhibitor ZK191732 (10 µM) or the 
combination of sulforaphane and ZK191732 for 24 h. Semi-quantitative analysis of PCR 
products was performed using Pico Green. All values for mRNA levels are normalized to 
corresponding mRNA amounts of the housekeeping gene GAPDH. Induction of β-defensin-
2 mRNA is displayed as relative percentage to solvent treated control cells. ***p < 0.001, *p 
< 0.05, n.s. = not significant (B) Western blot for VDR expression after treatment of HT-29 
and Caco-2 cells with SFN (10-20 µM) for 24 h. One representative blot of three 
independent experiments is shown.   
 
Fig. 5: (A) Influence of the p38 MAPK inhibitor SB203580 (20 μM) and the ERK1/2 
inhibitor PD98059 (40 μM) on sulforaphane-induced (10 µM) β-defensin-2 mRNA 
expression after 24 h of treatment in Caco-2 cells. β-defensin-2 expression was analysed by 
semi-quantitative RT-PCR with the fluorescent dye Pico Green. All values for mRNA levels 
are normalized to corresponding mRNA amounts of GAPDH. One representative gel of 
three independent experiments is shown. Induction of β-defensin-2 mRNA is displayed as 
relative percentage to solvent treated control cells. ***p < 0.001, n.s. = not significant (B) 
Western blot for ERK1/2, phospho-ERK1/2, p38 MAPK and phospho-p38 MAPK 
expression after treatment of Caco-2 cells with SFN (10-20 µM) for 8 h. One representative 
blot of three independent experiments is shown.       
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Abstract
Background: NFB plays a major role in the control of immune responses and inﬂammation. Recently, butyrate has not only been demonstrated
to suppress NFB activation in colorectal cancer cells, but also to modulate the activity and expression of the Peroxisome-Proliferator-Activated-
Receptor  (PPAR) and the vitamin D receptor (VDR). Therefore, we investigated a putative involvement of both receptors in butyrate-mediated
inhibition of inducible NFB signalling.
Results: Treatment of HT-29 cells with butyrate attenuated basal p50 as well as TNF- and LPS-induced p50 and p65 NFB dimer activity in
the nucleus as measured by transcription factor assay. Cytosolic expression of IB protein was reduced by butyrate, and TNF but not by LPS.
ChallengeofcellswiththeVDRantagonistZK191732up-regulatedbasalNFBactivitybydecreasingIBsimultaneously,whilebasalsignalling
was not inﬂuenced by the PPAR inhibitor GW9662. Pre-treatment with ZK191732 reduced the inhibitory effect of butyrate on NFB activation
caused by TNF whereas no activation was noted in transfected dominant-negative PPAR mutant vector cells. Adversely, the inhibitory effect of
butyrate on NFB activity induced by LPS was almost reversed in dominant-negative PPAR mutant cells while pre-incubation of ZK191732 did
not affect butyrate-mediated attenuation of LPS-induced NFB signalling.
Conclusion: These ﬁndings provide evidence for the involvement of the nuclear hormone receptors PPAR and VDR in butyrate-mediated
inhibition of inducible NFB activation dependent on the stimulated signalling pathway. Moreover, VDR appears to play an inhibitory role in the
regulation of basal NFB signalling.
© 2007 Elsevier Ltd. All rights reserved.
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1. Introduction
Theshortchainfattyacid(SCFA)butyrateresultsfromanaer-
obic fermentation of undigested carbohydrates and dietary ﬁber
in the colon (Wachtershauser and Stein, 2000). Butyrate reg-
ulates many epithelial cell activities in the colon including
the induction of differentiation, inhibition of cell prolif-
eration and the initiation of apoptosis (Klurfeld, 1999;
Wachtershauser and Stein, 2000). Moreover, butyrate exerts
immune-modulatory effects and anti-inﬂammatory properties
bystimulatingthereleaseofantimicrobialpeptidesandbyinﬂu-
encing cytokine-activated gene expression in colonic epithelial
cells (Inan et al., 2000; Schauber et al., 2004; Schwab et
al., 2007). Thus, deﬁciencies in luminal butyrate produc-
0161-5890/$ – see front matter © 2007 Elsevier Ltd. All rights reserved.
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tion have been linked to chronic bowel inﬂammation (Ogawa
et al., 2003; Segain et al., 2000). There is substantial evi-
dence that butyrate exerts some of its anti-inﬂammatory effects
through suppression of nuclear factor-B (NFB) activity
(Inan et al., 2000; Luhrs et al., 2002; Yin et al., 2001).
However, the regulatory mechanisms are far from being under-
stood.
NFB is an ubiquitously expressed family of transcription
factors controlling the expression of numerous genes involved
in inﬂammatory and immune responses and cellular prolifer-
ation (Ben-Neriah, 2002; Ghosh and Karin, 2002; Karin and
Ben-Neriah, 2000). NFB rapidly enhances the transcription
of various inﬂammatory cytokines, adhesion molecules, and
chemokines (Baeuerle and Baltimore, 1996; Siebenlist et al.,
1994). The NFB family consists of ﬁve different proteins (p50
(NFB1), p52 (NFB2), p65 (RelA), RelB, and c-Rel) which
tend to dimerize (Baeuerle and Baltimore, 1996; Siebenlist et
al., 1994). The majority of NFB dimers are composed of the
p65 and the p50 or p52 subunits (Baeuerle and Baltimore, 1996;
Siebenlist et al., 1994). In resting cells, NFB is sequestered
in the cytoplasm by association with inhibitory proteins called
IBs (Baeuerle, 1998). In response to cellular stimulation, by
e.g. inﬂammatory cytokines, IB kinase (IKK) is activated
and phosphorylates IB on two serine residues (Ben-Neriah,
2002; Quivy and Van Lint, 2004). IB is then ubiquitinated and
degraded by the proteasome, freeing NFB to be translocated
into the nucleus and to exert its functions as transcription factor
(Ben-Neriah, 2002; Quivy and Van Lint, 2004; Schutze et al.,
1992).
Previously, we have demonstrated that the nuclear hor-
mone receptors Peroxisome-Proliferator-Activated-Receptor 
(PPAR) and the vitamin D receptor (VDR), transcription fac-
tors with anti-inﬂammatory capacities, are up-regulated and
activated by butyrate (Gaschott and Stein, 2003; Gaschott et al.,
2001;Schwabetal.,2006;Wachtershauseretal.,2000).PPAR
and VDR are highly expressed in the colonic epithelium indi-
catingthatbothreceptorsareimportantagentsinthephysiology
of the human colon (Desvergne and Wahli, 1999; Nagpal et al.,
2005). Ligands for both receptors have been shown to interfere
with the activity of NFB and to inﬂuence the ability of colono-
cytes to express immune-modulatory cytokines (Segain et al.,
2000; Sun et al., 2006). Our aim in this study was to examine
the role of PPAR and VDR in butyrate-mediated inhibition
of NFB activity induced by TNF and LPS. Moreover, the
involvement of both receptors for basal NFB signalling was
explored.
2. Materials and methods
2.1. Cell culture
The human colorectal cancer cell line HT-29 was obtained
from the European Collection of cell cultures (ECACC).
Cells were cultured in a humidiﬁed incubator at 37 ◦Ci n
an atmosphere of 95% air and 5% CO2. HT-29 cells were
grown in McCoy’s 5A Medium, supplemented with 10% foetal
calf serum (FCS) and 1% penicillin/streptomycin. Medium
of the dominant-negative PPAR mutant and empty-vector
HT-29 cells was supplied with 400g/mL Geneticin 418 sul-
fate (G418, Gibco-BRL, Eggenstein, Germany). Cells were
regularly screened for mycoplasma contamination using the
VenorGem Mycoplasma detection kit (Minerva Biolabs, Berlin,
Germany).
For experiments, cells were seeded in plastic cell culture
wells and cultivated in McCoy’s 5A Medium until 80% con-
ﬂuency was reached. Medium was then removed and replaced
by medium containing either the solvent, butyrate (4mM),
TNF (100ng/mL), LPS (10g/mL), the vitamin D recep-
tor antagonist ZK191732 (10M), the PPAR antagonist
GW9662 (5M) or one of the combinations of butyrate (4mM)
with TNF, LPS, ZK191732, GW9662, TNF+ZK191732 or
LPS+ZK191732, respectively.
In the experiments, cells were pre-incubated with the
inhibitors for 2h, followed by challenge of cells with butyrate
for up to 24h and then stimulated with TNF or LPS for
30min. Butyrate (Merck-Schuchardt, Hohenbrunn, Germany)
was solubilized in phosphate buffered saline (PBS) and added
to the medium. TNF (Cell Concepts, Umkirch, Germany)
and LPS (lipopolysaccharides from Escherichia coli 055:B5,
Sigma–Aldrich Chemie, Steinheim, Germany) were dissolved
in aqua ad injectabilia (DeltaSelect, Pfufﬂingen, Germany),
GW9662 (Sigma, Saint Louis, Missouri, USA) was dissolved
in dimethyl sulfoxide (DMSO, Fluka, Sigma–Aldrich Chemie,
Steinheim, Germany) and ZK191732 (supplied by the Depart-
mentofMedicinalChemistryatScheringAG,Berlin,Germany)
was solubilized in ethanol (Merck, Darmstadt, Germany). Final
maximal concentration of solvents in medium was kept below
0.1% (v/v). Solvent controls did not differ from the control
group. The medium was changed every day. Cells were then
harvested at the times indicated in the ﬁgure legends.
2.2. Transfection assay
The following plasmids were used for transfection: pcDNA3
(Invitrogen, Karlsruhe, Germany), as an empty-vector for con-
troltransfectionandtheplasmidpcDNA3-PPARL468A/E471A,a
dominant-negative PPAR double-mutant, that was kindly pro-
videdbyVKChatterjee(DepartmentofMedicine,Universityof
Cambridge, Addenbrooke’s Hospital, Cambridge, United King-
dom) (Gurnell et al., 2000). These constructs were transfected
into subconﬂuent HT-29 cells with lipofectamine 2000 (Invitro-
gen, Karlsruhe, Germany) in serum-free conditions. After 6h,
thecellsweresuppliedwithfreshmediumcontaining10%FCS.
24hlater,thecellsweresuppliedwithmediumcontainingG418
(400g/mL) and culture medium supplemented with G418 was
replaced twice a week. G418-resistant colonies were collected
and used for further analysis.
2.3. Cytotoxicity
Cytotoxicity was excluded by lactate dehydrogenase (LDH)
release assay using a commercial kit (LDH kit, Roche,
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2.4. Cytoplasmatic and nuclear protein extraction
HT-29 cells were stimulated with indicated substances at
80% conﬂuency. Cytoplasmatic and nuclear extraction was
performed using the Active Motif Nuclear cell extraction kit
(Rixensart, Belgium) according to the manufacturer’s instruc-
tions. Protein content was determined via Bio-Rad colorimetric
assay according to the method of Bradford (Bio-Rad Laborato-
ries, Munich, Germany).
2.5. NFκB p65/NFκB p50 transcription factor assay
NFB activity was determined with the TransAM® tran-
scription factor assay kit (Active Motif, Rixensart, Belgium)
following the manufacturer’s protocol. In brief, 5g of nuclear
extract was added to each well of a 96-well plate precoated with
NFB consensus binding oligonucleotide (5 -GGGACTTTCC-
3 ). After 1h of incubation with smooth agitation, wells were
washedthreetimeswithwashingbufferandthenincubatedwith
p50 or p65 antibody (dilution 1:1000) for 1h at 20 ◦C, respec-
tively.Afterthreesuccessivewashings,thewellswereincubated
for1hwithdilutedhorseradishperoxidase-conjugatedantibody
(dilution 1:1000) followed by addition of 100L of developing
solution. After 5min of incubation, the reaction was blocked
by adding 100L of stop solution reagent. Optical density was
determined by a spectrophotometer at 450nm with a reference
wavelength of 655nm.
2.6. PPARγ transactivation assay
PPAR activity was assayed using an ELISA-based trans-
activation TransAM® PPAR kit (Active Motif, Rixensart,
Belgium) following the manufacturer’s protocol (see NFB
transcription factor assay). The PPAR TransAM® kit con-
tains a 96-well plate with immobilized oligonucleotides
containing a peroxisome proliferator response element (5 -
AACTAGGTCAAAGGTCA-3 ).
2.7. SDS-polyacrylamide gel electrophoresis and
immunoblot analysis
Equal amounts of cytoplasmatic protein lysates were sep-
arated on a 12.5% SDS-polyacrylamide gel for IB and
PPAR, respectively. Proteins were transferred onto a nitro-
cellulose membrane (Schleicher & Schuell, Dassel, Germany).
Subsequently, membranes were blocked for 1h with 5% (w/v)
nonfat dried milk in Tris-buffered saline containing 0.05%
Tween 20 (TBS-T). Membranes were then incubated overnight
with a 1:500 dilution of IB-antibody (Santa Cruz Biotech-
nologies, Santa Cruz, CA, USA) or a 1:2000 dilution of
PPAR-antibody (Calbiochem, La Jolla, CA) in 0.05% TBS-T
and 5% (w/v) nonfat dried milk, respectively. After washing,
the blots were incubated for half an hour with correspond-
ing horseradish peroxidase-conjugated antibody (Santa Cruz
Biotechnologies, Santa Cruz, CA, USA, dilution 1:2000) in
0.05% TBS-T and 5% (w/v) nonfat dried milk. The washing
stepswererepeated,andsubsequentlyenhancedchemolumines-
cence detection was performed according to the manufacturer’s
instructions (ECL, Amersham Pharmacia Biotech, Bucking-
hamshire, UK) on Hyperﬁlm-MP (Amersham International plc,
Buckinghamshire, UK). Blots were then reprobed with -actin
antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA).
For quantitative analysis, bands were detected by scanning
densitometry, using a Desaga CabUVIS scanner and Desaga
ProVilDoc software (Desaga, Wiesloch, Germany).
2.8. Statistics
All statistical analyses were performed using GraphPad
Prism 4.01 (San Diego, CA, USA). Analysis of variance
(ANOVA) was performed when more than two groups were
comparedand,whensigniﬁcant,multiplecomparisonswereper-
formed with the Tukey’s test. If not otherwise stated, data are
expressedasmeans±S.D.fromthreeindependentexperiments.
A p value <0.05 was considered to be signiﬁcant.
3. Results
3.1. Butyrate reduces the basal, TNFα- and LPS-induced
nuclear activation of NFκB
Challenge of HT-29 wild-type cells with butyrate (4mM) for
24h resulted in a reduction of basal p50 dimer NFBD N A
binding activity in the nucleus (Fig. 1)( −45% versus control,
p<0.001). In contrast, basal p65 NFB DNA binding activity
was not affected in response to butyrate (Fig. 2).
Fig. 1. Inﬂuence of butyrate (4mM), TNF (100ng/mL), LPS (10g/mL) or
oneofthecombinationsofbutyratewithTNForLPSonNFBp50DNAbind-
ingactivityinHT-29wild-typeandPPARdominant-negativevectorcells.Cells
werepre-treatedwithbutyratefor24hfollowedbyTNForLPSstimulationfor
30min. Nuclear extracts were prepared and NFB activity was analysed with
theTransAM® transcriptionfactorassaykit.***p<0.001,**p<0.01,n.s.=not
signiﬁcant.3628 M. Schwab et al. / Molecular Immunology 44 (2007) 3625–3632
Fig. 2. Inﬂuence of butyrate (4mM), TNF (100ng/mL), LPS (10g/mL) or
oneofthecombinationsofbutyratewithTNForLPSonNFBp65DNAbind-
ingactivityinHT-29wild-typeandPPARdominant-negativevectorcells.Cells
werepre-treatedwithbutyratefor24hfollowedbyTNForLPSstimulationfor
30min. Nuclear extracts were prepared and NFB activity was analysed with
theTransAM® transcriptionfactorassaykit.***p<0.001,n.s.=notsigniﬁcant.
Moreover, stimulation of HT-29 wild-type cells with TNF
(100ng/mL) or LPS (10g/mL) led to a strong increase of
both p50 (TNF: +73%, p<0.001; LPS: +52%, p<0.001) and
p65 NFB DNA binding activities (TNF: +389%, p<0.001;
LPS: +205%, p<0.001) (Figs. 1 and 2). Co-incubation with
butyrate (4mM) signiﬁcantly attenuated these effects (TNF:
p50:−54%,p<0.001;p65:−52%,p<0.001;LPS:p50:−63%,
p<0.001; p65: −49%, p<0.001) (Figs. 1 and 2).
3.2. Butyrate and TNFα decrease IκBα levels in the
cytosolic fraction
Cytosolic expression of IB was reduced in response to
TNF (100ng/mL; −37%, p<0.001) stimulation for 30min
and was also decreased after butyrate (4mM; −60%, p<0.001)
incubationfor24h(Fig.3).Co-incubationofbutyrateandTNF
enhancedthedecreaseofIB(−83%,p<0.001;Fig.3).Stim-
ulation of cells with LPS (10g/mL) for 30min did either not
affect cytosolic IB expression nor IB levels caused by
butyrate (data not shown).
3.3. PPARγ is involved in butyrate-mediated inhibition of
LPS-induced NFκB activity
To investigate whether PPAR plays a role in the inhibition
ofNFBactivitycausedbybutyrate,NFBp50andp65activity
was examined in HT-29 cells transfected with a dominant-
negative PPAR mutant (Figs. 1 and 2). In this mutant the
highly conserved hydrophobic and charged residues (Leu468
andGlu471)inhelix12oftheligandbindingdomainaremutated
to alanine. As a consequence, this cell mutant indeed retains
Fig. 3. Effect of butyrate (4mM), TNF (100ng/mL) or the combination of
both substances on IB protein expression in HT-29 wild-type and PPAR
dominant-negativevectorcells.Cellswerepre-treatedwithbutyratefor24hfol-
lowedbyTNFstimulationfor30min.Cytoplasmicextractswerethenprepared
and analysed by western blotting. One representative blot of three independent
experiments is shown. Quantitative data are normalized for -actin levels. IB
protein expression after stimulation with the substances was comparable in all
cell types.
PPARligandandDNAbinding,butexhibitsmarkedlyreduced
transactivationduetoimpairedcoactivatorrecruitment(Gurnell
et al., 2000). In the mutant cell line, basal and inducible NFB
transcriptional activation was similar compared to wild-type
and empty-vector HT-29 cells after stimulation with butyrate
(4mM), TNF (100ng/mL) or their combination. Even the
down-regulation of IB levels was comparable in all three cell
lines (Fig. 3). The ﬁndings for basal NFB activity were con-
ﬁrmedbyco-incubationofbutyrate(4mM)withtheirreversible
PPAR antagonist GW9662 (5M). Administration of both
substances did not reverse the effect of butyrate on both basal
NFB p50 dimer (Fig. 4A) and p65 dimer activity (Fig. 4B).
Similarly,thedecreaseofIBwasnotaffectedbyco-treatment
of GW9662 and butyrate compared to single stimulation with
butyrate (Fig. 4C). In contrast, butyrate-mediated inhibition of
LPS-induced (10g/mL) NFB activity was almost reversed in
dominant-negative PPAR mutant cells (Figs. 1 and 2).
To evaluate receptor activity of PPAR in HT-29 wild-type
and dominant-negative PPAR mutant Caco-2 cells, PPAR
activation was determined via a transcriptional factor assay
(Fig. 5). Treatment of both HT-29 wild-type and empty-vector
cells with butyrate increased PPAR activity up to +215%
(versus control, p<0.001). As expected, PPAR activity was
not increased in butyrate-challenged HT-29 dominant-negative
PPAR mutant cells. In addition, co-incubation of butyrate with
the PPAR antagonist GW9662 reversed the increase in PPAR
activity caused by butyrate (Fig. 5).
3.4. LPS up-regulates the expression of PPARγ
To unveil whether PPAR is a target of the LPS signalling
pathway, HT-29 cells were stimulated with LPS (10g/mL)
for several time points. As depicted in Fig. 6, LPS increased
PPAR protein expression in a time-dependent manner, already
beginning at 0.5h of stimulation.
3.5. VDR plays a role in butyrate-mediated inhibition of
TNFα-induced and basal NFκB signalling activity
ChallengeofHT-29cellswiththeVDRantagonistZK191732
for 24h increased both, basal p50 (+58%, p<0.01) and p65M. Schwab et al. / Molecular Immunology 44 (2007) 3625–3632 3629
Fig. 4. NFB p50 (A) and p65 (B) dimer DNA binding activity in HT-29 wild-type cells after stimulation with butyrate (4mM), the PPAR antagonist GW9662
(5M) or the combination of both substances. Cells were pre-treated with GW9662 for 2h followed by butyrate stimulation for 24h. Nuclear extracts were then
prepared and NFB activation was analysed with TransAM® transcription factor assay kit. ***p<0.001, n.s.=not signiﬁcant. (C) Western blot for IB levels after
treatment with butyrate (4mM), the PPAR antagonist GW9662 (5M) or the combination of butyrate and GW9662 in HT-29 wild-type cells. Cells were pre-treated
withGW9662for2hfollowedbybutyratestimulationfor24h.Onerepresentativeblotofthreeindependentexperimentsisshown.***p<0.001,n.s.=notsigniﬁcant.
dimer (+78%, p<0.001) NFB DNA binding activity (Fig. 7A
and B) while reducing the expression of IB (Fig. 7C). The
decrease in IB caused by combined treatment of TNF and
butyrate was attenuated in response to ZK191732 (Fig. 7C).
Moreover, co-incubation of ZK191732 in presence of TNF
almostabolishedtheinhibitoryeffectofbutyrateonNFBDN A
binding activity (Fig. 7A and B). In contrast, butyrate-mediated
inhibition of LPS-induced (10g/mL) NFB activity was not
affected by co-stimulation with ZK191732 (Fig. 7A and B).
4. Discussion
Much of the diversity attributed to NFB functions can be
ascribed to speciﬁc cell surface receptors recognizing a variety
of unrelated ligands (Orange and Geha, 2003). Two main key
receptor families that can activate NFB include the Toll-like
Receptors (TRL) which recognize LPS, a cell wall compo-
nent of Gram-Negative bacteria and Tumor-Necrosis-Factor
Receptors (TNFR) which are triggered by their ligand TNF
(AkiraandTakeda,2004;CarioandPodolsky,2005;Orangeand
Geha, 2003). Each of the different groups of receptors activates
NFB utilizing a speciﬁc signalling cascade (Orange and Geha,
2003).Highlevelsofcirculatingandmucosalpro-inﬂammatory
cytokines resulting from increased NFB activity have been
reported in the intestinal mucosa of patients with IBD, espe-
cially ulcerative colitis and Crohn’s disease (CD) (Brynskov et
al., 1994; Di Sabatino et al., 2005; Sartor, 1997). NFB may
therefore be an interesting clinical target to suppress inﬂam-
mation and also the development of cancer in IBD. Several
studies have demonstrated that the SCFA butyrate is able to
modulate NFB signalling in epithelial cells (Inan et al., 2000;
Luhrs et al., 2002; Yin et al., 2001). However, comprehensive
knowledgebywhichbutyrateinteractswiththeNFBsignalling
pathway is still lacking. Our study demonstrates for the ﬁrst
time that PPAR plays part in butyrate-mediated inhibition of
LPS-induced NFB activation. Moreover, the VDR seems to
modulate both the expression of basal NFB signalling as well
as attenuation of TNF-induced NFB activation.
Inrestingcells,butyratehasbeenshowntoinhibitp50butnot
p65 NFB DNA binding activity (Inan et al., 2000). In addition,
recent studies provide evidence that butyrate is able to attenu-
ate both p50 and p65 NFB dimer activity induced by TNF3630 M. Schwab et al. / Molecular Immunology 44 (2007) 3625–3632
Fig. 5. Effect of butyrate (4mM) on PPAR DNA binding activity in HT-29
wild-type, PPAR dominant-negative and empty-vector cells. In addition, the
inﬂuence of butyrate (4mM), the PPAR antagonist GW9662 (5M) or the
combination of butyrate and GW9662 on PPAR activity in HT-29 wild-type
cells was measured. Cells were pre-treated with GW9662 for 2h followed by
butyrate stimulation for 24h. Nuclear extracts were prepared and PPAR bind-
ing activity was determined with the TransAM® transcription factor assay kit.
***p<0.001, n.s.=not signiﬁcant. PPAR binding activity was similar for HT-
29 wild-type and empty-vector cells after stimulation and was suppressed using
dominant-negative PPAR cells or GW9662.
or LPS in several cell lines including HT-29 cells (Chakravortty
et al., 2000; Inan et al., 2000; Luhrs et al., 2002; Segain et al.,
2000; Yin et al., 2001). Our data corroborate these ﬁndings.
Moreover, TNF and LPS were reported to provoke a time-
dependent decrease of IB, an inhibitor protein for NFB
activity, which was prevented by co-treatment with butyrate
(Place et al., 2005; Segain et al., 2000; Yin et al., 2001). A
decreaseinIBexpressionwasalsoobservedafterTNFstim-
ulation in our experiments. However, this reduction was even
stronger after butyrate pre-treatment. Comparable results were
reported in the study of Inan et al. (2000) suggesting that, for
this speciﬁc point in time, the inhibitory effect of butyrate on
NFB activity is not achieved via the expression of IB.N e v -
ertheless,othermechanismsorothermembersoftheIBfamily
may be also responsible for the inhibitory effects of butyrate on
NFB actions.
Fig. 6. Western blot for PPAR expression after treatment of HT-29 wild-type
cells with LPS (10g/mL) for 0.5, 1 and 6h. One representative blot of three
independent experiments is shown.
Fig. 7. NFB p50 (A) and p65 (B) dimer DNA binding activity in
HT-29 wild-type cells after stimulation with butyrate (4mM), the VDR
antagonist ZK191732 (10M), TNF (100ng/mL), LPS (10g/mL),
butyrate+ZK191732, butyrate+TNF, butyrate+LPS, or one of the combi-
nations of butyrate+ZK191732 with TNF or LPS, respectively. Cells were
pre-treated with ZK191732 for 2h followed by butyrate stimulation for 24h.
Cells were then stimulated with TNF or LPS for 30min. Nuclear extracts were
preparedandNFBactivationwasanalysedwithTransAM® transcriptionfactor
assay kit. ***p<0.001, **p<0.01, *p<0.05, n.s.=not signiﬁcant. (C) Western
blot for IB expression after treatment with butyrate (4mM), the VDR antag-
onist ZK191732 (10M), the combination of butyrate and ZK191732, TNF
(100ng/mL) or the combination of all three substances. Cells were pre-treated
withZK191732for2hfollowedbybutyratestimulationfor24h.Cellswerethen
stimulated with TNF for 30min. One representative blot of three independent
experiments is shown.M. Schwab et al. / Molecular Immunology 44 (2007) 3625–3632 3631
There is increasing evidence that the expression and activity
of PPAR and VDR are under the control of butyrate implying
that the receptors may participate in butyrate-mediated suppres-
sion of NFB activation (Gaschott and Stein, 2003; Gaschott
et al., 2001; Schwab et al., 2006; Wachtershauser et al., 2000).
PPAR and VDR are both ligand-activated transcription fac-
tors that belong to the nuclear hormone receptor family and
participate in a variety of immune processes (Tirona and Kim,
2005). VDR is widely expressed in epithelial tissues, cells of
the immune system and several cancer cell lines including col-
orectal cancer cells (Giuliano et al., 1991; Segaert and Bouillon,
1998). PPAR is activated by natural ligands such as fatty acids
and eicosanoids and is highly expressed in colonic epithelium,
indicating an important role of the receptor in the physiology
of the human colon (Desvergne and Wahli, 1999). All these
characteristicsmakebothreceptorspotentialtargetsinbutyrate-
mediatedinhibitionofNFBsignalling.Toscrutinizeapossible
involvement of the receptors for the activation of NFB in rest-
ing HT-29 cells and also after stimulation with butyrate, NFB
activity was examined after application of the VDR inhibitor
ZK191732 or the PPAR antagonist GW9662. Indeed, treat-
ment of cells with ZK191732 alone or in combination with
butyrateincreasedbothp50andp65basalNFBdimeractivities
whilereducingtheexpressionIBsimultaneously.Incontrast,
challenge of cells with the PPAR antagonist GW9662 did nei-
ther affect basal NFB activity, nor the expression of IB.
Similarly, co-stimulation of GW9662 did not alter the effect
of butyrate on NFB activity and IB expression. Compara-
ble results were obtained in dominant-negative PPAR mutant
HT-29 vector cells.
In addition, the role of both receptors in butyrate-mediated
inhibition of inducible NFB activity was scrutinized. HT-29
cells were stimulated with TNF or LPS, substances leading to
increased NFB activity via two different pathways, i.e. TNFR
and TRL signalling, respectively. To reveal the involvement of
the receptors in both pathways, experiments were performed
in presence of the VDR inhibitor ZK191732 or in the PPAR
mutantHT-29cellline.Inourinvitromodel,pre-treatmentwith
ZK191732 in presence of TNF almost reversed the inhibitory
effect caused by butyrate on both p50 and p65 NFB dimer
activities while the effects on NFB activity in HT-29 PPAR
mutant cells were comparable to wild-type cells. These results
indicate that the VDR seems to play part in TNFR signalling
pathway leading to increased NFB activation. Previous works
reporting direct modulation of NFB activity through the active
metabolite of vitamin D, 1,25-dihydroxyvitamin D3 (VD3) sup-
port our ﬁndings for the involvement of the VDR in basal and in
butyrate-mediated inhibition of TNF-stimulated NFB activ-
ity. In human lymphocytes, VD3 suppressed NFB p50 and its
precursor proteins p105 and p65 (Yu et al., 1995). Furthermore,
VD3 has been shown to decrease the DNA binding capacity of
NFB in human ﬁbrinoblasts (Harant et al., 1998). In periph-
eral blood mononuclear cells of healthy controls and patients
with CD, the vitamin D analogue TX 527 not only decreased
basalandTNF-inducedactivationofNFB,butalsoincreased
IB protein levels, even in association with TNF (Stio et
al., 2007). In addition, in a mouse model lacking the VDR
receptor a reduction of IB was observed (Sun et al., 2006).
The degradation of IB induced by TNF was inhibited by
VD3 in normal but not in VDR lacking cells (Sun et al., 2006).
Revealing NFB activation via the TLR signalling pathway our
experiments demonstrate that butyrate-mediated inhibition of
LPS-induced NFB activity was almost completely abolished
in HT-29 PPAR mutant cells while inhibition of the VDR did
not affect LPS-induced inhibition of NFB activity caused by
butyrate. Thus, butyrate-mediated inhibition of NFB activa-
tion via the TLR seems to be modulated by PPAR. Several
mechanisms have been reported by which PPAR can inhibit
the actions of NFB activity. The transcription factor can not
only physically interact with the NFB subunits p65, subunit
p50, or both, but also inhibit degradation of the inhibitory pro-
tein IB( Daynes and Jones, 2002; Dubuquoy et al., 2002). In
addition,up-regulationofIBlevelsandanincreasedinteraction
of PPAR with cyclic AMP response element binding protein
(CREB), a coactivator interacting with p65 have been described
(Daynes and Jones, 2002; Dubuquoy et al., 2002). Moreover,
thepresentstudydemonstratesthatPPARproteinexpressionis
increasedafterstimulationwithLPS.Ourﬁndingissupportedby
otherinvitroandinvivostudiesdemonstratingtheabilityofLPS
to elevate PPAR levels through TLR4 signalling (Dubuquoy
et al., 2003, 2006; Eun et al., 2006). This up-regulation may
ultimately lead to attenuation of the pro-inﬂammatory NFB
signalling pathway induced by LPS (Dubuquoy et al., 2003;
Eun et al., 2006).
Inconclusionthedatapresentedheredemonstratefortheﬁrst
time that the nuclear hormone receptors PPAR and VDR play
part in butyrate-mediated inhibition of inducible NFB activa-
tion dependent on the stimulated signalling pathway. Moreover,
VDRappearstoplayaninhibitoryroleintheregulationofbasal
NFB signalling. Our results thereby complete the puzzle of
several in vivo studies demonstrating that the anti-inﬂammatory
actionsofbothnuclearhormonereceptorsareexhibitedviainter-
feringwithNFBsignalling(DiSabatinoetal.,2005;Kaplanet
al.,2005;Leeetal.,2006;Stioetal.,2007;Sunetal.,2006).Elu-
cidating the NFB pathway will add value to the understanding
of the regulation of inﬂammatory processes. This in turn, may
provideopportunitiesforthedevelopmentofnewpreventiveand
therapeutic strategies in the treatment of IBD.
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PPARγ als molekulares Target epithelialer Funktionen im 
Intestinaltrakt 
 
Schlüsselworte: Peroxisome Proliferator-Activated Rezeptor (PPARγ), Vitamin D Rezeptor 
(VDR), nukleäre Hormonrezeptoren, kolorektales Karzinom, gastrointestinale 
Zellregulierung, Butyrat, Mesalazin, Sulforaphan, Caspase-Kaskade, antimikrobielle Peptide, 
Cathelicidin, Beta-Defensin-2, NFκB-Signaltransduktionsweg 
 
Die Mukosa des Gastrointestinaltraktes befindet sich in einem komplexen dynamischen 
Gleichgewicht. Schon kleinste Störungen dieses epithelialen Systems können zu einer 
veränderten Expression von antimikrobiell wirkenden Peptiden, zur Initiierung von 
unkontrolliertem Zellwachstum sowie zur Aktivierung des Transkriptionsfaktors NFκB 
verbunden mit der Freisetzung zahlreicher Entzündungsparameter führen. Diese Faktoren 
begünstigen die Entstehung gastrointestinaler Erkrankungen wie des kolorektalen Karzinoms 
und chronisch entzündlicher Darmerkrankungen.  
Die vorliegende Arbeit mit dem Titel „PPARγ als molekulares Target epithelialer 
Funktionen im Intestinaltrakt“ hatte das Ziel, das Verständnis molekularer Mechanismen, die 
zur Aufrechterhaltung der gastrointestinalen Homöostase beitragen, zu vertiefen. Neben der 
Entschlüsselung wichtiger Funktionen von Mesalazin sowie der natürlich vorkommenden 
Histondeacetylase-Inhibitoren Butyrat und Sulforaphan in a) der Regulierung des 
Zellwachstums, in b) der Induktion der antimikrobiellen Peptide Beta-Defensin-2 und 
Cathelicidin, sowie in c) der Modulation des NFκB-Signaltransduktionsweges in kolorektalen 
Tumorzellen, konnte die Beteiligung der nukleären Hormonrezeptoren PPARγ und VDR als 
sog. „Gatekeepers“ in diesen komplexen Regulierungsvorgängen aufgezeigt werden.  
  Im Rahmen dieser Arbeit wurde erstmals die Bedeutung von PPARγ als zentrales 
zwischengeschaltetes Signalmolekül an den durch Butyrat- und Mesalazin-vermittelten pro-
apoptotischen Effekten entlang der Caspase-Kaskade in Kolonozyten nachgewiesen. Die 
durch Butyrat-induzierte Caspase-3 Aktivität resultierte dabei aus der Initiierung sowohl des 
intrinsischen als auch des extrinsischen Signaltransduktionsweges bei simultaner 
Expressionshemmung der beiden inhibitorischen Apoptoseproteine Survivin und Xiap. Im 
Gegensatz dazu aktivierte Mesalazin diese Kaskade lediglich über den extrinsischen Weg. 
Zudem konnte ein durch Butyrat-vermittelter p38-MAPK-PPARγ-Caspase-3-Signalweg etabliert werden. Im vorliegenden in vitro Zellsystem wurden ferner PPARγ-abhängige und    
-unabhängige Regulierungsmechanismen an den durch Mesalazin-induzierten pro-
apoptotischen und anti-proliferativen Wirkungen nachgewiesen. Diese Vorgänge werden u.a. 
über die modulierende Funktion von Mesalazin auf das Tumor-Suppressor-Gene PTEN bzw. 
auf das Onkoprotein c-Myc vermittelt.  
  Des Weiteren konnte aufgezeigt werden, dass die durch Butyrat- und Sulforaphan-
induzierte Expressionssteigerung der antimikrobiellen Peptide Beta-Defensin-2 und 
Cathelicidin von einer Vielzahl von Signalkaskaden und Rezeptoren reguliert wird. In diesem 
Induktionsprozess konnte erstmalig die essentielle Bedeutung des VDR aufgezeigt werden. 
Eine Beteilung von PPARγ wurde hingegen ausgeschlossen. Zudem wird die durch Butyrat-
gesteigerte Cathelicidin-Expression vorwiegend über den p38-MAPK-Signalweg sowie über 
TGF-β1 reguliert. Der ERK1/2-Signalweg ist hingegen in die durch Sulforaphan-induzierte 
Expressionssteigerung von Beta-Defensin-2 involviert. 
 Im Rahmen dieser Arbeit konnte außerdem erstmals die Bedeutung von PPARγ und 
VDR als zwischengeschaltete Signalmoleküle der supprimierenden Wirkung von Butyrat auf 
die NFκB-Aktivität in Abhängigkeit von dessen Triggerung durch die pro-inflammatorischen 
Stimuli LPS und TNFα aufgezeigt werden. Darüber hinaus wurde eine regulatorische 
Funktion des VDR auf die basale NFκB-Aktivität nachgewiesen. Eine modulierende Wirkung 
von PPARγ auf die basale NFκB-Aktivität konnte hingegen nicht beobachtet werden. 
Mit den vorliegenden Resultaten in kolorekatalen Tumorzellen wird das Spektrum der 
intestinalen Zellregulierung durch die modulierende Funktion von Mesalazin, Butyrat und 
Sulforaphan auf die Caspase-Kaskade, auf antimikrobielle Peptide sowie auf den NFκB- 
Signaltransduktionsweg erweitert. Ferner konnte eine Beteiligung der nukleären 
Hormonrezeptoren PPARγ und VDR an den genannten Signaltransduktionsprozessen 
aufgezeigt werden. Die vorliegende Arbeit unterstreicht somit nicht nur die allgemeine 
zellbiologische Bedeutung der beiden nukleären Hormonrezeptoren PPARγ und VDR an 
gastrointestinalen Regulierungsvorgängen, sondern impliziert auch deren Potential zur 
Entwicklung neuer therapeutischer Ansätze in der Behandlung des kolorektalen Karzinoms 
und von chronisch entzündlichen Darmerkrankungen. Die prinzipielle Relevanz der 
gefundenen Daten muss jedoch durch weitere grundlagenwissenschaftliche und intensive 
klinische Forschungsbemühungen untersucht werden. 